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Trypanosoma brucei is a protozoan that causes Human African Trypanosomiasis and 
nagana in cattle. The bloodstream form (BSF) of T. brucei has a dense surface-coat of 
variant surface glycoprotein (VSG) that acts as the first line of defence against the host 
immune system while the main cell surface glycoproteins of the procyclic form (PCF) 
are the procyclins. VSGs and procyclins are attached to the cell membrane through 
glycosylphosphatidylinositol (GPI) anchors. Despite its importance, the  GPI 
biosynthetic pathway in T. brucei is not fully elucidated.  
In this thesis, we have applied epitope tagging, chemical crosslinking and quantitative 
proteomics methods to look for new components of protein complexes of the GPI 
pathway. Three components of the pathway were tagged and immunoprecipitated with 
or without chemical crosslinking and the results were as follows:  
For TbGPI12, the GlcNAc-PI de-N-acetylase, we discovered that, contrary to 
expectations, it is not complexed with TbMTI but with a different potential partner 
protein. We also optimised methodologies in this part of the study. 
For the TbGPI3 component of GPI GnT, we identified its expected partner proteins 
TbGPI15, TbGPI19, TbGPI2, TbGPI1 and TbERI1 and also identified two new 
components of the complex, namely an Arv1-like protein (TbArv1) and a putative E2-
ligase. 
For the GPI inositol deacylase (TbdeAc2) that catalyses inositol deacylation of GPI 
intermediates, we showed that it is present in  a ~240 kDa complex and, using both 
crosslinking and stable isotope in cell culture (SILAC) methodology, identified partner 
protein(s) encoded by genes Tb927.11.11740 and/or Tb927.11.11750. Individual reverse 
pull-down experiments showed that only Tb927.11.11750 was directly associated with 
TbdeAc2. Our attempts to generate a null and conditional null mutant for 
Tb927.11.11750 were not successful. However, we considered the possibility that 
Tb927.11.11750 (which contains a lipase motif) encodes a GPI PLA2 enzyme; an 
activity adjacent to TbdeAc2 in the pathway. We therefore used immunoprecipitated 
Tb927.11.11750 in an in vitro assay for GPI PLA2 activity using a radiolabelled and 
purified glycolipid A’ substrate. However, no GPI-PLA2 activity could be detected 
under the conditions used. Taken together, we postulate that Tb927.11.11750 encodes 
an essential product for the survival of BSF T. brucei and hypothesise that the 




1 Introduction  
1.1 Trypanosoma brucei 
1.1.1 Phylogenetics: The position of kinetoplastids in the eukaryotic kingdom and 
the position of T. brucei in the kinetoplastids 
Trypanosoma brucei gambiense and Trypanosoma brucei rhodesiense are protozoan 
pathogens of the genus Trypanosoma and order Trypanosamatida that cause Human 
African trypanosomiasis (HAT) or sleeping sickness in humans. They are closely 
related to T. brucei brucei that, together with T. congolense species and T. vivax cause 
Nagana in cattle in sub-Saharan Africa. With the exception of T. vivax, all of these 
African trypanosomes are transmitted to their mammalian hosts via a blood meal of 
tsetse fly (Glossina genus). In this thesis I have performed experiments with clones of T. 
brucei brucei (Lister strain 427), referred to as T. brucei from herein.  
All of the aforementioned trypanosomatid organisms belong to the class kinetoplastidea. 
The kinetoplastids, named after the morphological feature of a kinetoplast (containing 
DNA) in their mitochondrion and close to the basal body of their single flagellum, 
include other human pathogen trypanosomatids, notably T. cruzi, the causative agent of 
Chagas’ disease endemic to South and Central America, and the leishmania which cause 
a variety of sandfly-transmitted pathologies throughout the tropics and sub-tropics. The 
kinetoplastids belonging to the phylum Euglenozoa in the major taxon group Excavata 
(Fig. 1.1).  
Understanding biological origin and historical relationships with other organisms can 
help our understanding of parasite adaptation in invertebrate vectors and the vertebrate 
hosts. Phylogenetic analyses can be used to compare biological variants, providing 
information for disease-causing organisms in a molecular epidemiological perspective 
(Hillis, 1997). With the advances of molecular biology in the last century, the molecular 
phylogenetic analyses for the kinetoplastids has become available (Stevens and Gibson, 
1999).  
In the current consensus tree, a complex Last Eukaryotic Common Ancestor (LECA) is 
predicted to precede many unicellular organisms (Padilla-Mejia et al., 2021). Before 
this specific period, but after the divergence from the archaeal lineage, it is thought that 
a prokaryotic lineage acquired typical features of eukaryotic cells, including organelle 
like compartments, including flagellum and endomembrane system, a cytoskeleton and 
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the mitochondrion. T. brucei is a unicellular organism that branches from this unique 
position in this early stage of the evolutionary tree, where the LECA emerged. Thus, the 
molecular evidence strongly suggests that the eukaryotic Trypanosoma genus emerged 
early from prokaryotes.  
 
 
Figure 1.1 Schematic phylogenetic tree depicting the evolutionary relationships between 
the major eukaryotic taxa. 
These taxon groups are annotated and colour-coded, while the Trypanosoma brucei clade is 
highlighted with a red rectangle in the tree. The tree is generated based on a recent study 
described in (Burki et al., 2020). Image is taken from (Padilla-Mejia et al., 2021).  
 
Small-subunit ribosomal RNA (rRNA) sequences (Sogin, Elwood and Gunderson, 
1986) or mitochondrial rRNA sequences (Lake et al., 1988) were originally chosen to 
understand the relationships between kinetoplastid species. Using rRNA gene 
sequences, it was postulated that the evolutionary history of these eukaryotic parasites 
has connections with the origin of their insect hosts (Fernandes, Nelson and Beverley, 
1993).  It was also proposed that vertebrate parasitism arose multiple times in the 
trypanosomatids, with the evolution of trypanosomes is influenced more by their 
adaption to the invertebrate vectors than adaption to vertebrate hosts (Lukeš et al., 
1997). The most recent analysis, based on 18S rRNA sequences, places T. brucei in a 





Figure 1.2 Phylogenetic trees based on bootstrapped maximum parsimony analysis of the 
18S rRNA gene. T. brucei clade is highlighted in the red rectangle. Bootstrap values from 
100 pseudo-replicates, mapped at the appropriate internodes, are from maximum likelihood- 
(ML) and neighbor-joining-analyses. Image is taken from (Borges et al., 2021)  
 
1.1.2  Human African trypanosomiasis and Nagana  
HAT or sleeping diseases in humans is caused by two subspecies of Trypanosoma 
brucei: T. b. rhodesiense causing acute African trypanosomiasis endemic in Western 
and Central Africa, and T. b. gambiense causing chronic African trypanosomiasis 
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endemic in Eastern and Southern Africa. Currently, this sub-species causes more than 
95% of reported HAT cases. The two subspecies are morphologically indistinguishable.  
After infection, trypanosomes enter the haemo-lymphatic stage as they multiply in 
subcutaneous tissues, blood and lymph. The patients' symptoms in this stage include 
fever, headaches, enlarged lymph nodes, joint pains, and itching. The parasites can also 
cross the blood-brain barrier leading to the infection of the central nervous system. This 
stage is called the neurological stage. The symptoms for the patient in this stage are 
more evident with the most characteristic feature, which is the disturbance of the sleep 
cycle.  
Trypanosomiasis caused devastating epidemics in the 20th century. With sustained 
control efforts over the past 20 years, the number of reported cases dropped below 
10,000 for the first time in 50 years, and in 2020 led to a historically low number of 565 
cases. This record has met the target of eliminating HAT as a public health problem, 
with fewer than 2000 cases per year (WHO, 2021) (Franco et al., 2020).  
The diagnosis for HAT alters depending on the patients' infection stage and varies 
between the diseases caused by different sub-species of T. brucei. In the case of T. b. 
rhodesiense, field diagnosis uses light microscopy to visualise the parasites on the 
infected individuals' thin or thick peripheral blood smear. It is typical for the patients to 
harbour high blood parasite levels with this infection (Kennedy, 2006).  Primary 
screening for T. b. gambiense infection uses serological methods. The Card 
Agglutination Test for Trypanosomiasis (CATT) has been wildly adopted for disease 
screening due to its quick and straightforward testing features. However, the CATT 
methodology has several limitations, such as the high frequency of false-positive results 
and limited sensitivity (Kennedy, 2013). Therefore, this methodology is usually 
conducted in a region considered to have a high prevalence of disease (Kennedy and 
Rodgers, 2019).  
Some advanced molecular techniques may improve the sensitivity and accuracy of the 
testing results. For example, Polymerase Chain Reaction (PCR) has been tested in HAT; 
however, it has been proved to have enormous technique-related issues and therefore 
not practical in the African region.  
More recently, alternative effective diagnostic devices have been developed, called 
Rapid Diagnostic Tests (RDTs). One of the RDTs originated from our lab in 
collaboration with Professor Mark Carrington at Cambridge, an 
immunochromatographic test. To establish this test, antigens recognised specifically by 
HAT patients were first identified by proteomics and the four most promising were 
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expressed as recombinant proteins and tested by ELISA to compare immunoreactivities 
between T .b. gambiense infected and non-infected sera pools and individual sera. One 
of these, the extracellular domain of a T. b. gambiense invariant surface glycoprotein 65 
(ISG65) gene was prototyped by itself (Sullivan et al 2013) and together with native 
soluble-form variant surface glycoprotein 117 (sVSG117) (Sullivan et al., 2014) and 
compared with other native and recombinant antigens (Sternberg et al., 2014). This 
strategy led to the development of the commercial BIOLINE HAT 2.0 test which uses 
recombinant ISG65 and a recombinant VSG that has high sensitivity and specificity. It 
was recently announced that 450,000 copies of this RDT will be donated by global 
healthcare company Abbott to scale up the testing for sleeping sickness from 2021. 
For HAT treatment, World Health Organisation (WHO) has updated the 
pharmacological therapy for gambiense HAT in 2020 with substantial changes for 
clinical practice, including the oral fexinidazole monotherapy into the first-line 
treatment (Lindner et al., 2020). Before this new treatment, previous pharmacological 
therapy for gambiense HAT depended on a few old drugs which have toxicity liabilities. 
Here is a summary of current treatment guidelines from WHO (Lindner et al., 2020): 
Drug treatment for HAT is dependent on the stage of the disease for both HAT variants. 
For early-stage T. b. gambiense infection, fexinidazole or pentamidine are the first-line 
drug treatments with the recommendation of using fexinidazole in most cases. However, 
pentamidine is the only approved treatment for patients under age six or whose weight 
is below 20 kg. For the second-stage T.b. gambiense infection, fexinidazole or 
nifurtimox-eflornithine combination therapy (NECT) are used.  
As for the treatment for the early-stage of T. b. rhodesiense, suramin is given by 
intravenous administration. This treatment is proven to be effective but has several 
potential side effects. Drug treatment for the second-stage disease is more problematic 
with the only treatment currently available being intravenous melarsoprol. This drug, 
although very effective, is very toxic, with a fatality rate of around 5-9% (Kennedy and 
Rodgers, 2019).  
Fexinidazole has proven to be effective for the treatment of T. b. gambiense with a 10-
day oral course (Lindner et al., 2020). However, there is a high risk of relapse after the 
treatment, and this relapse may occur late after the treatment, up to 12-24 months. 
Therefore, further studies need to be conducted to solve these risk factors, and more 
clinical trials need to be carried out for its use in children under six and patients whose 
weight is less than 20 kg. In conclusion, fexinidazole has a prospect for simplifying the 
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treatment of gambiense HAT. It will be easier to utilise in poorly resourced areas where 
the standard pharmacovigilance systems are challenging to set up.  
Recently, the mode of action of two new benzoxaboroles drugs that are now in clinical 
trial were revealed with targeting the Cleavage and Polyadenylation Sepcificity Factor 3 
(CPSF3) (Wall et al., 2018). These benzoxaboroles could be orally taken which will 
provides an additional patient-friendly therapies for both sleeping sickness and Nagana.  
As mentioned, the goal of WHO to eliminate sleeping sickness as a public health 
problem by 2020 has been achieved. However, there are still several challenges that 
should be taken into consideration: ⅰ: Resurgence of HAT, as were recorded in the 
1960s even after it had appeared to have been brought under control. ⅱ: The frequency 
of asymptomatic patients is still unknown, and there is a reservoir of trypanosomes 
being identified in the skin and extravascular tissues in asymptomatic humans, which 
will all be an issue for the elimination of HAT as a public health issue. ⅲ: Some cases 
occur in the rural area of sub-Saharan Africa, which poses a problem for identifying and 
recording infections. ⅳ: The current drug treatment for rhodesiense HAT is not 
adequate for the second-stage disease. Melarsoprol treatments are extremely painful and 
bring many side effects with even consequences of post-treatment fatality (Kennedy and 
Rodgers, 2019).  
African Animal trypanosomiasis (AAT) is caused by subspecies of the Trypanosoma 
genus, mainly T. congolense, T. vivax and T. brucei brucei subspecies. In cattle, this 
disease is called Nagana. The animal trypanosomiases, especially Nagana, are a 
significant economic burden that affects many rural areas of Africa. In addition, animals 
(mainly cattle) can act as a reservoir for the human infectious parasites, especially T. b. 
rhodesiense. The fact that cattle are reservoirs of T. b. rhodesiense posts more 
challenges to control this HAT variant. Although local control has been successful, it is 
probably not a realistic proposition to eliminate the tsetse fly vector, given that there is 
no evidence of diminishing regions that the tsetse fly infests over the last 100 years.  
In conclusion, the surveillance, diagnosis and drug treatment for gambiense HAT and 
early-stage rhodesiense HAT are now quite well established. However, the drug 
treatment for second-stage rhodesiense HAT with the only first-line drug melarsoprol 
that causes severe side effects are far from adequate. Therefore, developing more 
reliable and affordable diagnostic staging biomarkers that could discriminate the early-
stage disease from late-stage disease is an alternative way to helping providing 
sufficient treatment in time and avoid the use of toxic drugs for late-stage disease. 
Meanwhile, more effective, safer, and easier administration of new drugs need to be 
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developed to achieve better treatment for rhodesiense HAT. As for animal 
trypanosomiasis, more obstacles remain to be tackled, such as new treatment methods 
and control of the transmission. Recently, a new study has broadened the field’s view 
on how to control the disease, introducing in vivo protective immunity against invariant 
Trypanosoma vivax vaccine antigen (Autheman et al., 2021). The authors managed to 
find a single recombinant flagellum membrane protein for vaccination that could induce 
long-lasting protection. The monoclonal antibodies to this protein could clear the 
parasitaemia in the mouse model, including the significant role for a complement. Their 
study shows that protective vaccines against trypanosome infections can be achieved 
and provides a vaccine candidate for controlling and curing T. vivax trypanosomiasis.  
1.1.3  Life cycle of Trypanosoma brucei 
T. brucei undergoes a complex life cycle between its teste fly vector and mammalian 
hosts. It is a unicellular protozoan with six main cellular morphologies dependent on 
different cellular organisations, like the position of the kinetoplast relative to the 
posterior end of the cell.  The life cycle of T. brucei is summarised in (Fig 1.3). The 
metacyclic trypomastigotes are co-injected with saliva into the mammalian host's skin 
tissue, entering the lymphatic system and bloodstream. Here, they differentiate into long 
slender bloodstream trypomastigotes, and the proliferative life cycle stage starts with 
replication of the parasites by binary fission. When the parasitaemia in the mammalian 
host increases, some cells develop into a stumpy form and are arrested in the G1/G0 
phase, ready to be taken by the insect vector (McKean, 2003). The short stumpy 
trypomastigotes that tsetse fly takes then enter the vector's midgut and differentiate to 
procyclic trypomastigotes in which stage the binary fission takes place for proliferation. 
During the migration to the salivary glands, the parasite transforms into epimastigotes 
and continue multiplication by binary fission. Inside the salivary glands, some 
epimastigotes will differentiate into metacyclic trypomastigotes. Studies (Peacock et al., 
2014) have also shown the identification of haploid gametes in the insect stage. 
Interactions and cell fusions are detected between these gametes, indicating the sexual 





Figure 1.3 Life cycle of Trypanosoma brucei. 
 The transmission of T. brucei starts with a bite on the mammalian host by a tsetse fly. After the 
metacyclic trypomastigotes enter the mammalian host, these cells differentiate to dividing 
slender bloodstream-form and then some of these to non-dividing stumpy form. At this stage, 
they can be taken up by the insect vector, where the differentiation to procyclic form takes place 
in the fly midgut. Asymmetric division gives rise to the short epimastigote form that migrates 
and attaches to the salivary gland. Here the cells proliferate and mature to the infectious 
metacyclic form. The image is taken from CDC (Centers for Disease Control and Prevention). 
 
1.2 Surface structures of Trypanosoma brucei  
1.2.1 Overview of the known and predicted GPI-anchored glycoproteins of T. 
brucei 
The glycosylphosphatidylinositol (GPI) anchor is an almost universal eukaryotic protein 
attachment mechanism. In T. brucei, there are a lot of proteins with different functions 
that are GPI anchored. With the help of the GPI anchor prediction tool (Eisenhaber, 
Bork and Eisenhaber, 1999) applied to the predicted proteins of T. brucei, a list of 155 
proteins (zenodo:10.5281/zenodo.5338935) predicted to be GPI-anchored was 
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generated. For some of these there are experimental data supporting the prediction.  The 
GPI prediction algorithm looks for sequences that contain an N-terminal signal peptide 
(to enter the lumen of the ER) and for a GPI attachment signal peptide with the 
following features: The amino acid to which GPI is attached is termed the ω site amino 
acid (Gerber, Kodukula and Udenfriend, 1992), which is usually a relatively small and 
polar residue (Ala, Asn, Asp, Cys, Gly, or Ser). The GPI attachment signal peptide 
contains 20-30 amino acid and starts from the ω+1 amino acid. The repertoire of amino 
acids in the ω+1 and ω+2 sites are similar to that for the ω site and the algorithms 
sometimes struggle to correctly pick the ω site for this reason. These are followed by 5-
10 relatively polar amino acids and then a run of 15-20 hydrophobic amino acids to the 
predicted C-terminus. This C-terminal signal peptide is recognised by the GPI 
transamidase (which will be introduced later), and cleavage occurs between the ω and 
ω+1 amino acids.  
1.2.2 Main surface structure of BSF T. brucei-GPI anchored VSGs and antigenic 
variation  
The bloodstream form (BSF) of T. brucei produces a dense coat of GPI anchored 
(Ferguson et al Science 1988) variant surface protein (VSG) which consists of ~10 
million molecules that accounts for at least 95% of  cell-surface proteins (Ziegelbauer 
and Overath, 1992) (Grünfelder et al., 2002). This dense layer acts as the first defence 
and protects the parasite from the innate immune system of the host. The expression of 
a VSG coat on T. brucei starts on the metacyclic trypomastigotes (from a specific 
metacyclic VSG gene repertoire) when it resides in the salivary glands of the teste fly 
(Rotureau and Van Den Abbeele, 2013). Upon differentiation to the BSF a wider 
repertoire of VSG genes is available for expression (Cross et al., 2014). 
Although efforts have been put into understanding the molecular mechanisms of how 
VSGs defend the against the host’s immune system for decades, it is only recently years 
that the molecular organisation of the intact VSG coat has been proposed (Bartossek et 
al., 2017). The first crystal structures of two VSGs, MITat1.2 and ILTat1.24, were 
solved three decades ago with a resolution of 6 Å (Freymann et al., 1984) (Metcalf et 
al., 1987). These early structures have provided essential basic understandings of the 
structures of VSGs as, generally, VSG homodimers of 100-120 kDa with a conserved 
coiled coil tertiary architecture, despite low similarity in primary sequence. However, 
these and later VSG crystal structures (Pinger et al., 2018) only provide structures for 
the N-terminal domain (NTD) of VSGs. The crystallisation of intact VSGs purified by 
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standard purification methods leads to crystals containing only the NTDs. The lack of 
C-terminal domain (CTD) of VSG through purification provides evidence that the 
unstructured region, Linker 1(L1) (Schwede et al., 2015), connecting the NTD and the 
CTD is likely accessible and sensitive to proteases. With continuous efforts on solving 
the structures of VSGs, the NMR solution structures of CTD of VSGs MITat1.2 and 
ILTat1.24 were determined in 2005 (Chattopadhyay et al., 2005) and 2008 (Jones et al., 
2008), respectively. In 2017, another NMR solution structure of the CTD of VSG 
M1.1.a was added to the database. The comparison of these three different CTDs of 
different VSGs highlights that they all share conserved core structure despite the 
differences in the primary sequences. Models for the complete structure of VSG M1.1 
were determined by fitting the x-ray crystallographic NTD and solution NMR CTD 
structures into small angle X-ray scattering (SAXS) envelopes of intact VSG.  These 
suggested that it could adopt two main groups of conformations with evident flexibility 
of the Linker 1 of VSGs (Fig 1.4). The authors of this paper proposed that the 
conformation of VSGs is greatly affected by the environment when they are bound to 
the cell membrane. The NTDs and CTDs of VSGs structure can also be grouped into 
two types for NTDs and six types for CTDs (Schwede et al., 2015).  
 
 
Figure 1.4 Proposed two packing methods of GPI-anchored VSGs on the cell surface. 
 Illustration of two forms of VSGs surrounded in two different environments with tightly 
packed VSGs at left and the relaxed version at right.  Image is taken from (Bartossek et al., 
2017). 
 
T. brucei has a reservoir of up to 2000 VSG genes and gene-fragments, which make up 
of 30% of its genome (Horn, 2014). Of these, about 20% are competent to encode full-
length functional VSGs (Cross et al., 2014) (Only one out of these VSG genes is 
activated and transcribed at a time by polymerase-Ⅰ (pol-Ⅰ) (Horn, 2014) as part of the 
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polycistronic transcription unit at the expression site (ES) (Vol et al., 1982). In a natural 
infection, only a small number of “early” VSG genes are being expressed by the 
parasite population and the host develops a specific immune response to these VSGs, 
and the parasitaemia is attenuated by the antibody response. However, some parasites 
switch to expressing another VSG gene in a different telomeric expression site, Further, 
telomeric expression sites can change VSG genes  by homologous recombination due to 
the 70 bp repeats and the conserved 3’-UTR flanked with these VSG genes (Fig 1.5). 




Figure 1.5 VSG expression and antigenetic variation. 
 Simplified scheme of successive immune responses due to the antigenic variation of VSGs. The 
image is taken from (Horn, 2014). DNA recombination is central to VSG switching. 
 
In addition to this fundamental mechanism of antigenic variation by VSG gene 
switching, a recent structural study of VSG3 also shows that post-translational 
modification on the surface of VSGs can add to the variability of VSGs (Pinger et al., 
2018). Heterogeneous O-glycosylation with zero to three hexose was present on VSG3 
and other VSGs. This O-glycosylation increased the parasites’ virulence by interfering 





Figure 1.6 Identification of O-linked glycosylation of VSG3 through crystallisation. 
 Left: Structure of VSG3 (blue) and VSG 2 (gold) with identifying a red space-filling α -glucose 
moiety attached to Ser 317 of VSG3. Right: A 1.4-Å-resolution electron density map showing 
the linkage between the modelled glucose ad the Ser 317 representing the main protein chain. 
Image is taken from (Pinger et al., 2018) 
 
1.2.3 Other known and predicted BSF GPI-anchored glycoproteins 
In T. brucei, there are also other proteins that are known to be attached to the BSF cell 
membrane through GPI anchors. Several proteomics analyses that focused on the cell 
surface proteins of T. brucei (Shimogawa et al., 2015) (Zoltner et al., 2015)have also 
expanded the datasets for analysing potential GPI anchored proteins that are present on 
the parasites’ plasma membrane. For example, an important surface molecule that has 
been shown structurally to possess a GPI anchor is the ESAG6-subunit of the BSF 
transferrin receptor (TfR) (Mehlert and Ferguson, 2007), although surprisingly the GPI 
anchor itself can be replaced by a transmembrane domain to still yield a functional TfR 
in BSF T.brucei (Kabiri and Steverding, 2021).  
The BSF haptoglobin-haemoglobin receptor is also predicted to be a GPI-anchored 
protein in T. brucei with an N-terminal signal peptide and C-terminal GPI addition 
signal peptide (Vanhollebeke et al., 2008) (Lane-Serff et al., 2014). This protein plays a 
role in mediating high-affinity binding with haptoglobin-haemoglobin for the uptake 
and incorporation of heme into intracellular hemoproteins. It also acts as a receptor of 
host serum trypanolytic factor-1 that protects humans from T. brucei brucei infections.  
The factor H receptor is another protein with the predicted N-terminal signal peptide 
and C-terminal GPI addition sequences. This factor H receptor can bind mammalian 
factor H with the inhibitory domain free to inactivate complement C3b deposited on the 
trypanosome surface (Macleod et al., 2020). It has been shown to be a virulence factor 
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for the transmission of trypanosomes, with the highest expression level in the 
developmental stages transmitted to the tsetse fly vector and those exposed to blood 
meals in the tsetse gut. Other examples like the epimastigote stage-specific surface 
protein BARP glycoprotein (Urwyler et al., 2007) and the metacyclic trypomastigote 
invariant surface protein (MISP) (Casas-Sánchez et al., 2018) have also been predicted 
to be GPI-anchored proteins.  
 
1.2.4 Main surface structure of PCF T. brucei – procyclins 
The major surface glycoproteins of the tsetse mid-gut dwelling procyclic form (PCF) of 
the parasite are the procyclins and these are also a GPI-anchored proteins. The change 
of trypanosome surface coat happens when the stumpy forms differentiate to the 
procyclic forms where the VSGs coat exchanged to the procyclin coat (Metcalf et al., 
1987) (Matthews and Gull, 1994), which has two main forms. The procyclins, which 
were also previously called procyclic acidic repetitive protein (PARP), comprises about 
1% PCF trypanosome protein and was first isolated in 1989 (Clayton and Mowatt, 
1989) by purification methods involving cell fractionation, ion exchange and 
concanavalin A-Sepharose affinity chromatography. The structures of two forms of 
PARP/procyclin were determined from material purified from long-term cultures of T. 
brucei PCF. These were purified by solvent extraction and hydrophobic interaction 
chromatography, which has become the preferred route to procyclin purification. This 
procedure yielded both Glu-Pro (EP) repeat domain-containing procyclin, which 
contains an N-glycosylation site,  and a Glu-Pro-Pro-Thr (GPEET) repeat domain-
containing procyclin that lacks an N-glycosylation site (Treumann et al., 1997). The 
GPEET-procyclin was later also shown to be hyper-phosphorylated (Treumann et al., 
1997). 
Later, the procyclins were analysed in vivo during the establishment of midgut 
infections in the tsetse flies (Acosta-Serrano et al., 2001) by mass spectrometry. The 
procyclins are the products of a small multigene family, and the analysis showed the 
expression of different procyclins in an orderly manner. In the early infection, GPEET2 
is the only procyclin detected. As the infectious days' increase, GPEET2 is gradually 
replaced by several isoforms of glycosylated EP forms. Also, the N-terminal domains of 
all procyclins are sensitive to proteolysis in the tsetse fly. In contrast, the C-terminal 
domain appears to be protease-resistant, indicating that the C-terminal domain 
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containing the polyanionic amino acid repeats may protect the parasite surface from 
digestive enzymes in the tsetse fly gut.  
 
1.3 GPI anchor  
1.3.1 GPI anchor structures – common core structure and species and tissue-
specific lipid, carbohydrate side-chain and phosphodiester substituent variations 
Together with proteins mentioned previously, dozens of GPI-anchored proteins have 
been identified and several hundred postulated in many eukaryotes, suggesting that 
protein-lined GPI-anchors ubiquitous among eukaryotes. Proteins containing a GPI 
anchor play roles in a wide variety of biological processes, including cell-cell 
recognition, cell signalling, cell surface enzymology and cell protection.   
Thus far, GPI anchor structures have been completely or partially solved for four T. 
brucei VSGs (Ferguson et al., 1988) (Mehlert et al., 1998) (Mehlert et al., 2010) 
(Treumann et al., 2010) , the TfR (Mehlert et al., 2012) and the procyclins (Field et al., 
1991) (Treumann et al., 1997). As for the structure of GPIs, research on T. brucei was 
the first to yield methodologies to delineate the steps of GPI biosynthesis that were 
subsequently applied to mammalian cells and yeast (Masterson et al., 1989) (Masterson 
et al., 1990) (Menon et al., 1990). GPI structures have also been completely or partially 
solved for several other eukaryotic species both unicellular (T. congolense, T. cruzi, 
Leishmania major, Plasmodium, Toxoplasma, Neospera, Paramecium, Saccharomyces, 
Aspergillus) and multicellular (Dictyostelium, Pyrus, Torpedo, as well as mammalian 
(rat, bovine, human, hamster, pig))(Nett et al., 2009) (Ferguson et al., 2017) 
The analysis of the protein GPI anchor structures shows that GPI anchors have a 
conserved core structure of ethanolamine-P-6Manα1-2Manα1-6Manα1-4GlcNα1-
6myo-inositol-1-P-lipid. The ethanolamine phosphate (EtNP) acts as a bridge to the C-
terminal amino acid of a mature protein, making a amide bond to the C-terminal amino 
acid α-carboxyl group. The lipid moiety is generally the sole means of attachment of 
such proteins to the membrane (Fig 1.7).  However, outside of T. brucei, not all GPI 
anchors have a diacylglycerol lipid component, alkyacyl-glycerol and ceramide lipids 
are also common, particularly in mammalian and yeast GPI anchors, resectively]. The 
structure shown in (Fig 1.7) is the general structure for all protein-linked GPI anchors.  
For BSF T. brucei, the R1 and R2 fatty acid chains are exclusively myristic acid (C14:0) 
due to the trypanosome-specific phenomenon of fatty acid remodelling of the GPI 
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precursor prior to exchange for the GPI anchor addition signal peptide (Masterson et al., 
1990) (Güther et al., 1994), see (Fig 1.8). For the mature VSG and TfR GPI anchors, R3 
is OH, whereas the BSF GPI biosynthetic precursors are in dynamic equilibrium 
between R3 being OH and an ester-linked fatty acyl group (Güther and Ferguson, 1995), 
which is mostly palmitate (C16:0) (Güther et al.,1996) (Fig 1.8). The latter are referred 
to as being inositol-acylated. After the non inositol-acylated GPI anchor precursor 
(referred to as glycolipid A) is transferred to protein by the GPI transamidase complex 
in the ER, it is further processed in the ER and Golgi apparatus where the GPI anchor 
can be galactosylated at the R6, R8 and R10  positions (see Fig 1.8). The GPI anchor 
structure is different for PCF T. brucei (Treumann et al., 1997) such that: (ⅰ) R1 at the 
sn-2 position of PI is OH with R2 mostly stearic acid (C18:0); (ⅱ) The inositol is 
acylated with predominantly palmitate acid at the R3 position. (ⅲ) The side chain 
modifications are extremely complex, containing at R8 Gal and GlcNAc in the form of 
N-acetyl-lactosamine (Gal1-4GlcNAc) and lacto-N-biose (Gal1-3GlcNAc) repeats 
capped with α2-3 linked sialic acids (see Fig 1.8).  
 
Figure 1.7 General structure of glycosylphosphatidylinositol (GPI) anchors attached to 
proteins. 
They all share a common core consisting of ethanolamine-PO4-6Manα1-2Manα1-6Manα1-
4GlcNα1-6myo-inositol-1-PO4-lipid. Various substitutions on different GPI anchors are 






Figure 1.8 The structures of (A) the BSF T. brucei VSG GPI anchor (Ferguson et al., 1988) 
and (B) a consensus structure of the PCF T. brucei procyclin GPI anchor (Treumann et al., 
1997) (Izquierdo et al., 2009). Images taken from (Ferguson et al., 2017).  
 
The chemical properties of GPI anchors are quite complex as they contain amide, 
glycosidic, phosphodiester and hydroxyester linkages between their various 
components. The determination of the GPI anchor structure was favoured by several 
chemical and enzyme cleavages of the GPI anchor. Several of these reactions were later 
applied to the detection of GPI anchors on GPI-anchored proteins and to the 
characterisation of GPI biosynthetic intermediates. The commonly used reagents, 
enzymes and corresponding reactions with products are illustrated in (Fig 1.9). Panel A 
shows two key chemical reactions of GPI anchor. Aqueous hydrogen fluoride treatment 
releases the GPI glycan from PI and the ethanolamine phosphate, allowing the released 
glycans to be permethylated and analysed by tandem mass spectrometry. Nitrous acid 
deamination of the glucosamine residue causes a highly selective cleavage of the 
glucosamine-inositol glycosidic bond, releasing the PI moiety. The liberated PI can be 
extracted by solvent partition and analysed by mass spectrometry. The general 
enzymatic digestions are shown in Fig 1.9 panel B. The digestion of a mature GPI 
anchor with jack bean α mannosidase (JBαM) does not liberate any free mannose from 
the structure as the terminal mannose is linked to the ethanolamine phosphate residue 
(Ferguson et al., 1988). However, a GPI intermediate lacking the ethanolamine 
phosphate will be fully digested.  Phospholipase A2 (PLA2) digestion will release the 
fatty acid chain at sn-2 position from the GPI anchor, which helps to distinguish 
different GPI anchor intermediates. Both phosphatidylinositol-specific phospholipase C 
and D (Fig 1.9 panel C) can release the lipid or phosphatidic acid portion from the GPI 
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anchor while the susceptible substrates for the reactions are different. PI-PLC cannot 
digest the GPI anchor if the inositol ring is acylated, while PI-PLD works on both 




Figure 1.9 Digestion patterns of GPI anchors by chemical reagents or enzymatic reactions. 
 A: Aqueous HF releases the PI portion from the GPI anchor while the nitrous acid deamination 
of the GlcN releases the PI component. B: JBαM cannot digest a GPI anchor intermediate 
where the terminal mannose is protected by ethanolamine phosphate. PLA2 can liberate the sn-2 
fatty acid chain from GPI anchor. PI-PLC will release lipid portion from non inositol-acylated 
GPI anchors but not inositol-acylated GPI anchors D: PI-PLD will liberate phosphatidic acid 
from inositol acylated and non-acylated GPI anchors.  
 
1.3.2 GPI anchor biosynthesis pathway in T. brucei 
The biosynthesis of GPI anchor in T. brucei has been illustrated through a series elegant 
radiolabelling experiments using living cells and BSF and PCF trypanosome cell-free 
systems (Masterson et al., 1989) (Masterson et al., 1990) (Menon et al., 1990) (Field et 
al., 1991) (Güthee et al., 1994) (Güther and Ferguson, 1995). The scheme of the GPI 
anchor biosynthesis pathway of BSF T. brucei is shown in (Fig 1.10). The pathway is 
located in the endoplasmic reticulum (ER) compartment of the parasite (Vidugiriene 
and Menon, 1994). The whole process starts in the cytosolic face of ER where N-
acetylglucosamine is added to phosphatidylinositol (PI) following by the de-N-
acetylation of GlcNAc-PI yielding to glucosamine-PI (GlcN-PI). The GlcN-PI is flipped 
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into the lumenal leaflet of ER where it is mannosylated sequentially with three 
mannoses using the donor dolichol-phosphate-mannose (DPM). After the addition of 
the first mannose, all GPI intermediates are in equilibrium between their inositol-
acylated and non-acylated forms. The ethanolamine phosphate is attached to the third 
mannose from the donor phosphatidylethanolamine, after which the fatty acid re-
modelling of the PI occurs involving the sequential exchange from longer chain fatty 
acids to myristic acids on the sn-2 and sn-1 positions. After the synthesis of the mature 
GPI anchor precursor (glycolipid A),  proteins displaying a C-terminal GPI addition 
sequence have the glycolipid A precursor transferred to them by the GPI transamidase 
complex (Nagamune et al., 2003) (Hong et al., 2006). Following this, sidechain 
glycosylation in the ER and Golgi apparatus occurs and the processed GPI-proteins are 
transported to the plasma membrane via the flagellar pocket. Each step of the GPI 
anchor biosynthesis pathway is catalysed by an enzyme or a protein complex, the list of 
enzymes that are involved in this pathway is listed in (Table 1.1).  
 
 
Figure 1.10 General scheme for GPI biosynthesis in the ER of T. brucei BSF. 
 The ER is depicted as a topologically closed compartment. The mature GPI precursor in PCF T. 




1.3.3 Comparison of GPI anchor biosynthesis pathways in T. brucei, mammalian 
cells and yeast 
Despite conservation in the core structure of GPI anchors across eukaryotic evolution, 
notable differences between the T. brucei and mammalian GPI biosynthetic pathways 
occur from GlcN-PI onwards (Güther et al., 1994), including the addition of extra 
ethanolamine phosphate groups to mammalian anchors, fatty-acid remodelling of T. 
brucei GPI precursors and the timing of inositol acylation and deacylation (i.e., the 
addition of a fatty acid to the 2-OH of the myo-inositol residue). The latter occurs in T. 
brucei only after the addition of the first Man residue to GlcN-PI and intermediates 
from Man1GlcN-(acyl)PI onwards are in equilibrium between their inositol acylated and 
non-acylated forms through the action of inositol acyltransferase(s) and inositol 
deacylase(s). In mammalian cells, inositol acylation occurs at the level of GlcN-PI and 
strictly precedes mannosylation to Man1GlcN-(acyl)PI. Furthermore, the acyl chain 
remains attached once added until the mature GPI anchor is added to protein in the 
endoplasmic reticulum. Thereafter, it may remain but is usually removed by an inositol 
deacylase, prior to a form of lipid remodelling that is distinct from the fatty acid 
remodelling of T. brucei (Fujita and Kinoshita, 2012) (Kinoshita et al., 2013) (Kinoshita 
and Fujita, 2016). The lipid remodelling in yeast differs from both T. brucei and 
mammalian cells. It happens in the ER but after the GPI anchor precursor is transferred 
to protein. The unsaturated fatty acid at the sn-2 position is removed and replaced with a 
C26:0 chain. In some cases, the diacylglycerol is further exchanged for ceramide in the 
Golgi (Orlean and Menon, 2007).  
 
1.4 Enzymes catalysing GPI anchor biosynthesis in T. brucei 
1.4.1 Known enzyme complexes in the T. brucei GPI anchor biosynthesis 
pathway  
Since the GPI anchor pathway is a potential drug target, significant work has been 
performed to characterise the enzymes of this pathway. However, it was the power of 
mammalian cell and yeast genetics that led to the identification of the majority of GPI 
biosynthesis genes, reviewed in (Kinoshita, 2020) (Pittet and Conzelmann, 2007). We 
currently have reasonably advanced models for GPI anchor biosynthesis and processing 
in trypanosomes, mammalian cells and yeast and the similarities and differences in 
these pathways have been reviewed extensively elsewhere (Kinoshita, 2020) (Kinoshita 
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and Fujita, 2016) (Jaquenoud et al., 2008) (Pittet and Conzelmann, 2007) (Ferguson  et 
al., 2017). For most organisms, the functions and interactions of putative GPI pathway 
gene products have been inferred from experimental work in mammalian or yeast cells. 
In a few cases, these functions have been experimentally confirmed in T. brucei. Fig 
1.11 is the GPI anchor biosynthesis pathway in T. brucei BSF and Table 1.1 is a list of 
enzymes (known or homologs of mammalian or yeast enzymes) that catalyse GPI 
anchor biosynthesis in T. brucei. The enzymes of this pathway have some common 
features:  
(ⅰ) They tend to be very low abundance proteins. [The ranking of these proteins (from 
1= most abundant, to 7150 = undetectable) in BSF T. brucei has been estimated by 
combining numerous deep proteomics datasets (Tinti et al., 2019) (Ji et al., 2021). The 
rankings (Table 1.1) show that several GPI pathway components are undetectable and 
that many (apart from several of the GPI transamidase complex) are in the bottom 
quartile of cellular protein abundance].  
(ⅱ) Where tested, they appear to be essential for the survival of BSF T. brucei. 
Experimental evidence has been reported for GlcNAc-PI de-N-acetylase (TbGPI12) 
(Chang et al., 2002), the third mannosyltransferase (TbGPI10) (Nagamune et al., 2000), 
the inositol deacylase 2 TbdeAc2 (Hong et al., 2006) and TbGPI8 of the GPI 
transamidase (Lillico et al., 2003)  
(ⅲ) They tend to function as protein complexes. Three known examples of  GPI 
pathway complexes in T. brucei are the UDP-GlcNAc: PI α1-6 GlcNAc-transferase 
complex, the GPI transamidase complex (Lillico et al., 2003) (Nagamune et al., 2003) 
(Hong et al., 2006) and the ethanolamine phosphate transferase 2 complex (Stokes et 
al., 2014). The first step of GPI biosynthesis is the addition of GlcNAc to PI by a UDP-
GlcNAc : PI α1–6 GlcNAc-transferase (GPI GnT) complex. The composition of this 
complex was determined in mammalian cells, where seven subunits have been 
identified: PIGA, PIGC, PIGH, PIGP, PIGQ and PIGY (a homologue of ERI1 first 
identified in yeast and shown to associate with GPI2 (Sobering et al., 2004)), and 
DPM2 (Table 1.1) (Kinoshita, 2020). The DPM2 component is a non-catalytic subunit 
of dolichol phosphate mannose synthetase. The complex was realised through a series 
of elegant functional cloning and co-immunoprecipitation experiments using 
individually epitope-tagged bait and prey components. A similar multi-subunit complex 
has been proposed in yeast where homologues for all the subunits, except DPM2, have 
been identified (Table 1.1) (Pittet and Conzelmann, 2007). However, experimental 
evidence for physical associations between most of these yeast subunits is lacking. The 
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T. brucei homologous of these components were found by BLASTp search, and the 
experimental determination of this complex is illustrated later in the results chapter. The 
ethanolamine phosphate transferase 2 complex contains TbGPI13, the catalytic subunit, 
that is stabilised by TbGPI11, as described in (Stokes et al., 2014). With respect to the 
GPI anchor transamidase, the catalytic (TbGPI8) subunit and the four other subunits 
(TbGAA1, TTA1 and TTA2 and TbGPI16) have all been shown to belong to the same 
complex (Nagamune et al., 2003) with TbGP16 being disulphide linked to TbGPI8 and 
shown to form a complex (Hong et al., 2006).  
 
 
Figure 1.11 Scheme of GPI anchor biosynthesis pathway of BSF T. brucei. 
 Each step is annotated with numbers sequentially and the enzymes catalysing each step are 
listed in Table 1.1. Red annotated enzymes are experimentally determined known components 
in this pathway. Enzymes annotated in amber are homologous to known GPI pathway 
components in mammalian and/or yeast cells but without experimental data. Enzymes annotated 
in blue are the unknown “missing links” in the T. brucei GPI pathway. 
 




Enzymes Genes Protein ranking in BSF proteomics (Ji et 
al., 2021) 

















2 GlcNAc-PI de-N-acetylase TbGPI12 
(Tb927.11.12080) 
5818 
3 Flippase Not identified  
4 α1-4 mannosyltransferase Ⅰ TbGPI14 (Tb927.6.3300) 7150 
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5 Inositol acyltransferase Not identified   
6 α1-4 mannosyltransferase Ⅱ TbGPI18(Tb927.10.13160) 7150 
7 α1-4 mannosyltransferase Ⅲ TbGPI10 (Tb927.10.5560) 5212 









10 GPI-phospholipase A2 Not identified   
11 Lyso-GPI acyltransferase Ⅰ TbGUP1(Tb927.10.15910) 4053 
12 GPI-phospholipase A1 Not identified  
13 Lyso-GPI acyltransferase Ⅱ Not identified  











1.4.2 Other known GPI pathway enzyme complexes in mammalian cells and 
yeast  
In addition to the GPI-GnT and GPI transamidase complexes, there are two more GPI 
pathway enzyme complexes known in mammalian cells and yeast.  
GPI-mannosyltransferase Ⅰ (GPI MTⅠ) that in mammalian cells and yeast transfers the 
first mannose to GlcN-(acyl)PI and produce Man1GlcN-(acyl)PI contains two subunits: 
The catalytic subunit PIG-M and its associated subunit PIG-X. PIG-M is an ER resident 
protein with its active site on the  lumenal side of the ER membrane (Maeda et al., 
2001) and PIG-X binds to and stabilises PIG-M (Ashida et al., 2005). The latter study 
also reported that Gpi14p and Pbn1p are the yeast homologous of PIG-M and PIG-X. 
The other GPI pathway complexes present in mammalian and yeast cells, but not in T. 
brucei, are the GPI ethanolamine phosphate transferase-2 (EtNP-T2) and ethanolamine 
phosphate transferase-3 (EtNP-T3) complexes. The common subunit in these two 
complexes PIG-F (Inoue et al., 1993), stabilises both PIG-G (Shishioh et al., 2005) and 
PIG-O (Hong et al., 2000), which are the catalytic subunits for EtNP-T2 and EtNP-T3, 
respectively.  
 
1.4.3 Enzymes involved in side-chain modifications of GPI-anchors  
The GPI anchor side-chain modifications produce structural microheterogeneity and 
also differentiate different organisms. The BSF T. brucei GPI anchor side-chain consists 
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of galactose components (Ferguson et al., 1988), whereas the PCF T. brucei GPI anchor 
side-chain carries sialylated poly-N-acetyllactosamine and poly-lacto-N-biose 
structures, reviewed in (Duncan et al., 2021). However, there are only a few enzymes 
have been identified catalysing the steps of the side-chain modification. The trans-
sialidase was the first enzyme found that modifies the GPI-anchored procyclins on the 
cell surface of PCF T. brucei (Engstler et al., 1993) (Pontes De Carvalho et al., 1993) 
(Montagna et al., 2002) (Montagna et al., 2006). Our lab has characterised three more 
enzymes that elaborate the GPI anchor side chain in PCF T. brucei, which are TbGT8, 
TbGT3 and TbGT10.  TbGT8 is a UDP-GlcNAc : β-Gal-GPI β1-3 GlcNAc transferase 
(Izquierdo et al., 2009) and TbGT10 is a UDP-GlcNAc : βGal β1-6 GlcNAc-transferase 
(Duncan et al., 2021). The absence of their enzymatic activity does not impair the 
growth of the PCF T. brucei in culture but results in incomplete glycan branches of the 
GPI-anchor. TbGT3 is a UDP-Gal : β-GlcNAc-GPI β1-3 Gal transferase. The PCF 
conditional null mutant of TbGT3 also shows a reduction in the molecular weight of the 
GPI-anchor side-chain glycans, but no defect in either cell growth or ability to infect 
tsetse flies (Izquierdo et al., 2015).  
In mammalian cells, βGalNAc appears to be a common side-chain modification of GPI 
anchors, catalysed by a GPI-specific GalNAc transferase PGAP4 (Hirata et al., 2018). 
Later, through CRISPR-Cas9 mediated phenotypic screening, Kinoshita’s group 
showed that the β1,3-galactosyltransferase 4 (B3GALT4), previously characterized 
GM1 ganglioside synthase, has a dual function in transferring galactose to a β1,4-linked 

















The aim of this project was to take new approaches to try to identify currently 
unidentified proteins that catalyse, or participate in, key steps of GPI anchor 
biosynthesis in T. brucei (Fig 2.1).  
The basic idea was to epitope tag known components of the GPI biosynthetic pathway 
and perform affinity immunoprecipitation experiments with antibodies to the tags. In 
parallel, I performed affinity immunoprecipitation from non-tagged cells to exclude  
non-specifically bound proteins. We then investigated label-free, cross-linking and 
stable isotope labelling in cell culture (SILAC) proteomics methodologies (Fig 2.1). We 
hope that some of the proteins specifically pulled down with the tagged GPI pathway 
enzymes may also be GPI pathway components, based on the fact that it is quite 
common for proteins involved in biosynthetic pathways to be physically associated with 
each other.  
We tested this idea by seeing whether the pull-down of the GlcNAc-PI de-N-acetylase 
(TbGPI12) also pulls-down the first mannosyltransferase (MTⅠ), and vice-versa. This 
association has been predicted from biochemical data that suggest substrate channelling 
between the two enzymes (Smith et al., 1996). Another test was to pull down the main 
catalytic subunit of GPI GlcNAc transferase, TbGPI3, to see if other subunits that are 
predicted to be associated with it can also be pulled down. We then applied the 
approaches and conditions successful to either of these test situations to the pull-downs 
of the tagged GPI enzymes such as TbdeAc2 (Honget al., 2006) and TbGup1 
(Jaquenoud et al., 2008), that catalyse inositol-deacylation and the re-acylation the GPI 
anchor glycerolipid moiety (via acyl- (myristoyl-) transferase activity), respectively. 
With respect to the TbdeAc2-tag and TbGup1-tag pulldowns, our hypothesis was that 
we may also capture upstream and downstream ‘missing components’ of the fatty acid 
remodelling machinery. For example, we might expect GPI-phospholipase A2 (PLA2), 
GPI-phospholipase A1 (PLA1), GPI-inositol-acyltransferase and/or fatty acid 
remodelling myristoyltransferases to be found in this way (see Fig 1.11). We would 
look for sequence motifs typical of such enzymes (for example, GDSL/A lipase or 
HDXXY and YXGXG PLA2 motifs) in the co-immunoprecipitated proteins. If so 
identified, we would attempt to construct conditional null mutants of these genes to 
assess (a) whether they are essential to the parasite in vitro and/or in vivo, and therefore 
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potential drug targets, and (b) to prepare cell-free systems from parasites where the 
proteins are missing (or at very low levels just prior to cell death) to provide 
biochemical evidence for the activity of the gene products. Tagged-proteins may also be 
immunoprecipitated to perform on-bead digestions to test the enzymatic activity using 






















3 Materials and Methods 
3.1 Reagents  
All general chemicals were purchased from Sigma or VWR BDH unless otherwise 
indicated. HPLC grade solvents were obtained from VWR BDH with the exceptions of 
acetonitrile (Thermo) and methanol (Sigma). 
 
3.2 Trypanosoma brucei cell culture  
3.2.1 T. brucei bloodstream form (BSF) cell lines and cell cultures  
T. brucei brucei Lister strain 427 bloodstream form (BSF) parasites expressing VSG 
variant 221 (also known as MITat1.2) and transformed to stably express T7 polymerase 
and the tetracycline repressor protein (TetR) under G418 antibiotic selection (Wirtz et 
al., 1999) was used in this study and will be referred as bloodstream form wild type 
(BSF WT). BSF WT cells were cultivated in HMI-11T medium containing 2.5 µg/mL 
G418 at 37˚C in a 5% CO2 incubator as previously described (Wirtz et al., 1999). HMI-
11T is a modification of the original HMI-9 (Hirumi and Hirumi, 1989) that uses 56 
mM 1-thioglycerol in place of 200 mM 2-mercaptoethanol, and contains 10% heat 
inactivated fetal bovine serum (PAA) and lacks of serum plus (Hazleton Biologics, 
Lenexa, Kansas) (Table 3.1).  
Bloodstream form T. brucei Lister 427 (MITat 1.2), clone 221a, 2T1 cells (Alsford et 
al., 2005) were used for the RNA interference (RNAi) knock down using the pRPa 
construct in this study and will be referred as bloodstream 2T1 wild type (BSF 2T1 
WT). BSF 2T1 WT cells were cultivated in HMI-11T medium containing 1 µg/mL 
phleomycin, 1 µg/mL puromycin. 
Bloodstream form T.brucei Lister 427 (MITat1.2), clone 221a, 2T1T7-Cas9 cells (Rico et 
al., 2018) were used for CRISPR Cas9 mediated gene manipulations and will be 
referred as bloodstream form Cas9 wild type (Cas9 WT). Cas9 WT cells were cultivated 
in HMI-11T medium containing 2 µg/mL blasticidin and 1 µg/mL hygromycin.  
All  BSF cells were maintained in culture to mid log (1-2 × 106 cells/mL) and then sub-




3.2.2 T. brucei procyclic form cell line and cell culture 
T. brucei brucei Lister 427 procyclic form (clone 29.13.6) that stably expresses T7 
polymerase and tetracycline repressor (TetR) protein under G418 and hygromycin 
antibiotic selections, respectively, was used in this study and will be referred as 
procyclic wild type (PCF WT). PCF WT was cultivated in SDM-79 medium (Table 3.1) 
containing 15 µg/mL G418 and 50 µg/mL hygromycin in a 28 °C incubator to the mid 
log (3-5 × 107 cells/mL) and sub-cultured to fresh medium at a density of 1-2 × 106 
cells/mL. 
Table 3.2 lists the concentration of antibiotics used to maintain selection for the cell 
lines used in this study.  
  
Table 3.1 Full composition of culture media. 






18 g HMI-9 powder  Invitrogen 
36 mM NaHCO3  VWR 
2 mM glutamine  Invitrogen 
10% FBS heat inactivated  Thermo Fisher 





25 g SDM-79 powder  Invitrogen 
24 mM NaHCO3  VWR 
11.5 μM haemin  Sigma 
0.2 mM glutamine  Invitrogen 
10% FBS heat inactivated  Thermo Fisher 
  
Table 3.2 Antibiotics used in the cell culture and genetic manipulation of T. brucei. 












4  15 Gibco 
Hygromycin Hygromycin phosphotransferase 
(HYG) 
4 1 50 Roche 
Puromycin Puromycin acetyltransferase 
(PAC) 
0.1 1 1 Sigma 
 
Phleomycin Phleomycin resistance protein 
(PHLEO) 
1 1 1 Invitrogen 
Blasticidin Blasticidin S deaminase 2.5 2 10 Invitrogen 




3.3 General T. brucei cell culture protocols 
3.3.1 Cell density determination 
To determine the cell density, T. brucei bloodstream form cells were counted on a 
Neubauer haemocytometer directly or diluted 1:10 in 1× trypanosome dilution buffer 
(TDB) (Table 3.3). While for T. brucei procyclic form cells were first diluted 1:10 in 
counted 1× phosphate buffer saline (PBS) (Sigma) or in SDM-79 medium with viability 
assessed and cells counted on a haemocytometer. 
  
Table 3.3 5 × Trypanosoma Dilution Buffer (TDB). 
Composition pH Chemicals/L (g) 
KCl  1.86 
NaCl  23.4 
MgSO4·7H2O 7.4 1.23 
Na2HPO4  14.2 
NaH2PO4·2H2O  1.56 
Glucose  18 
 
3.3.2 Generation of stabilates for cryo-preservation  
For generation of the stabilates for cryo-preservation, 10 mL of T. brucei bloodstream 
form cells were grown to mid log phase (1-2 × 106 cells/ml) and collected by 
centrifugation (800 g for 10 min at 4°C). The cell pellets were resuspended in 1.5 mL 
HMI-11T medium containing 10% glycerol without antibiotics. Aliquots of 0.5 mL 
were transferred to 2 mL Cryovials (Alphalab), frozen overnight at -80 °C and then 
transferred to liquid nitrogen for long-term storage. 
For T. brucei procyclic form, 10 mL cells were grown to mid-log phase (2 × 107 
cells/ml) and centrifuged (600 g for 10 min at 4°C), the pellets were resuspended in 1.5 
mL SDM-79 containing 10% glycerol without antibiotics. Aliquots of 0.5 ml were 
transferred to Cryovials, frozen overnight at -80 °C and then transferred and stored 




3.3.3 Generation of clonal cell lines 
For bloodstream T. brucei cell lines, clonal parasite cell lines were obtained by limit 
dilution. Mid-log parasites were diluted to a density of 1.65 cells/mL in fresh culture 
medium with suitable antibiotics and then dispensed into a 96 well plate with 200 
µl/well. Growth was monitored over the following 5-7 days and cells collected for 
further analysis. 
 
3.3.4 T. brucei bloodstream form electroporation  
Bloodstream form cells were grown to mid log phase density (1-2 × 106 cells/mL), 
centrifuged (800 g for 10 min at 20 °C) and resuspended in either 100 µL Human T-Cell 
Nucleofector® solution containing supplement (Lonza) or 100 µL cytomix buffer 
(Table 3.4) made in house, transferred into the supplied cuvette and subjected to 
electroporation using Amaxa Nucleofector™ electroporator with program X-001, or 
program Z-001 for CRISPR Cas9 edition. For each cuvette, 1 × 107 cells alongside 1– 
20 µg of ethanol-precipitated DNA (Section 3.4.15) were used for each transfection. 
One cuvette without DNA was served as a negative control for each experiment. After 
the electroporation, the cells from each cuvette were transferred to 10 mL or 50 mL 
HMI-11T medium and allowed to recover for 6-8 h or overnight at 37°C before adding 
selection antibiotics. The choice of DNA amount and cell recovery time ranges 
depended on the experimental purposes. For in situ epitope tagging, 20 µg DNA was 
used per transfection and the cells were recovered overnight before adding selection 
antibiotics. For generation overexpression or RNAi knock down cell lines, 2 µg 
linearised plasmid was used and the cells were recovered for 6-8 h before antibiotics 
were added. For knock out constructs, 10 µg DNA was used for transfection and the 
recovery time for the cell line was overnight. For CRISPR Cas9 mediated gene 
manipulation transfection, single guide RNA (sgRNA) and repair templates mixture (20 
µg) was electroporated to the cells and the antibiotic was added after the cells recovered 
overnight.  
 
Table 3.4 Cytomix buffer. 
Composition pH 
2 mM EGTA  
120 mM KCl  
   25 mM HEPES  
50 
 
5 mM MgCl2·6H2O  
0.5% Glucose 7.6 
100 µg/mL defatted BSA  
1.0 mM Hypoxanthine  
10 mM KH2PO4  
10 mM K2HPO4  
3.4 Molecular biology protocols 
3.4.1 In silico analyses and searches of DNA and protein sequences 
For T. brucei, DNA and amino acid sequences for genes of interest were retrieved from 
TriTrypDB (Aslett et al., 2010) in FASTA format (http://tritrypdb.org/tritrypdb/). 
Untranslated regions of genes were identified based on the latest released whole genome 
sequencing (Müller et al., 2018) for T. brucei Lister 427 strain but also taking the 
annotations for T. brucei 927 strain into account.  
For identification of putative subunits of UDP-GlcNAc : PI α1-6 GlcNAc-transferase 
(GPI GnT) complex in T. brucei, conventional BLASTp with default settings (Acland et 
al., 2012) or Domain Enhanced Lookup Time Accelerated BLASTp (Boratyn et al., 
2012) were applied to find the homologous. The protein sequences of mammalian cells 
and yeast were retrieved from UniProt (Bateman et al., 2021), and the gene IDs of the 
query input sequences are listed in (Table 5.1). Protein sequence multiple alignments 
were assembled and visualised using ClustalW (Chenna et al., 2003). In silico plasmid 
constructs sequences used in this study were all assembled using CLC Main Benchwork 
(CLC Bio). The applications in this software also allowed for the design of 
oligonucleotide primers, sequence alignment, and in silico cloning and endonuclease 
digestion mapping.  
 
3.4.2 Primers 
Primers used for different applications in this study were listed from (Table 3.5) to 
(Table 3.11). Primers were designed using CLC Main Benchwork with following 
features: ⅰ, they should contain ~45 – 55 % guanine-cytosine (GC) content and the 3’ 
end of the primer should have a guanine (G) or cytosine (C); ⅱ, the melting temperature 
(Tm) of the primers were mainly calculated by the NEB Tm Calculator 
(https://tmcalculator.neb.com/#!/main) and less than 5 °C difference in Tm between 
primer pairs were designed. The primers were synthesised either by Thermo Fisher or 




3.4.3 Polymerase chain reactions (PCR) 
Polymerase chain reactions (PCR) for DNA amplification were carried out using Q5® 
High-Fidelity DNA polymerase (New England Biolabs) or LongAmp® DNA 
polymerase according to the manufacturer’s instructions. The template concentrations 
used ranged from 1 – 10 ng for genomic DNA (gDNA), 10 – 100 pg for purified 
plasmid DNA and optimised for each target of interest. The general conditions and 




Table 3.5 List of primers used for in situ epitope tagging proteins in this study. 
Oligo Names  Description Gene ID Sequence Lower case letters  
OL1 (Forward) In situ epitope 
tagging TbGPI3 















OL3 (Forward) In situ epitope 
tagging TbdeAc2 














OL5 (Forward) In situ epitope 
tagging 
Tb927.11.11740 














OL 7 (Forward) In situ epitope 
tagging TbdeAc2 
with 12 × c-Myc 
Tb927.3.2610 5’-cccaagcttGCACACGGCTGTTGTTATG-3’ HindⅢ  




Table 3.6 List of primers for generation the RNAi knock down and overexpression plasmid. 
Oligo Names  Description Gene ID Sequence Restriction sites  
OL9 (Forward) Generation of RNAi knock down 




5′-CCGCTCGAGTGTCCAGGTGGTTCATCGTG-3′ XhoⅠ  
OL10 (Reverse) 5’-CGGGATCCTCCCTCCCCATCGTACCAATA-3’ BamHⅠ 
OL11 (Forward) Generation of RNAi knock down 



























Table 3.7 List of primers for Gibson assembly in this study. 
Oligo Names  Description Gene ID Sequence  
OL15(Forward) Amplification of CDS of 
Tb927.11.11750 for Gibson 
assembly 
Tb927.11.11750 5’-GTAAAATTCACAAGCTTTAGATGATGCGTCCACTCTCAC-3’  
OL16(Reverse) 5’-CCAACTAAATGGGCAGGATCCTTAGACAGCCATCTTTTGTTTAAAC-3’ 
OL17(Forward) Amplification of linearised 




OL19 (Forward) Amplification of 12 × c-Myc 
with optimised codon for 
Gibson assembly  
Tb927.11.11750 5’-ATATCGGATCCGGCCCCCGCTCGAGGAGCAAAAGCTTATTAGCGAG-3’  
OL20 (Reverse) 5’-TACGCCAAGCTTTGGCACGCGTCGACGCGCGGGAGATCCTCCTCCGA-3’ 
OL21 (Forward) Amplification of linearised 
plew100_v5 
Tb927.11.11750 plasmid for 
Gibson assembly 
5’-TCGGAGGAGGATCTCCCGCGCTACGTGCTGGAGCTTGTCCA-3’  
OL22 (Reverse) 5’-CTCGCTAATAAGCTTTTGCTCCGAGCAATTTGCGCCCGTAG -3’ 
OL23 (Forward) Amplification of 5’UTR of 






OL24 (Reverse) 5’-GTACTCGGTCATAATGCGTTACGGCTTGTGTG-3’  
OL25 (Forward) 5’-GCCGTAACGCATTATGACCGAGTACAAGCCCACGGTG -3’  
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OL26 (Reverse) Amplification of PAC for 
Gibson assembly  
5’-ACCTGTATAACATctaGGCACCGGGCTTGCG -3’ 
OL27(Forward) Amplification of 3’UTR of 
Tb927.11.11750 for Gibson 
assembly  
5’-CCCGGTGCCTAGATGTTATACAGGTCGCTATG -3’  
OL28(Reverse) 5’- GGTACCCGGGGATCCTCTAGAGTCGAGAGCCTGAGCTTTGAAGGTA-3’ 
OL29(Forward) Amplification of linearised 
vector pUC57 
5’- CGACTCTAGAGGATCCCCG-3’  
OL30(Reverse) 5’-CATGCAAGCTTGGCGTAATC-3’ 
OL31(Forward) Amplification of HYG for 
Gibson assembly 
Tb927.11.1150 5’-AAACCCCGGCATTATATCGAAGCTTATGAAAAAGCCTGAACTCAC-3’  
OL32(Reverse) 5’-ATAGCGACCTGTATAACATGGATCCCTATTCCTTTGCCCTCGG-3’ 
OL33(Forward) Amplification of linearised 
pUC57-PAC KO construct 




Table 3.8 List of primers for real time RT-qPCR. 
Oligo Names  Description Gene ID Sequence  
OL35 (Forward) Amplicons of identical region of 
Tb927.11.11740 & Tb927.11.11750 
Tb927.11.1140 & 
Tb927.11.11750 
5′- ACGACTGGATGCTGTTGCAACTG-3′  
OL36 (Reverse) 5’-ATTCCCAAAAGAAGTTCCTGTGCCAA-3’ 
OL37 (Forward) Amplicon of specific region of 
Tb927.11.11750 
 Tb927.11.11750 5’-ATGCGGATGAAGCGATTCTCACA-3’  
OL38 (Reverse) 5’-TCACCGGGTACATTTCAACCATG-3’ 
 
Table 3.3.9 List of primers for sgRNA used for CRISPR Cas9 mediated gene manipulation 
Oligo Names  Description Gene ID Sequence  







Amplification of sgRNA for CRISPR 









Table 3.10 List of primers used for probe synthesis for Southern blot. 
Oligo Names  Description Gene ID Sequence  
OL41 (Forward) Amplification of 1000 bp identical 




5′- ATGATGCGTCCACTCTCACTTG-3′  
OL42 (Reverse) 5’-ACACTTCCGTAGTGTCGTCA-3’ 
OL43 (Forward) Amplification of PAC ORF  5′- ATGACCGAGTACAAGCCCACG-3′  
OL44 (Reverse) 5′- TCAGGCACCGGGCTTGCG-3′ 
OL45 (Forward) Amplification of HYG ORF  5′- ATGAAAAAGCCTGAACTCAC-3′  
OL46 (Reverse) 5′- CTATTCCTTTGCCCTCGGA-3′ 
  
Table 3.11 List of primers for genotype check for mutant cell lines. 
Oligo Names  Description Gene ID Sequence  
OL47 (Forward) Amplification of CRISPR Cas9 mutant 




5′- ATAACACTGTGTAGTGCGA-3′  
OL48 (Reverse) 5’-TTAGACAGCCATCTTTTGTTTAAAC-3’ 
OL47 (Forward) Amplification of original locus of 
Tb927.11.11750 (section 6.8.2) 
Tb927.11.11750 5′- ATAACACTGTGTAGTGCGA-3′  
OL49 (Reverse) 5′- TCAGGCACCGGGCTTGCG-3′ 
OL51 (Forward)  5′- ATGAAAAAGCCTGAACTCAC-3′  
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OL52 (Reverse) Amplification of BSD replaced 





Table 3.12 PCR amplification reactions and program. 
PCR reaction of Q5® High-Fidelity DNA polymerase 
Component Volume (µL) Final concentration 
5× Q5 reaction buffer 10 1× 
 10 mM dNTP mix  1 200 µM 
10 µM forward primer 2.5 0.5 µM 
10 µM reverse primer 2.5 0.5 µM 
Template DNA variable < 1,000 ng 
Q5 High-Fidelity DNA Polymerase 0.5 1 U 
5× Q5 High GC Enhancer 5 1 × 
ddH2O* to 50 µl   
Thermo cycle programme 
Step Temperature (°C) Time (sec) Number of cycles 
Initial denaturation 98 30 1 
Denaturation 98 10 
35 Annealing 50 - 72 30 
Elongation 72 20 - 30 /kb 
Final extension 72 120 1 
 
PCR reaction of LongAmp® Tag DNA polymerase 
Component Volume (µl) Final concentration 
5× LongAmp Taq Reaction Buffer 10 1× 
 10 mM dNTP mix  1.5 300 µM 
10 µM forward primer 2 0.4 µM 
10 µM reverse primer 2 0.4 µM 
Template DNA variable < 1,000 ng 
LongAmp Taq DNA Polymerase 2 5 U 
ddH2O to 50 µl   
Thermo cycle programme 
Step Temperature (°C) Time (sec) Number of cycles 
Initial denaturation 94 30 1 
Denaturation 94 30 
30 Annealing 45 - 65 50 
Elongation 65 20 - 30 /kb 
Final extension 65 600 1 
*: ddH2O = double-distilled water  
 
3.4.4 Agarose gel electrophoresis 
DNA samples in this study were analysed by agarose gel electrophoresis. Agarose 
(VWR) were prepared in 1 × TAE buffer (40 mM Tris, 20 mM acetic acid, and 1 mM 
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EDTA) at 0.8% (w/v) containing 0.4 µg/mL ethidium bromide. For loading, DNA 
samples were mixed with 1× Blue Loading Dye (Promega) while 1kb DNA ladders 
(Promega) were served by side to indicate the size of the DNA fragments. The 
electrophoresis was carried out at 40-120 V in 1× TAE buffer with BioRad Mini-Sub 
Cell GT tanks until the desired separations for DNA fragments were achieved. The gels 
were visualised and imaged with a GelVue UV Transilluminator on a UGenius gel 
documentation system (Syngene).     
 
3.4.5 Gel extraction and PCR purification of DNA fragments 
Plasmid vectors or DNA fragments digested with endonuclease enzymes were separated 
and visualised using a UV transilluminator (Merck), gel bands of interest were excised, 
and DNA fragments were extracted with a Gel Extraction kit (Qiagen) according to 
manufacturer’s instructions. PCR amplified DNA fragments were cleaned up using a 
PCR Purification kit (Qiagen) following the manufacturer’s instructions. Final purified 
DNA was eluted with 2 mM TrisHCl (pH 8.5).  
 
3.4.6 Quantification of DNA concentration of purity 
The concentration of DNA was quantified on a NanoDrop 1000 Spectrophotometer 
(NanoDrop) through the absorption at 260 nm (A260), the purity of the DNA was 
estimated by checking the ratio of A260 to A280 (nucleic acid to protein).  
 
3.4.7 Restriction endonuclease digestions  
All endonucleases that were used in this study were purchased from New England 
Biolabs (NEB) and used according to the manufacturer’s instructions. Analytical 
digestions were carried out for 1-2 h while preparative digestions were performed 
overnight. For double digestions, the optimum reaction conditions were checked using 
the Double Digest Finder tool (https://nebcloner.neb.com/#!/redigest). Digestion mxi or 




3.4.8 Transformation of E. coli competent cells  
For routine transformations of the ligation reactions, DH5α competent cells from MRC 
PPU reagents units (University of Dundee) were used. 50 µL competent cells were 
mixed with 1-5 µL 1-100 ng purified plasmid DNA or the ligation reaction generated 
with T4 ligase from Promega (Section). Cells were incubated on ice for 20 minutes 
before heat-shocked at 42 °C for 30 seconds, following by cooling on ice for 2 minutes. 
1 mL Super Optimised Broth (SOC) medium were added to the cells and the 
transformed cells were incubated at 37 °C with agitation at 200 rpm for 1h. 50-200 µL 
aliquot of the cells was then spread onto Lysogeny Broth (LB) agar plate containing 
appropriate antibiotic for selection. Plates were then incubated overnight at 37 °C and 
individual colonies were then selected for further analysis. For Gibson assembly 
reactions, NEB® 5α Competent E. coli cells (NEB) within the kit was used for the 
transformation while for the T/A cloning for sequencing the Cas9 mutant clone 1 
(Section 6.6.3) the competent cells that was supplied within the kit (Aligent, 
StrataClone PCR Cloning Kit) was used. The transformations for these two experiments 
were performed following the manufacturer’s instructions.  
 
3.4.9 Bacterial culture and storage  
Recovered colonies from the transformation were picked up and inoculated into LB 
liquid medium with suitable antibiotic (Ampicillin 50 µg/mL), the bacteria were 
cultured overnight at 37°C with agitation at 200 rpm and subjected for plasmid DNA 
extraction. For long term storage, bacteria stabilates were prepared by mixing equal 
volumes of bacteria culture with 80% (v/v) glycerol. The stabilates were flash-frozen on 
dry-ice prior transferring to -80°C freezer. All media were prepared and sterilised by 
autoclavation by Central Technical Services at the University of Dundee.  
 
3.4.10 Purification of plasmid DNA 
Plasmid DNA was purified from E. coli cell pellet harvested from 5 mL LB culture 
using the QIAprep® Spin Miniprep Kit (Qiagen) following the manufacturer’s 
instructions. For large scale preparation, 100 mL bacterial cells were prepared at log 




3.4.11 Dephosphorylation  
To minimise the self-ligation background when performing the ligation, plasmids that 
were digested with endonuclease were dephosphorylated prior to the ligation reaction. 
The plasmid was incubated with Antarctic Phosphatase (NEB) according to 
manufacturer’s instructions and the reactions was stopped by heat-inactivation at 80 °C 
for 20 minutes.  
 
3.4.12 Ligation  
Linearised plasmids and endonuclease digested inserts that contained cohesive ends 
were ligated using T4 DNA ligase (NEB or Promega). Plasmid backbone and insert 
DNA fragments were mixed in equimolar with a ratio of 1:1 or 1:3 in 10 µL reaction 
volume with supplement of 1× Ligase Buffer and T4 DNA ligase. In general, 100 ng of 
the plasmid DNA was used for the reaction and an additional ligation without insert was 
performed as an indication of self-ligation of the plasmid. Reactions were incubated for 
1-2 h at room temperature or overnight at 4 °C followed by transformation described in 
Section 3.4.8.  
For T/A end cloning, the ligation was set up following the instructions of StrataClone 
PCR Cloning Kit (Agilent) and the transformation was described in Section 3.4.8.  
 
3.4.13 Gibson Assembly 
For generation the plew100_v5 internal 12 × c-Myc tagged Tb927.11.11750 plasmid 
and the knock out constructs for Tb927.11.11740 and/or Tb927.11.11750, Gibson 
Assembly reactions were performed to DNA fragments following manufacturer’s 
instruction of NEBuilder® HiFi DNA Assembly kit(Table 3.13) (NEB). The reactions 
were then transformed to supplied competent bacteria cells according to the 
manufacturer’s instruction.  
 






DNA molar ratio vector:insert = 1:2 vector:insert =1:1 
 Total amount of fragments  0.03-0.2 pmol (X µL) 0.2-0.5 pmol (X µL) 
NEBuilder HiFi DNA Assembly Master Mix 10 µL 10 µL 
ddH2O (10 – X) µL (10 – X) µL 
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Total volume 20 µL 20 µL 
 
3.4.14 DNA sequencing  
DNA sequencing in this study was performed by the DNA Sequencing and Services 
(MRC PPU, University of Dundee, http://www.dnaseq.co.uk.) using Eurofins MWG 
Operon (i54 Business Park, Valiant Way, Wolverhampton, WV9 5GB) SmartSeq kit 
sequencing by cycle sequencing technology on Applied Biosystems model 3730XL 
DNA sequencer. DNA sequencing data was the analysed on CLC Main Workbench 
(CLC bio). 
 
3.4.15 Ethanol precipitation  
To concentrate and purify DNA for transfection into T. brucei, a 10% volume of 3 
molar (M) sodium acetate pH 5.3 and 3 × volume of 100 % ethanol were added to the 
DNA sample and the mixture was gently mixed and incubated at -20 °C for overnight. 
Precipitated DNA was centrifuged at 13,000 × g for 10 min at 4 °C and washed three 
times with 70% ice cold ethanol, the supernatant was removed by centrifugation at 
13,000 × g for 10 min at 4 °C. Resulting DNA pellet was air-dried in sterile hood and 
re-suspended with sterile water for further usage.  
 
3.4.16 Quantitative reverse transcription polymerase chain reaction (RT-qPCR) 
To perform quantitative reverse transcription polymerase chain reaction (RT-qPCR) on  
QuantStudio™ 3 Real-Time PCR System for checking the transcriptional level of gene 
of interest, total RNA was extracted from 1 × 107 T.brucei cells using RNAeasy kit 
(Qiagen) according to manufacturer’s instructions. RT-qPCR reaction was then set up 
for RNA samples using the Luna Universal One-Step RT-qPCR Kit (NEB). The 
protocol used for the RT-qPCR Kit was summarised in Table 3.14. 
 
Table 3.14 RT-qPCR reaction and program. 





Luna Universal One-Step reaction Mix (2×) 10 1 × 
Luna WarmStart® RT enzyme mix (20×) 1 1 × 
10 µM forward primer 0.8 0.4 µM 
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10 µM Reverse primer 0.8 0.4 µM 
 20 ng µl-1 template RNA 5 100 ng 
Nuclease-free water to 20    
Thermal cycles 
Cycle Step Temperature (°C) Time (sec) Number of cycles 
Reverse transcription 55  600 1 
Initial denaturation 95  10 1 
Denaturation 95  10 
40 
Extension 60  30 
Melt curve 
95  15 
1 60  60 
95  15 
 
 
3.4.17 Southern blotting  
3.4.17.1 Probe synthesis   
The DNA probes used in this study were digoxigenin (DIG)-labelled. These were 
generated using PCR DIG Probe Synthesis Kit (Roche) according to the protocol 
summarised in Table 3.15. For each probe, a reaction which uses normal dNTP solution 
was included as a control to indicate the specificity and efficiency of the DIG-labelled 
probe synthesis. Pair of primers for synthesis different probes were listed in (Table 
3.10).  
 
3.4.17.2 DIG-labelled probe detection  
For analysis of T. brucei mutants, 5 µg of gDNA from the clones were digested solely 
with NcoⅠ or double digested with NcoⅠ and EcoRⅤ (NEB) overnight at 37 °C. RNAase 
(Sigma) was added to the reaction to avoid RNA contamination for later detection. 
Endonuclease digested gDNA was separated on a 0.8% (w/v) agarose gel for 4 h at 40 
V in TAE buffer and imaged as described in Section 3.4.4. The gel was then washed 
with 0.25 M HCl with mild agitation (30 rpm) for 10 min to depurinate the DNA 
following by 15 min denaturation with 0.5 M NaOH and 20 min neutralisation with 
buffer 1 M Tris-HCl, 1.5 M NaCl, pH 7.5. After these washing steps, the DNA samples 
were transferred to a positively charged nylon membrane (Roche) through reverse 
capillary action overnight with 10 × saline-sodium citrate buffer (SSC) buffer.  
Transferred DNA fragments were covalently cross-linked to the membrane by UV 
cross-linking in a CL-100 (UVP) UV crosslinker at 1200 mJoules. The membrane was 
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pre-incubated with 20 mL DIG Easy Hyb™ Granules solution (Roche) at 42 °C for 1 h 
in a hybridisation oven (Techne™ Hybridisation Oven). The DIG-labelled probe 
(Section 3.4.17.1) was denatured for 5 min at 100 °C following by a rapid cool down on 
ice prior to mixing with 20 mL DIG Easy Hyb™ Granules solution. The membrane was 
incubated overnight with this hybridisation solution with 20 µL denatured probe. 
Following the hybridisation, the membrane was washed twice with low-stringency 
condition (42 °C, 5 min, 1 × SSC with 0.01% (w/v) SDS) and high-stringency condition 
(65 °C, 15 min, 0.5 × SSC with 0.01% (w/v) SDS) sequentially. The blot was then 
developed with DIG wash and block buffer set (Roche) following the manufacturer’s 
instructions. In general, the blot was equilibrated in 1 × wash buffer for 5 min at room 
temperature before being blocked in blocking buffer for 30 min. The anti-DIG AP-
conjugate antibody (Roche) was then added to the blocking buffer with a 1:10,000 
dilution and the blot was incubated further for 30 min followed by 15 min washing with 
1 × wash buffer for twice. The membrane was placed in a plastic folder and 
chemiluminescent substrate CSPD (Roche) was applied and incubated for the detection. 
The blots were exposed onto Amersham Hyperfilm™ ECL film for 1-30 min and 
developed with a KODAK film developer. For stripping the blot, 0.4 M NaOH was 
applied to the membrane and washed for 5 min at 42 °C in the hybridisation oven for 
twice. The blot was then washed with 1 x SSC buffer for 10 min at 42 °C for three times 
before re-probing.  
 










 10× PCR buffer with MgCl2 5 5 1× 
PCR DIG probe synthesis mix 5 - 
200 µM dATP, dCTP, dGTP, 130 
µM dTTP, 70 µM DIG-dUTP 
dNTP stock solution - 5 200 µM each dNTP 
10 µM forward primer 5 5 1 µM 
10 µM reverse primer 5 5 1 µM 
Enzyme mix 0.75 µl 0.75 µl  
DNA template (100 pg/µL) 1 µl 1 µl 100 pg 
 Thermal cycles    
Step Temperature (°C) Time (sec) Number of cycles 
Initial denaturation 95 120 1 
Denaturation 95 30 20 
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Annealing 60 30 
Elongation 72 40 
Final elongation 72 420 1 
 
3.4.18 CRISPR-Cas9 mediated gene editing  
3.4.18.1 Design of sgRNA 
Single-guide RNA (sgRNA) sequences used for CRISPR-Cas9 gene editing were 
designed using following criteria: ⅰ, sgRNA sequence were chosen besides the 
protospacer adjacent motif (PAM, 5′-NGG-3′) with a general high melting temperature 
(Tm); ⅱ, the GC content of the 6 nucleotides preceding the PAM site were at least 50%; 
ⅲ, there should not be any TT or GCC motifs ahead of the PAM site. The sgRNA 
sequence was then BLAST searched against T. brucei genome to minimise any off-
target effect.  
 
3.4.18.2 PCR amplification of sgRNA 
To generate double stranded sgRNA, PCR reactions were set up as described in (Table 
3.16) with OL39 and OL40 primers using Q5® High-Fidelity DNA polymerase (NEB). 
OL39 was a gene specific primer while OL40 was a universal primer used for T. brucei 
CRISPR Cas9 editing (Rico et al., 2018). The success of the annealing of the primers was 
checked on a 1% (w/v) agarose gel.  
 
 
Table 3.16 Amplification of sgRNA for CRISPR Cas9. 
Reaction mix 
Reagent Volume (µl) Final quantity 
5× Q5 reaction buffer  8 1× 
10 µM gene-specific forward primer 8 2 µM 
10 µM G00 reverse primer (sgRNA scaffold) 8 2 µM 
 10 mM dNTP mix  0.8 0.2 mM 
Q5 HiFi Polymerase 1.2 2.4 U 
ddH2O to 40 µl   
 Thermal Cycles  
Step Temperature (°C) Time (sec) Number of cycles 
Initial denaturation 98 30 1 




3.5 Protein biochemistry  
3.5.1 Stable isotope labelling in cell culture (SILAC) of T. brucei BSF and PCF 
For stable isotope labelling in cell culture of T. brucei BSF cells, HMI-11T medium 
used for culturing was prepared as described in (Table 3.1) with changes in the 
following components: ⅰ, the usage of dialysed heat-inactivated FBS (PAA labs); ⅱ, the 
addition of folic acid (Sigma); ⅲ, the addition of stable isotope  labelled L-arginine:HCl 
(13C6) (R6) and L-lysine:HCl 4(13C4)  (K4). For PCF, SDM-79 medium was prepared 
as described in (Table 3.1) with the changing to dialysed heat-inactivated FBS and 
addition of stable labelled R6K4 amino acids.  
The SILAC labelling of the cells were performed as described (Urbaniak et al., 2012). 
In general, for T. brucei BSF, the cells were kept in culture in the HIM11-T + R0K0 
medium for several divisions to let the cell adapt to the relatively low Arg and Lys 
medium. The BSF WT cells were then kept in culture with the HMI11-T + R0K0 
medium while the mutant cell lines were cultured with HMI11-T + R6K4 medium. 
Cells were cultured for nine divisions to allow full labelling to steady-state and to reach 
mid log phase. For T. brucei PCF, cells were inoculated directly to the SDM-79 + R0K0 
or + R6K4 medium and nine divisions time were allowed to achieve full labelling to 
steady-state.  
 
3.5.2 T. brucei cell lysate preparation  
For general cell lysate preparation of T. brucei, 5 × 106 – 1× 107 log phase of T. brucei 
BSF and PCF cells were harvested and washed twice with 1 × TDB buffer (BSF) or 1 × 
PBS (PCF) cells at 4°C. After the last wash, the cells were transferred to 1.5 mL 
Eppendorf tube and pelleted for 10 s at 16,000 g following by re-suspension in equal 
volume of corresponding buffer and 2 × sodium dodecyl sulphate polyacrylamide 
(SDS) sample buffer (Table 3.16) with addition of 100 mM DTT at final concentration. 
The cell lysate was then heated up at 50°C for 20 min before further analysis. After 
cooling down, nuclease (Pierce™ Universal Nuclease for Cell Lysis) was added to 
samples to decrease the DNA viscosity.  
 
Annealing 50 30 
Elongation 72 15 
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Table 3.17 4 × SDS sample buffer for Licor. 
Composition pH Amount  
Tris-HCl  0.666 g 
EDTA  0.006 g 
SDS 8.5 0.4 g 
Glycerol  4 g 
Orange G  0.02 g 
ddH2O  to 10 mL 
 
3.5.3 Cross-linking using DTSSP 
For cross-linking reactions, 2 × 108 or 1 × 109 of T. brucei PCF and BSF cells were 
harvested at 600 g or 800 g, respectively, 4 °C for 10 min and subjected to hypotonic 
lysis with water containing 0.1 mM Nα-Tosyl-L-lysine chloromethyl ketone 
hydrochloride (TLCK), 1 µg /µL leupeptin, 0.1 mM phenylmethylsulphonylfluoride 
(PMSF) at 1 × 109 cells/mL. After incubation on ice for 5 min, the supernatants 
containing soluble cytosolic proteins were removed by centrifugation at 16,000 g for 
5min, 4C, except for the TbGPI3 cross-linking reaction where some experiments were 
carried out using the whole hypotonic cell lysate. The pelleted membrane fractions (or 
the whole cell lysates) were then re-suspended in 196 µL cross-linking reaction buffer 
(20 mM NaHEPES pH 7.8, 25mM KCl, 2 µg/µL E-64 (Sigma), 1 µg/µL leupeptin) 
containing different concentrations of cross-linker DTSSP (3,3'-
dithiobis(sulfosuccinimidyl propionate)) (Thermo). The reactions were carried out for 1 
h on ice and quenched by adding Tris-HCl buffer (pH8.0) to a 20 mM final 
concentration. The membranes were then pelleted (16,000 g, 10 min, 4C), resuspended 
in 1 mL washing buffer (50 mM Tris-HCl, pH7.4, 150 mM NaCl) pelleted again and 
solubilised in 196 µL lysis buffer (50 mM Tris-HCl, pH7.4, 150 mM NaCl, 2% TX-
100) containing protease inhibitors (0.1 mM TLCK, 1 µg /µL leupeptin, 1 µg /µL 
aprotinin, 0.1 mM PMSF) and immunoprecipitation was performed described in Section 
3.5.4.  
 
3.5.4 Immunoprecipitation  
For immunoprecipitation, cells were harvested at 600 g (for PCF) or 800 g (for BSF), 
4 °C for 10 min and then lysed in 1 mLlysis buffer (50 mM Tris-HCl, pH7.4, 150 mM 
NaCl containing different detergents; 0.5% digitonin, 1% digitonin, 1% Triton X-100 
68 
 
(TX-100), 1% n-octyl-beta-glucoside (NOG) or 1% decyl-β-D-maltopyranoside (DM)) 
with final concentration equivalent to 1 × 109 cells/mL. All buffers contained 1 mM 
TLCK, 1 µg /mL leupeptin, 1 µg /mL aprotinin, 1 mM PMSF as protease inhibitors. 
After centrifugation at 16,000 g, 4 °C for 20 min, supernatants were collected and 
incubated with MycTrap™ agarose beads (Chromotek) or anti-HA magnetic beads 
(Thermo) for 1 h at 4 °C. The beads were washed three times in the 1 mL washing 
buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl containing the corresponding 
detergents) and the bound proteins were eluted under either denaturing or native 
conditions. The denaturing elution condition used in this study was heating the beads in 
30 µL1 × SDS sample buffer at 50 °C for 20 min in the presence of reducing agent (100 
mM dithiothreitol (DTT)) and the native elution condition was to elute the beads three 
times with 10 µL 0.5 mg/mL c-Myc peptide (Thermo) or 1 mg/mL HA peptide (Sigma) 
in the corresponding detergent containing buffer. The denatured eluates or the 
combining native eluates for each sample were subjected to either SDS-PAGE 
(Invitrogen) or NativePAGE (Invitrogen) and further analysed either by Western 
blotting or proteomics.  
 
3.5.5 SDS-PAGE and Native-PAGE 
Protein samples from cell lysates and from the denaturing elution of tag-affinity beads 
beads were subjected to SDS-PAGE using various (10%, 12%, 4-12 %) pre-cast 
NuPAGE™ Bis-Tris gels (Invitrogen) gels with 1 × NuPAGE™ MOPS SDS Running 
Buffer (Invitrogen). Electrophoresis was performed in an XCell SureLock™ Mini-Cell 
tank (Invitrogen) at 200 V using a Power Pac 300 (BioRad). Aliquots (2 µL) of 
Precision Plus Protein™ All Blue Prestained Protein Standards (BioRad) were loaded 
alongside the protein samples to serve as an indication for the protein sizes on the gel. 
Protein samples eluted from beads under native conditions were separated on 3-12% 
gradient NativePAGE™ Bis-Tris gels (Invitrogen) following the manufacture’s 
instruction with electrophoresis with 1× dark blue NativePAGE Cathode Buffer 
(Invitrogen) at 150 V for 30 min and then changed to 1 × light blue NativePAGE 
Cathode Buffer running at 150 V for another 60-80 min until the desired separation for 
proteins was achieved. In the process of electrophoresis, cathode buffers were filled in 
the inner chamber of the XCell SureLock™ Mini-Cell tank while the 1 × NativePAGE 




3.5.6 Western blotting  
3.5.6.1 Generation of anti-Myc magnetic beads 
For generation of home-made anti-Myc magnetic beads, 1 mL NHS-activated magnetic 
beads (Pierce™) were washed in ice cold wash buffer (1 mM hydrochloric acid) once 
and re-suspended with 262 µL coupling buffer (50 mM sodium tetraborate decahydrate 
(pH 8.5)). Equal volume of anti-Myc mouse monoclonal antibody (0.38 mg/mL) gained 
from University of Dundee MRC PPU reagent unit was added to the magnetic beads 
and incubated at 4 °C overnight. After the reaction, the supernatant was removed with 
the help of magnetic stand and 1 mL quenching buffer (3 M ethanolamine pH 9.0) was 
added to the beads to quench the reaction. The anti-Myc magnetic beads were washed 
three times with 0.1 M glycine buffer (pH 2.0) and stored in 1 × PBS buffer for future 
usage.  
After separation by SDS-PAGE or NativePAGE, proteins were transferred onto either 
nitrocellulose membrane or PVDF using a iBlot™ 2 Gel Transfer Device (Invitrogen) at 
25 V for 7-10 min according to the manufacturer’s instructions. The membrane was 
then incubated with Ponceau S buffer (Sigma) for 5 min following de-staining in water 
for 5 min, three times. to verify the success of protein transfer. This also served as a 
quantitative control for protein loading. Blocking of the membrane was achieved using 
SNAP i.d. ® 2.0 Protein Detection System for Western Blotting (Merck) according to 
manufacturer’s instruction with the application of 30 mL blocking buffer (50mM Tris-
HCl pH7.4, 0.15M NaCl, 0.25% BSA, 0.05% (w/v) Tween-20, 0.05% NaN3 and 2% 
(w/v) Fish Skin Gelatin). This step was to prevent non-specific binding of antibodies 
introduced in the following steps. After blocking, the membrane was incubated with 
primary antibody diluted in blocking buffer to an appropriate concentration for 1 h at 
room temperature with a gentle rotation. Relevant dilutions of primary antibodies are 
indicated specifically for each experiment in the results chapters and/or in (Table 3.18). 
The membrane was then transferred to the iBlot assembling cassette and washed three 
times with 30 mL 1 × phosphate buffered saline plus Tween (PBST) (137 mM NaCl, 
2.7 mM KCl, 10 mM Na2HPO4, and 1.8 mM KH2PO4, 0.1 % Tween 20) buffer before 
incubation with IRDye® 680RD and 800CW conjugated secondary antibodies or horse 
radish peroxidase (HRP)-conjugated secondary antibodies. The primary and secondary 
antibodies used for Western blotting in this study were listed in (Table 3.18).  The 
membranes were imaged either by LI-COR Odyssey infrared imaging system (LICOR 
Biosciences, Lincoln, NE) or incubated with the ECL Plus Western Blotting detection 
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reagent (GE Healthcare) according to the manufacturer’s instruction and exposed to 
ECL Hyperfilm (GE Healthcare) and developed with a KODAK film developer. 
 
Table 3.18 List of antibodies used for Western blotting. 
Antibodies Dilution Suppliers 
Anti-Myc rat monoclonal antibody 1:1,000 Chromotek, 9E1 
Anti-HA rat monoclonal antibody 1: 500/1:1,000 Sigma, 3F10 
IRDy 800CW conjugated goat anti-rat IgG antibody 1:15,000 LICOR Biosciences 
IRDy 680RD conjugated goat anti-mouse IgG antibody 1:20,000 LICOR Biosciences 
HRP-conjugated anti-rat antibody  1:3,000 Sigma, A9037 
 
3.5.7 PNGase F digestion  
To set up the Peptide-N-Glycosidase F (PNGase F) digestion, 5 × 107 BSF WT and 
Tb927.11.11740-3HA expressing cells were harvested and immunoprecipitation was 
performed as described in Section 3.5.4 until the end of the washing steps. The on-bead 
PNGase F digestion was then set up using reagents from the PNGase F kit (NEB). The 
beads from the IPs with BSF WT or Tb927.11.11740-3HA lysates were denatured in 10 
µL 1 × Glycoprotein Denaturing Buffer in the absence of 10 mM DTT at 50 °C for 10 
min. The PNGase F digestion was then performed on the denatured samples in the 
reaction buffer (1× GlycoBuffer 2) containing 1 % NP-40 with or without 1 µL PNGase 
F (NEB).   
 
3.6 Immunofluorescence microscopy (IFM) 
3.6.1 Cell fixing, staining, and imaging 
All the solutions used in this protocol were filtered either on a 0.2 µm Minisart filtering 
unit (Sartorious) or with TPP® Filtermax rapid bottle filter unit (Merck). Aliquots of 1 × 
107 of T. brucei BSF or PCF cells were harvested at 800 g or 600 g, 4 °C for 10 min and 
washed once with ice-cold 1 × TDB or 1 × PBS buffer, respectively. The cells were 
then resuspended in 0.5 mL of TDB or PBS and transferred to 1.5 mL Eppendorf tubes 
containing 0.5 mL 8 % paraformaldehyde (PFA) in either TDB or  PBS to achieve a 
final concentration of 5 × 106 cells/mL and 4% paraformaldehyde. The cells were fixed 
for 30 min on ice and 10 µL aliquot of the cells were dried on 12-well diagnostic 
microscope slides (Thermo). The slides were pre-treated with Poly-L-Lysine solution 
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(Sigma) prior to the cell coating to enhance cell attachment. The cells fixed on the 12-
well slides were rehydrated in 1 × PBS buffer for 5 min and then permeabilised with 1 × 
PBS containing 0.5% TX-100 for 15 min. The slides were washed three times with 1 × 
PBS followed by applying the blocking buffer for 1 h at room temperature, the 
composition of the blocking buffer is given in (Table 3.18). After the blocking step, the 
slides were washed with 1 × PBS buffer for 5 min, twice, and then incubated with 
primary antibodies diluted in blocking buffer for 1 h at room temperature. The slides 
were washed three times with 1 × PBS buffer and incubated with secondary antibodies 
diluted in the blocking buffer for 1 h at room temperature in the dark. The antibodies 
and corresponding dilutions for IFM used in this study were listed in Table (3.20). For 
both primary antibodies and secondary antibodies, if more than one antibody was used, 
they were diluted in the same dilution, buffer and centrifugated at 16000 × g, 4°C for 10 
min before applying to the slides. ProLong® Gold antifade reagent with DAPI 
(Invitrogen) was spotted on the slide and cover glasses (VWR) were lowered slowly on 
the drop of the mounting agent. The slides were left curing overnight in the dark at 
room temperature before being sealed with nail varnish. Cells were analysed by a Zeiss 
LSM 700 confocal microscope and all the images were processed using Fiji v. 2.0.0 
(Schindelin et al., 2012).  
 
Table 3.19 Blocking buffer for IFM. 
Composition Amount Final quantity  Supplier 
Fish skin gelatin 0.5 g 5% (w/v) Sigma 
Normal goat serum  1 mL 10 % Sigma 
Sodium Azide 25 µL 0.05% (v/v) Sigma 
10% TX-100 50 µL 0.05% (w/v) Sigma 
1 × PBS 9 mL 90 % (v/v) Sigma 
  
Table 3.20 List of antibodies used for IFM. 
Antibodies Dilution Suppliers 
Anti-Myc mouse monoclonal antibody 1:1,000 Cell signalling  
Anti-HA rat monoclonal antibody 1: 500 Sigma, 3F10 
Rabbit anti-BiP 1:2,000 Kind gift from Jay Bangs  
(University of Buffalo) 
Alexa Fluor® 488- conjugated goat anti-mouse  1:1,000 Invitrogen 
Alexa Fluor® 488-conjugated goat anti-rat 1:1,000 Invitrogen 




3.7 Proteomics   
3.7.1 Label free quantitative proteomics  
3.7.1.1 Sample preparation and data acquisition  
BSF WT and mutant cell lines, PCF WT and mutant cell lines were cultured and 2 × 108 
– 1 × 109 cells of each cell line were harvested, washed in washing buffer (50 mM Tris-
HCl, pH7.4, 150 mM NaCl) and lysed in 1 mL lysis buffer (50 mM Tris-HCl, pH7.4, 
150 mM NaCl containing different detergents). The detergent conditions are indicated 
specifically for each experiment in the results chapter. After centrifugation at 16,000 g, 
4 °C for 20 min. The supernatants were mixed with either 20 µL Myc-Trap™ 
(Chromotek) or 20 µL anti-HA magnetic beads (Thermo) and incubated for 1 h at 4 °C. 
The beads were washed three times in the 1 mL same buffer and bound proteins were 
eluted with 1 × SDS sample buffer by heating at 50 °C for 20 min and subjected to 
SDS-PAGE, running the proteins only 10 cm into the gel. Whole lanes containing WT 
and mutant cell lines samples were cut identically into 3-4 slices and the gel pieces were 
dried in Speed-vac (Thermo Scientific) for in-gel reduction with 0.01M dithiothreitol 
(DTT) and alkylation with 0.05M iodoacetamide (Sigma) for 30 min in the dark. The 
gel slices were washed in 0.1M NH4HCO3, and digested with 12.5 µg/mL modified 
sequence grade trypsin (Roche) in 0.02M NH4HCO3 for 16 h at 30˚C. Samples were 
dried and re-suspended in 50 µL 1% formic acid and the liquid phase subjected to liquid 
chromatography on Ultimate 3000 RSLC nano-system (Thermo Scientific) fitted with a 
3 Acclaim PepMap 100 (C18, 100 µM× 2 cm) trap column and then separated on an 
Easy-Spray PepMap RSLC C18 column (75 µM× 50 cm) (Thermo Scientific). Samples 
(15 μL) were loaded in 0.1% formic acid (buffer A) and separated using a binary 
gradient consisting of buffer A and buffer B (80% acetonitrile, 0.1% formic acid). 
Peptides were eluted with a linear gradient from 2 to 35% buffer B over 70 min. The 
HPLC system was coupled to a Q-Exactive Plus Mass Spectrometer (Thermo Scientific) 
equipped with an Easy-Spray source with temperature set at 50˚C and a source voltage 
of 2.0 kV. The mass spectrometry proteomics data have been deposited to the 
ProteomeXchange Consortium via the PRIDE partner repository with the dataset 




3.7.1.2 Protein identification by MaxQuant  
RAW data files were analysed using MaxQuant version 1.6.10.43, with the in-built 
Andromeda search engine (Tyanova, Temu and Cox, 2016), using the T. brucei brucei 
927 annotated protein sequences from TriTrypDB release 46 (Aslett et al., 2010) 
supplemented with the T. brucei brucei 427 VSG221 (Tb427.BES40.22) protein 
sequence. The mass tolerance was set to 4.5 ppm for precursor ions and MS/MS mass 
tolerance was set at 20 ppm (MaxQuant default parameters). The enzyme was set to 
trypsin, allowing up to 2 missed cleavages. Carbamidomethyl on cysteine was set as a 
fixed modification. Acetylation of protein N-termini, and oxidation of methionine were 
set as variable modifications. Match between runs was enabled, allowing transfer of 
peptide identifications of sequenced peptides from one LC-MS run to non-sequenced 
ions with the same mass and retention time in another run. A 20-min time window was 
set for alignment of separate LC-MS runs. The false-discovery rate for protein and 
peptide level identifications was set at 1%, using a target-decoy based strategy. 
 
3.7.1.3 Data analysis 
Data analysis was performed using custom Python scripts, using the SciPy ecosystem of 
opensource software libraries (Virtanen et al., 2020). The data analysis pipeline is 
available at GitHub https://github.com/mtinti/TbGPI3 and Zenodo 
https://zenodo.org/record/4310034 repositories, DOI:10.5281/ zenodo.3735036. The 
MaxQuant proteinGroups.txt output file was used to extract the iBAQ scores for 
forward trypanosome protein sequences identified with at least two unique peptides and 
with an Andromeda score >4. The protein iBAQ scores were normalised for sample 
loading by dividing each iBAQ value by the median of all the iBAQ values in each 
experiment. Missing values were replaced by the smallest iBAQ value in each sample. 
Differential abundance analysis between the bait and control samples was performed 
with the ProtRank Python package (Medo, Aebersold and Medová, 2019). Briefly, 
ProtRank performs a rank test between each control and bait sample pair to output as 
signed-rank and false discovery rate values. The signed-rank is proportional to the 
significance of the differential abundance of the protein groups between the bait and 
control samples. The BSF protein intensity (abundance) rank (Ji, Tinti and Ferguson, 
2021) was computed from a recent dataset (Tinti et al., 2019) published by our 
laboratory of T. brucei protein half-lives computed from a label-chase experiment. In 
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those experiments, BSF parasites were labelled to steady-state in medium SILAC 
culture medium (M) and then placed into light SILAC culture medium (L). Seven time 
points, with three biological replicates, were sampled and each mixed 1:1 with BSF 
lysate labelled to steady state in heavy SILAC culture medium (H) to provide an 
internal standard for normalisation. Each sample was then separated into 10 sub-
fractions for LC-MS/MS (thus, a total of 210 LC-MS/MS analyses were performed). 
Here, we exploited the heavy-labelled internal standard in every sample: The log10 
summed eXtracted Ion Currents (XICs) of the heavy-labelled peptides for each protein 
were averaged across the BSF replicates and used to rank a very deep BSF proteome 
from the most abundant (rank = 1) to the least abundant (rank = 7149). Undetected 
proteins were given a rank of 7150. 
 
3.7.2 Cross-linking label free quantitative proteomics and data analysis  
For label free quantitative proteomics identification, the cross-linking reaction for the 
whole cell lysates or for the cell membrane fractions were set up as described in Section 
3.5.3 followed by immunoprecipitation indicated in Section 3.5.4. The sample 
processing was the same as the label free quantitative proteomics as introduced in 
Section 3.7.1.1. For protein identification by MaxQuant, a variable modification 
(145.02 Da) on lysine residue introduced by DTSSP cross linking was added when 
performing the MaxQuant search. The principle of reversible DTSSP cross-linking is 
shown in Fig 3.1.  
 
Figure 3.1  Peptide sequences (R and R1) containing lysine residues, with side chain 
primary amino groups, react with DTSSP replacing the N-hydroxy succinimide (NHS) 
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leaving groups. The cross-linked peptides provide the covalent cross-linking between the 
proteins containing the R and R1 peptides, thus allowing co-immunoprecipitation under stringent 
denaturing conditions. Once isolated, the cross-linked proteins can be separated from each other 
by reduction of the disulphide bond within the cross-liner with dithiothreitol (DTT). Image is 
taken from (Hermanson, 2013). 
 
3.7.3 SILAC proteomics 
3.7.3.1 Sample preparation 
BSF WT and mutant cell lines were cultured in HMI11-T + R0K0 and HMI11-T + 
R6K4 medium (as described in section 3.5.1), respectively, while PCF WT and mutant 
cell lines were cultured in SDM-79 + R0K0 and SDM-79+ R6K4 medium respectively 
(as described in section 3.5.1).  For each SILAC experiment, WT and mutant cells were 
count three individual times with haemocytometer and identical numbers of cells (2 × 
108 – 1 × 109 cells, depending on the experiment) from the WT and mutant samples 
were mixed together.  The cells were harvested and lysed in 1mL lysis buffer (50 mM 
Tris-HCl, pH7.4, 150 mM NaCl containing different detergents). The detergent 
conditions are indicated specifically for each experiment in the results chapter. After 
centrifugation at 16,000 g, 4 °C for 20 min. The supernatants were mixed with 20 µL 
Myc-Trap™ (Chromotek) and incubated for 1 h at 4 °C. The beads were washed three 
times in the same buffer and bound proteins were eluted with 1 × SDS sample buffer 
containing 100 mM DTT and boiled at 50 °C for 20 min and subjected to SDS-PAGE, 
running the proteins only one third of the gel. Whole lanes containing WT and mutant 
cell lines samples were cut identically into 3-4 slices and prepared for LC-MS/MS 
identification as described in (Section 3.7.1.1).  Samples were dried and re-suspended in 
50 µL 1% formic acid and then subjected to liquid chromatography on Ultimate 3000 
RSLC nano-system (Thermo Scientific) fitted with a 3 Acclaim PepMap 100 (C18, 100 
µM× 2 cm) trap column and then separated on an Easy-Spray PepMap RSLC C18 
column (75 µM× 50 cm) (Thermo Scientific). Samples (15μL) were loaded in 0.1% 
formic acid (buffer A) and separated using a binary gradient consisting of buffer A and 
buffer B (80% acetonitrile, 0.1% formic acid). Peptides were eluted with a linear 
gradient from 2 to 35% buffer B over 124 min. The HPLC system was coupled to a 
OrbiTrap Velos Pro (Thermo Scientific) equipped with an Easy-Spray source with 




3.7.3.2 Data processing  
For the SILAC experiments the RAW data files were analysed using MaxQuant version 
1.5.8.3, with the in-built Andromeda search engine (Tyanova, Temu and Cox, 2016), 
using the T. brucei brucei 927 annotated protein sequences from TriTrypDB release 32 
(Aslett et al., 2010). The mass tolerance was set to 4.5 ppm for precursor ions and 
MS/MS mass tolerance was set at 20 ppm (MaxQuant default parameters). The enzyme 
was set to trypsin, allowing up to 2 missed cleavages. Carbamidomethyl on cysteine 
was set as a fixed modification. The heavy (R6K4,) and light (R0K0) modifications 
were used for SLAC quantification. Acetylation of protein N-termini, and oxidation of 
methionine were set as variable modifications. Match between runs was enabled, 
allowing transfer of peptide identifications of sequenced peptides from one LC-MS run 
to non-sequenced ions with the same mass and retention time in another run. A 20-min 
time window was set for alignment of separate LC-MS runs. The false-discovery rate 
for protein and peptide level identifications was set at 1%, using a target-decoy based 
strategy. The heavy over light SILAC log2 ratios were analysed with a t-test 
implemented in the scipy python package (Virtanen et al., 2020) against the null 
hypothesis that the log2 ratio is zero. The minus log10 of the p-values were plotted 
against the mean log2 ratios.  For the experiments without biological replicates the log 
ratio was visualized against the log10 Score of the MaxQuant output. 
 
3.8 T. brucei cell free system and radiolabelling  
3.8.1 T. brucei cell free system preparation  
The T. brucei BSF cell free system for different cell lines used in this study was 
prepared as described previously (Güther, Masterson and Ferguson, 1994). Briefly, cells 
were lysed in buffer A (0.1 mM TLCK, 1 µg/mL leupeptin) for 5 min on ice, an equal 
volume of buffer B (0.1 M NaHEPES, 50 mM KCl, 10 mM MgCl2, 20% glycerol, pH 
7.4) were added, and the cell lysates could be kept in - 80°C for later use. Aliquots of 
trypanosome lysate (40 µL, equivalent to 4 × 107 cells) were incubated with 0.5 µCi 
GDP-[3H]Man (American Radiochemical Company, 20-30 Ci/mmol) and 2 mM UDP-
GlcNAc for 20 min at 37 °C in the incorporation buffer (50 mM HEPES, 25 mM KC1, 
5 mM MgCl2, 5 mM MnCl2, 0.5 mM dithiothreitol, 1.25 µg/ml tunicamycin,). In chase 
experiments, 1 mM cold GDP-mannose was added and incubated for 10 min at 37 °C. 
The reactions were terminated by the addition of 0.2 mL of chloroform, methanol (1:1, 
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v/v) and lipids were extracted in the solvent overnight.  The lipid extracts were dried 
under a stream of nitrogen, resuspended in 50 µL of water saturated with 1-butanol, and 
extracted three times with 50 µL of 1-butanol saturated with water. The combined upper 
phases were washed twice with 100 µL of water saturated with 1-butanol. The upper 1-
butanol phase were dried under N2 and re-suspend in 20 µL 1-butanol. Aliquots of the 
washed lipid extract were analysed by HPTLC.  
 
3.8.2 High Performance Thin layer chromatography (HPTLC) 
Radiolabelled samples were applied on Silica Gel 60 aluminium backed HPTLC plates 
(Merck) and developed with solvent (chloroform, methanol, 1 M ammonium acetate, 13 
M ammonia, water (180:140:9:9:23, v/v)). The HPTLC plates were fluorographed by 
spraying with En3hance® Spray solution (Perkin Elmer) and incubated for overnight or 
several weeks at -80°C to expose with film (Amersham Hyperfilm MP, GE Healthcare) 
in the presence of an intensifying screen (Kodak). Films were developed with a 
KODAK film developer. For purification of radiolabelled GPI glycolipids A’ and θ 
used in Section 6.9, the Rf values of these two products were first determined in a small 
scale experiment followed by a bulk radiolabelling of BSF WT cell free system as 
described in Section 3.8.1, except that 120 µl of cell free system and 1.5 µCi of GDP-
[3H]Man were used. After separation the radiolabelled GPI glycolipids mix on an 
HPTLC plate, the regions that contained glycolipids A’ and θ, which were estimated 
based on their Rf values, were scraped and the glycolipids were recovered by butanol 





4 Results Ⅰ – Studies on Trypanosoma brucei GlcNAc-
Phosphatidylinositol De-N-acetylase (TbGPI12) 
4.1 Identification by SILAC proteomics of proteins that co-immunoprecipitated 
with TbGPI12  
4.1.1 Analysis of TbGPI12 Gene Product.  
The gene TbGPI12 (Tb927.11.12080) has been shown to encode the de-N-acetylase that 
catalyses the second step in the T. brucei glycosylphosphatidylinositol biosynthesis 
pathway (GPI biosynthesis pathway), converting D-GlcNAcα1–6-D-myo-inositol-1-
HPO4-sn-1,2-diacylglycerol (GlcNAc-PI) to D-GlcNα1–6-D-myo-inositol-1-HPO4-sn-
1,2-diacylglycerol (Chang et al., 2002). A conditional null mutants for this gene have 
shown that it is essential for the survival of bloodstream form but not procyclic form T. 
brucei (Chang et al., 2002; Güther et al., 2006). TbGPI12 is predicted to be 252 amino 
acids in length, with a theoretical molecular mass of 28.6 kDa, and to contain a 
transmembrane domain at its C-terminus using the Phobius web server (Käll, Krogh and 
Sonnhammer, 2007). The enzymes of GPI anchor biosynthesis pathway have been 
shown to be generally of low abundance, with few of them appearing in the proteomic 
studies performed on BSF and PCF parasites (i.e., several do not appear TriTrypDB 
proteomics summary data) (Aslett et al., 2010) and see Table 1.1. Consistent with this 
theme of general low-abundance, and according to recent proteomics work from our lab 
that orders proteins based on their relative abundance (Tinti, Maria Lucia S Güther, et 
al., 2019), TbGPI12 ranks 5818th out of 7148 detected protein groups in bloodstream 
form  T. brucei.  
Previous studies (Smith et al., 1996) have shown that the addition of synthetic GlcNAc-
PI to a BSF cell-free system in the presence of GDP-[3H]Man primes the formation of 
radiolabelled downstream GPI intermediates far more efficiently than the addition of 
synthetic GlcN-PI. This suggests that there may be substrate channelling between 
TbGPI12 and the enzyme catalysing following step, α1-4 mannosyltransferase Ⅰ, 
(TbGPI14, gene ID: Tb927.6.3300) and that TbGPI12 and TbGPI14 may form and 
work as a complex in the ER (Smith et al., 1996). Therefore, we decided to look for this 
hypothetical complex and, while doing so, to optimise the conditions for 
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immunoprecipitation of low abundance ER transmembrane proteins in the GPI pathway. 
The first steps of GPI anchor biosynthesis pathway are identical in BSF and PCF 
parasites, so the co-immunoprecipitation of TbGPI12 could be performed in both forms 
of the parasite. Since PCF parasites are easier to culture to high density, we elected to 
use that life-cycle stage for these early studies. 
4.1.2 Generation of anti-Myc magnetic beads and immunoprecipitation (IP) of 
PCF TbGPI12-Myc.  
A T. brucei PCF cell line conditionally expressing TbGPI12-Myc previously generated 
in the lab (Güther et al., 2006) was used in the following IP experiments. In order to get 
an efficient IP, home-made anti-Myc magnetic beads were generated by covalently 
linking a mouse anti-Myc monoclonal antibody to NHS-activated magnetic beads 
(Section 3.5.6.1). The purity of the anti-Myc antibody was checked before coupling to 
the beads by SDS-PAGE and Coomassie blue staining, and the success of coupling the 
anti-Myc antibody to the magnetic beads was confirmed by identifying the antibody 
heavy and light chains eluted (by boiling for 20 min using SDS sample buffer) from the 
beads after coupling and washing (Fig 4.1A). The coupled anti-Myc magnetic beads 
were then used for immunoprecipitation of TbGPI12-Myc. In this experiment, 3 
sequential IPs from 1% TritonX-100 (TX-100) cell lysates of induced (+Tet) and 
uninduced (-Tet) PCF TbGPI12 conditional null mutant trypanosomes were performed, 
and SDS sample buffer eluted proteins were analysed by Western blot using rat anti-
Myc antibody. TbGPI12-Myc was successfully detected in all 3 IPs from the +Tet 
samples, but not the –Tet samples (Fig 4.1 B).  
It is clear from the TbGPI12-Myc data that the anti-Myc magnetic beads could IP the 
low abundance transmembrane protein TbGPI12-Myc, however the presence of 
TbGPI12-Myc in all three sequential IPs suggests that it is difficult to achieve 
quantitative IP of TbGPI12-Myc. This may be due to the use of a single Myc-tag and/or 





Figure 4.1 Coupling anti-Myc monoclonal antibody to NHS-activated magnetic beads and 
immunoprecipitation and Western blot of TbGPI12-Myc. 
A: Coomassie blue stained SDS-PAGE gel of the anti-Myc monoclonal antibody before (lane 1) 
and after (lane 2) coupling to NHS-activated magnetic beads. After coupling, the antibody 
chains were eluted from the beads with SDS-sample buffer. B: Cell lysates (in buffer containing 
1% TX-100) from the PCF TbGPI12 conditional null mutant Tet induced (lanes 1-3) and 
uninduced (lanes 4-6) were subjected to 3 sequential IPs, and the eluted proteins detected with 
rat anti-Myc antibody. The positions of molecular weight markers are shown on the left of each 
gel and blot.  
 
4.1.3 Optimisation of detergent lysis and protein elution conditions for TbGPI12-
Myc IPs. 
To try to maintain any membrane complexes that TbGPI12-Myc may form, different 
concentrations of digitonin were explored for lysing the cells and compared to the use 
of 1% TX-100. Digitonin is recognised as a much milder detergent than TX-100 and is 
more suitable for solubilising intact membrane protein complexes. Western blot after IP 
of TbGPI12-Myc using different lysing conditions indicates that 0.3%, 0.5% and 1% 
digitonin all supported the extraction of TbGPI12-Myc, albeit with lower efficiency 
than 1% TX-100 (Fig 4.2 B). Out of these conditions, 0.5% digitonin was selected as 
the lysis condition for subsequent experiments. However, Ponceau staining of the same 
blot (Fig 4.2 A) showed that the use of SDS sample buffer for elution of the anti-Myc 
magnetic beads after IP was eluting many non-specifically bound proteins from the 
beads which would likely interfere with subsequent Nano-LC-MS/MS detection of the 
co-IP proteins with TbGPI12-Myc. Therefore, two different mild elution buffers: low 
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pH sodium citrate buffer and c-Myc peptide (Sigma) were tested. Low pH sodium 
citrate gave a less efficient elution than SDS sample buffer but a similar Ponceau 
staining background (Fig 4.2 C & D), while the c-Myc peptide buffer in this experiment 
did not elute any TbGPI12-Myc (Fig 4.2 D, lane 2). This result indicates that although 
home-made coupled anti-Myc magnetic beads could achieve an efficient IP for 
TbGPI12-Myc, it could also give a high background binding of many non-specific 
proteins, despite using mild detergent lysis and mild (low pH) elution conditions. While 
the background of non-specific proteins was low in the c-Myc peptide elution (Fig 4.2 
C, lane 2), there was no specific elution of TbGPI12-Myc either. This was investigated 





Figure 4.2 Test of detergent extraction conditions and elution conditions for IP of 
TbGPI12-Myc. 
 A and B: TbGPI12-Myc lysates prepared using different detergents were immunoprecipitated 
and by anti-Myc magnetic beads and eluted proteins were analysed by Ponceau staining and 
Western blot detection using rat anti-Myc antibody. Lane1-3: 0.3 %, 0.5 %, 1% digitonin, lane 
4: 1% TX-100. C and D: Ponceau staining and anti-Myc Western blot of proteins eluted by 
different eluting buffers from anti-Myc magnetic beads. Lane 1: sodium citrate buffer pH 2.8, 
lane 2: 0.5 mg/ml c-Myc peptide (Sigma) in lysis buffer, lane 3: SDS sample buffer. All 




4.1.4 Standardisation of Myc-TrapTM beads for IP and selection of an alternative 
source of c-Myc peptide for specific elution. 
The high Ponceau background staining observed using anti-Myc coupled magnetic 
beads raised concerns with respect to the higher possibility of detecting “false positive” 
co-IP proteins with TbGPI12-Myc in later proteomics experiments, even when 
including samples IPs from wild type cell line lysates as a negative control. Therefore, 
Myc-TrapTM agarose beads were tested as an alternative for for IP as Myc-TrapTM uses 
an anti-Myc nanobody engineered to reduce non-specific protein-protein binding, 
according to the manufacturer. To test the efficiencies of the Myc-TrapTM agarose 
beads, equivalent amounts of 0.5% digitonin cell lysates containing TbGPI12-Myc were 
immunoprecipitated using Myc-TrapTM beads in parallel with our home-made anti-Myc 
coupled magnetic beads. Proteins were then eluted from the beads using low pH sodium 
citrate buffer and analysed by Western blotting. As shown in Fig 4.3 A and B, the yield 
of TbGPI12-Myc recovered from Myc-TrapTM beads was higher, while the Ponceau 
staining background was lower. Meanwhile, a new c-Myc peptide (from Thermo instead 
of Sigma) was tested as an eluant using Myc-TrapTM beads for IP. The Western blot 
shown in Fig 4.3 D suggests that Thermo c-Myc peptide elution buffer is more efficient 
than low pH sodium citrate.  
From the data described above, an IP procedure using 0.5% digitonin for lysing cells, 
Myc-TrapTM agarose beads for IP and c-Myc peptide from Thermo for eluting was 
selected for future TbGPI12-Myc IP experiments. In addition, we decided that these 





Figure 4.3 Introducing Myc-TrapTM agarose beads for IP and new c-Myc peptide as 
elution buffer. 
 A and B: TbGPI12-Myc PCF 0.5% digitonin lysates were sequentially immunoprecipitated 
twice using either Myc-TrapTM or home-made anti-Myc coupled magnetic beads. Proteins 
bound to the beads were eluted three times with pH 2.8 sodium citrate buffer and combined 
samples were analysed by SDS-PAGE followed by Ponceau staining and anti-Myc Western 
blot. Lanes 1 and 2: two sequential IPs with MycTrapTM beads; lanes 3 and 4: two sequential IPs 
with anti-Myc coupled magnetic beads. C and D: As panel A and B, except Myc-Trap TM beads 
were eluted with new (Thermo) c-Myc peptide (lane 1) or pH 2.8 sodium citrate (lane 2). 
 
4.1.5 Identification of protein complexes containing TbGPI12-Myc and of co-IP 
proteins by SILAC proteomics  
To investigate whether TbGPI12-Myc forms a protein complex or complexes, 
TbGPI12-Myc protein was extracted and immunoprecipitated from the Tet-induced 
TbGPI12 conditional null mutant cell line using the conditions described in Section 
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4.1.5. The eluted proteins were applied to a NativePAGE gel and detected by anti-Myc 
antibody. Wild type cells were included as negative control in the same experiment. 
Two bands were recognized in the TbGPI12-Myc samples; one fairly discrete at ~60 
kDa, the other a broad smear running with and above the 146 kDa marker (Fig 4.4 A). 
The apparent molecular weights (MW) of these two bands are greater than the 
theoretical MW of TbGPI12-Myc (~25 kDa), indicating that TbGPI12 does form a 
complex with other proteins and/or itself. To further identify the proteins that co-IP with 
TbGPI12, stable isotope labelling in cell culture (SILAC) proteomics was performed as 
described in Materials and Methods. Briefly, procyclic wild type (PCF WT) and 
TbGPI12-Myc expressing parasites were grown under identical conditions for nine cell 
divisions, except that the TbGPI12-Myc cell line was grown in “heavy medium” 
containing stable isotope-labelled Lys and Arg (R6K4), whereas the PCF WT cells were 
grown in “light medium” containing unlabelled Lys and Arg (R0K0). The TbGPI12-
Myc and the PCF WT cells were counted, mixed together in a 1:1 ratio and then 
harvested, washed and lysed in 0.5 % digitonin buffer. The IP was subsequently 
performed and the proteins eluted from the Myc-TrapTM beads were processed to tryptic 
peptides for LC-MS/MS analysis. The data set from the experiment was used to search a 
T. brucei predicted protein database using MaxQuant software. Each protein was 
displayed on a plot of the Log10 transform of the Andromeda protein score calculated 
by MaxQuant (abbreviated as protein score hereafter) (y axis) and the Log2 value of the 
heavy to light isotope ratios (x axis) (Figure 4.4 B). All the proteins that have a 
heavy/light ratio greater than 4 were annotated in red, of which the bait protein 
TbGPI12-Myc had the third highest ratio. There were 13 other proteins identified that 
might potentially physically associate with TbGPI12-Myc (Table 4.1). The majority of 
these co-IP proteins have a relatively low protein ranking, suggesting that they are high 
abundance proteins which indicates that they are unlikely to be true partner proteins of 
the low abundance bait protein TbGPI12. Two of the hits, Tb927.11.6210 (lanosterol 
14-alpha demethylase) and Tb927.10.7100 (delta-4 fatty acid desaturase), are relatively 
low abundance proteins that co-immunoprecipitated with TbGPI12. However, the 
associations between them need to be further validated.  
Of all the proteins in the TbGPI12-Myc IP, TbMTI (TbGPI14) was notably absent 
suggesting that, contrary to our hypothesis, TbGPI14 may not be in a complex with 
TbGPI12. This may be due to the fact that TbGPI12 simply does not have physical 
association with TbGPI14, or that the association between TbGPI12 and TbGPI14 is 
real but only transient, such that the complex they form could not be obtained under the 
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IP conditions used. Thus, we next investigated cross-linking methodology which is 
suitable for stabilising protein complexes before IP experiments. 
 
Figure 4.4 Identification of protein complexes containing TbGPI12-Myc and identification 
of potential co-IP proteins through SILAC proteomics. 
 A: NativePAGE Western blot of proteins immunoprecipitated from WT (lane 1) and TbGPI12-
Myc expressing (lane 2) PCF cell lysates. B: Plot of TbGPI12-Myc/WT SILAC IP results. The 
plot shows the Log2 of the heavy-to-light isotope ratio (x axis) versus the Log10 of protein 
score (y axis). The TbGPI12-Myc (bait) protein is highlighted and proteins whose heavy/light 
ratio are greater than 2 are in red. 
 
Table 4.1 List of co-IP proteins of TbGPI12 identified through SILAC proteomics. 














Tb927.11.9400 Hypothetical protein, conserved 1 684 
Tb927.5.1210 short-chain dehydrogenase, putative 2 250 
Tb927.11.12080  N-acetyl-D-glucosaminylphosphatidylinositol de-
N-acetylase ((TbGPI12) 
3 5818 
Tb927.11.6210 Lanosterol 14-alpha demethylase 4 7063 
Tb927.10.4040 3-keto-dihydrosphingosine reductase 5 1667 
Tb927.9.9630 TPR repeat/Tetratricopeptide repeat, putative 6 1474 
Tb927.9.9710 Histidine phosphatase superfamily (branch 1), 
putative 
7 2842 
Tb927.6.4210 aldehyde dehydrogenase, putative 8 1732 
Tb927.11.8380 NADPH--cytochrome P450 reductase, putative 9 1414 
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Tb927.10.7100 delta-4 fatty acid desaturase 10 6629 
Tb927.11.12500 hypothetical protein, conserved 11 3314 
Tb927.9.2050 membrane protein YIP1, putative 12 3082 




4.2 Investigating co-IP proteins of TbGPI12-Myc using cross-linking 
proteomics. 
4.2.1 Optimisation of cross-linking conditions for TbGPI12-Myc 
Since both TbGPI12 and TbGPI14 are predicted to be transmembrane proteins, a cross 
linking methodology appropriate for studying membrane protein association was 
established (Fig 4.5A). Basically, PCF T. brucei cells expressing TbGPI12-Myc and 
PCF WT cells were subjected to hypotonic lysis and, after centrifugation, the 
supernatant containing the majority of soluble cytosolic proteins was removed. 
Subsequently, the cross-linking reaction was performed on the resuspended membrane 
pellets using the chemical crosslinker DTSSP, see (Section 3.7.2) for details of how it 
works. After quenching the reactions, the membrane proteins were solubilized with 
detergent 2% TX-100 and IP was performed, as described above. To achieve a 
favourable cross-linking reaction, different concentrations of DTSSP were first tested. 
As shown in (Fig 4.5 C), smeared bands that ran with higher apparent molecular 
weights than TbGPI12-Myc were detected in the cross-linked samples, and the signals 
of these bands became stronger as the concentration of DTSSP increased. Of these 
conditions, the 4 mM DTSSP condition was chosen for subsequent scaled up cross 
linking IP experiments and subsequent proteomics because: First, more TbGPI12-Myc 
was present in complexes using 4 mM DTSSP when compared to 1 and 2 mM DTSSP. 
Second, we considered that 8 mM DTSSP might lead to more non-specific cross-linking 




Figure 4.5 Summary of cross-linking proteomics experiment. 
 A: Scheme of cross-linking quantitative proteomics to identify proteins that specifically co-IP 
with TbGPI12-Myc. B and C : Optimisation of the DTSSP crosslinker concentration: TbGPI12-
Myc expressing cells were lysed and the membrane fraction was collected and cross-linking 
reactions were performed using 0, 1, 2, 4 and 8 mM DTSSP (lanes 1-5, respectively). 
Membrane proteins were then solubilised in detergent and IPs were performed. Eluted proteins 
were separated on SDS PAGE. Ponceau staining (B) and anti-Myc Western blotting (C) were 
performed on the transferred membrane.  
 
4.2.2 Identification of co-IP proteins of TbGPI12-Myc through cross linking 
proteomics 
A scaled up IP experiment was then performed using the 4 mM DTSSP cross-linking 
condition and the proteins that were collected from the IP were applied to SDS-PAGE 
and gel regions that are outlined in the red (Fig 4.6 A) were cut and sent for label-free 
quantitative proteomics. The proteins identified from mass spectrometry were plotted by 
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the ratio of their Maxquant computed intensities detected in the TbGPI12-Myc IP 
sample (Bait) to the sum intensities (Sum) in both TbGPI12-Myc (bait) and PCF WT 
(control) IP samples (x axis) and the Log10 value of protein score (y axis) (Fig 4.6 B). 
This atypical x-axis value was adopted so that proteins undetected in the control are not 
lost in the analysis, as can happen when enrichments are “infinite” or “infinitesimal”, 
i.e., when proteins appear exclusively in only one sample of a pairwise comparison. 
Thus, in this experiment, TbGPI12 and the proteins that specifically associated with it 
should have a ratio very close to 1. Also, the quality of peptide identification by mass 
spectrometry was taken into consideration by applying a cut off of proteins whose 
scores were less than 15. Using this calculation, 16 protein groups were identified with 
a ratio of 1 including the bait protein TbGPI12-Myc. The other 15 proteins are potential 
co-IP proteins of TbGPI12 (Table 4.2), however, TbGPI14 was not among these. 
 
Figure 4.6 Identification of TbGPI12-Myc co-IP proteins following membrane protein 
cross linking. 
 A: Cross-linking experiments were performed on TbGPI12-Myc expressing and WT PCF 
washed cell membranes as described above using 4 mM DTSSP. An anti-Myc Western blot was 
performed on the proteins that were eluted after IP. A gel that was run in parallel was cut as 
indicated by the red rectangles and the gel slices sent for proteomics. Each gel slice was divided 
into four sub-slices which were processed to tryptic peptides and subjected to LC-MS/MS 
separately. Concatenated data from the four sub-slices were processed by Maxquant.  B: Plot of 
label free quantification proteomics data obtained from the regions shown in panel A. X axis: 
ratio of protein intensities detected in the TbGPI12-Myc IP sample compared with the sum of 
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their intensities detected in the TbGPI12-Myc and PCF WT samples. Y axis: log 10 value of the 
Andromeda protein score calculated by Maxquant.  
 
Table 4.2 List of co-IP proteins of TbGPI12 identified by cross-linking proteomics. 









Tb927.11.15990 Hypothetical protein, conserved 848 
Tb927.11.12080  N-acetyl-D-glucosaminylphosphatidylinositol de-N-acetylase 
((TbGPI12) 
5818 
Tb927.5.1210 Nucleoporin NUP152 1358 
Tb927.11.2950 Nucleoporin NUP89 1576 
Tb927.10.12240 3-ketoacyl-CoA reductase, putative 2486 
Tb927.10.14510 root hair defective 3 GTP-binding protein (RHD3), putative 1089 
Tb927.11.7060 acidocalcisomal pyrophosphatase 5598 
Tb927.6.3570 tubulin-tyrosine ligase-like protein, conserved 6779 
Tb927.11.13250 eukaryotic translation initiation factor 2 gamma, putative 637 
Tb927.11.7560 Component of motile flagella 15 433 
Tb927.11.9130 Replication factor A protein 1 956 
Tb927.8.2630 kinesin-C 837 
Tb927.4.2080 Coiled-coil and C2 domain-containing protein 256 
Tb927.7.3510 LSU ribosomal protein, mitochondrial, putative 6192 
Tb927.7.1070 KREX1 5995 
Tb927.7.5160 deoxyuridine triphosphatase, putative 1769 
 
4.3 Co-IP proteins in common between with the SILAC and cross-linking 
proteomics datasets. 
The two lists of proteins that co-IP with TbGPI12-Myc were generated through two 
different types of IP proteomics experiments. The proteins identified from these two 
results are overlapped (Fig 4.7) considering the following criteria: For the SILAC 
proteomics data, the protein heavy/light ratios should be >4. For the cross-linking 
proteomics data, only proteins whose Bait/Sum intensity ratio are 1 are considered. For 
both experiments, the proteins whose protein scores were less than 15 were removed. 
Using these stringent criteria, there are two proteins in common between these two 
datasets, and these are ranked by their heavy/light isotope ratio from the SILAC 
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experiment (Table 4.3).  The first of these is the TbGPI12-Myc bait protein, as expected. 
Since TbMTI (TbGPI14) did not appear in either dataset, or in in preliminary co-IP 
experiment, see (Section 7.1), we conclude that there is no evidence to support a physical 
association between TbGPI12 and TbGPI14 from these sensitive proteomics approaches. 
The most likely candidate that may have physical association with TbGPI12-Myc is 
Tb927.10.14510. According to TritrypDB, this gene encodes a putative root hair defective 
3 GTP-binding protein (RHD3). It contains a putative transmembrane domain near its C-
terminus and is localised in the ER (Dean et al., 2017). According to motif search, it has 
an RHD3 (PF05879 Pfam) motif which is thought to be a motif for a family of a novel 
class of GTP-binding proteins. Previous studies on the function(s) of the proteins 
containing this motif suggests that they are required for regulated cell enlargement (Wang 
et al., 1997) or involved in membrane trafficking (Brands and Ho, 2002), neither of which 
directly supports a potential function in the GPI anchor biosynthesis pathway. It is 
possible that Tb927.10.14510 could be a transiently associating regulatory protein for 
TbGPI12, however, more specific functional studies would need to be carried out for 
further characterisation through reverse pull down of epitope tagged of Tb927.10.14510.      
 
 
Figure 4.7 Overlapping of TbGPI12-Myc associated proteins identified by SILAC and 
cross-linking IP proteomics. 
 
Table 4.3 List of proteins that co-IP with TbGPI12-Myc identified by both SILAC and 
cross-linking proteomics. 






































5 Results Ⅱ- Studies on the Trypanosoma brucei UDP-
GlcNAc : PI α1-6 GlcNAc-transferase (GPI GnT) complex 
5.1 Identification of putative T. brucei UDP-GlcNAc : PI α 1-6 GlcNAc-
transferase complex components. 
Conventional BLASTp searches with default settings (Acland et al., 2012) were 
sufficient to identify T. brucei homologues of PIGA(GPI3), PIGC(GPI2), PIGP(GPI19), 
PIGQ(GPI1) and DPM2. However, the results for PIGH(GPI15) and PIGY(ERI1) were 
equivocal so a Domain Enhanced Lookup Time Accelerated BLAST (Boratyn et al., 
2012) using a PAM250 matrix was applied to find the corresponding T. brucei 
homologues (Table 5.1).   
 
Table 5.1 Genes encoding UDP-GlcNAc : PI α1-6 GlcNAc-transferase (GPI GnT) complex 





T. brucei  
gene 
(TriTrypDB gene ID) 
Calculated 












PIGA GPI3 TbGPI3 (Tb927.2.1780) 51.6 kDa 1 6475 
PIGH GPI15 TbGPI15 (Tb927.5.3680) 28.8 kDa 2 7038 
PIGP GPI19 TbGPI19 
(Tb927.10.10110) 
16.5 kDa 3 6185 
PIGC GPI2 TbGPI2 (Tb927.10.6140) 38.5 kDa 4 5285 
PIGQ GPI1 TbGPI1 (Tb927.3.4570) 81.5 kDa 5 6797 
  TbArv1 (Tb927.3.2480) 28.7 kDa 6 7150 
PIGY ERI1 TbERI1 (Tb927.4.780) 10.1 kDa  7 7150 
  TbUbCE (Tb927.2.2460) 22.6 kDa 8 2538 
DPM2 - TbDPM2 
(Tb927.9.6440)3 
9.3 kDa not present 7150 
1Taken from ((Ji et al., 2021) S2 File). 
2Taken from ((Ji et al., 2021) S1 File) where proteins are ranked from 1 (most abundant) to 
7149 (least abundant) and undetected proteins are ranked 7150. 
3Probable mis-annotation, see text. 
 
5.2 In situ epitope tagging of TbGPI3. 
To investigate whether a multi-subunit UDP-GlcNAc : PI α1-6 GlcNAc-transferase 
complex might exist in T. brucei we selected TbGPI3, which encodes a 455 amino acid 
protein with two predicted transmembrane domains, one near its N-terminus and one 
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near its C-terminus (Käll, Krogh and Sonnhammer, 2004), for epitope tagging. We 
chose this PIGA(GPI3) homologue as the bait protein because PIGA has been shown to 
have either direct or indirect interactions with all other subunits in the mammalian 
UDP-GlcNAc : PI α 1-6 GlcNAc-transferase complex (Kinoshita, 2020). Alignment of 
putative TbGPI3, yeast GPI3 and PIGA protein sequences show that the T. brucei 
sequence has 43.9% and 50.8% sequence identity with the yeast and human sequences, 
respectively (Fig 5.1).  
In situ tagging of the TbGPI3 gene was achieved by transfecting BSF T. brucei with 
PCR products amplified from the pMOTag43M plasmid (Oberholzer et al., 2006) with 
primers OL1 and OL2, (Fig 5.2A). Transfected cells were selected using hygromycin 
and subsequently cloned by limit-dilution. Lysates of four separate clones were 
subjected to anti-Myc Western blotting (Figs 1B and 1C). In situ tagged TbGPI3-3Myc 
protein was detected in all four clones at an apparent molecular weight of ~47 kDa, 
somewhat lower than the predicted molecular weight of 55 kDa (Fig 5.2C, lanes 1-4). 
The specificity of this staining, although weak, is illustrated by the absence of 
comparable staining for the un-transfected cell sample (Fig 5.2 C, lane 5). The weakness 
of the TbGPI3-3Myc staining with anti-Myc is a function of the extremely low 
abundance of TbGPI3 in the total cell proteome, where it ranks 6475th out of 7149 
detectable protein groups (Table 5.1), and the limitations of protein loading for BSF cell 
lysates on SDS-PAGE caused by the abundance of VSG and tubulin in these cells from 
their surface coat and subpellicular cytoskeleton, respectively. These can be seen 





Figure 5.1 Alignment of PIGA and TbGPI3 was generated by the Tcoffee program. 
 * = identical residues, : = conserved residues. GPI3, PIGA and TbGPI3 sequences are from 






Figure 5.2 In situ C-terminal tagging of TbGPI3 with 3Myc. 
 A: Map of plasmid pMOTag43M (Oberholzer et al., 2006) used for the in situ tagging of 
TbGPI3, and a scheme of how the PCR product generated with the indicated forward (For) and 
reverse (Rev) primers inserts into the 3’-end of the TbGPI3 ORF (checked box) and 3’-UTR 
(striped box) in the parasite genome to effect in-situ tagging.  HYG = hygromycin 
phosphotransferase selectable marker; igr = α-β tubulin intergenic region. B: Ponceau staining 
of denaturing SDS-PAGE Western blot shows similar loading and transfer of lysates 
(corresponding to 5×106 cells) from four in-situ tagged clones (lanes 1-4) and wild type cells 
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(lane 5). C: An identical blot was probed with anti-Myc antibody. TbGPI-3Myc is indicated by 
the arrow. The positions of molecular weight markers are indicated on the left of (B) and (C). 
 
 
5.3 Solubilisation and native-PAGE of TbGPI3-3Myc.  
The analysis of epitope-tagged membrane bound multiprotein complexes requires 
detergent extraction and anti-epitope pull-down under conditions that preserve 
intermolecular interactions within those complexes. To investigate detergent extraction 
conditions, TbGPI-3Myc expressing cells were cultured and lysed with 0.5% digitonin, 
1% digitonin, 1% TX-100, 1% NOG and 1% DM and centrifuged. The solubilised 
proteins in the supernatants from these treatments, along with a 1% TX-100 extract of 
wild type cells, were immunoprecipitated with Myc-TrapTM agarose beads that were 
washed three times and finally eluted with synthetic c-Myc peptide. The proteins in the 
eluates were separated by denaturing SDS-PAGE and by native PAGE (Schägger et al., 
1991) and analysed by anti-Myc Western blot (Figs 5.3A and 5.3B, respectively). All 
detergents, apart from DM, extracted the TbGPI3-3Myc protein (Fig 5.3A). Of these 
conditions, 1% TX-100 gave the highest efficiency of extraction but duplicate samples 
analysed by native PAGE and anti-Myc Western blot showed that digitonin best 
preserved a TbGPI3-3Myc-containing complex with a native apparent molecular weight 
of ~240 kDa and that 0.5% digitonin gave a higher-yield of the complex than 1 % 
digitonin (Fig 5.3B). The reason for not detecting any clear complexes in other 
conditions may be due to the ~240 kDa complex falling apart into multiple sub-
complexes below the limits of detection. In all of these experiments, we adopted a pull-
down (from 2 x 108 cell equivalents) prior to immunodetection approach because of the 
aforementioned low abundance of TbGPI3 and its expected partner proteins (Table 1.1) 





Figure 5.3 TbGPI3-3Myc is present in complexes in BSF T. brucei. 
 A: Aliquots of 2 × 108 cells were harvested and lysed in lysis buffer containing different 
detergents to assess TbGPI3-3Myc solubilisation. After immunoprecipitation of the 
supernatants with anti-Myc agarose beads, proteins were eluted with 0.5 mg/mL c-Myc peptide 
solution and aliquots were subjected to SDS-PAGE followed by anti-Myc Western blotting. B: 
Identical samples were also separated by native-PAGE and subjected to anti-Myc Western 
blotting. In both cases, lane 1 corresponds to wild type cells lysed with 1% TX-100 as a 
negative control and lanes 2-6 correspond to TbGPI3-3Myc clone1 lysed with 0.5% digitonin, 
1% digitonin, 1% TX-100, 1% NOG or 1% DM, respectively.  
 
5.4 Identification of T. brucei UDP-GlcNAc : PI 1-6 GlcNAc-transferase 
complex components by quantitative proteomics. 
Having established detergent solubilisation conditions that retained TbGPI13-3Myc in a 
complex, we performed label-free quantitative proteomics on Myc-TrapTM pull downs 
to identify the components within the complex. For this experiment, BSF WT and 
TbGPI13-3Myc expressing parasites were grown under identical conditions and the 
same numbers of cells were harvested and lysed in 0.5 % digitonin lysis buffer. 
Immunoprecipitation was performed using Myc-TrapTM beads and the proteins eluted 
from these two samples with SDS sample buffer were processed to tryptic peptides for 
LC-MS/MS analysis (Fig 5.4A). The experiments were performed in biological 
triplicates and the data were analysed using MaxQuant software and a newly developed 
data analysis method written in Python called ProtRank (Medo, Aebersold and Medová, 
2019), see Materials and Methods. The protein groups identified ((Ji et al., 2021) S2 
File) were displayed on a plot of the minus log10 value of their False Discovery Rate 
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(y-axis) and enrichment rank (x-axis) between the bait versus control samples (Fig 
5.4B). As expected, the bait protein TbGPI3-3Myc was the most highly enriched protein 
and its putative partner proteins TbGPI15, TbGPI19, TbGPI2, TbGPI1 and TbERI1 
were also significantly enriched. Notably, TbDPM2 (dolichol-phosphate-mannose 
synthetase 2) was not detected. However, although TbDPM2 is annotated in the 
TriTrypDB database it should be noted that, like yeast, T. brucei makes a single-chain 
dolichol-phospho-mannose synthetase (DPM1) (Mazhari-Tabrizi et al., 1996) rather 
than a trimeric enzyme made of a soluble catalytic DPM1 subunit associated with small 
transmembrane DPM2 and DPM3 subunits, as found in mammalian cells. For these 
reasons, we feel that the absence of DPM protein components in the T. brucei complex 
is to be expected.  
Interestingly, an Arv1-like protein (hereon referred to as TbArv1, Tb927.3.2480) 
and a putative ubiquitin-conjugating enzyme E2 (UbCE, Tb927.2.2460) were also co-
immunoprecipitated with TbGPI3 (Fig 5.4C). The data were also processed in a 
different way (see Materials and Methods) that plots the experimental rank (x-axis) 
against the rank order of estimated abundances of the protein groups in the total cell 
proteome, generated from data in (Tinti, Maria Lucia S Güther, et al., 2019), on the y-
axis (Fig 5.4C). In this plot, the very low abundance TbArv1 (undetectable in the total 
cell proteome) clusters better with the canonical and similarly low abundance UDP-
GlcNAc : PI 1-6 GlcNAc-transferase subunits. By contrast, although UbCE is clearly 
highly-enriched in the pull-down it is a much more abundant protein, suggesting that 




Figure 5.4 Identification of UDP-GlcNAc : PI α1-6 GlcNAc-transferase subunits by 
immunoprecipitation of TbGPI3-3Myc from BSF T. brucei digitonin lysates. 
 A: Scheme of the label-free proteomics approach to identify TbGPI13-3Myc binding partners. 
BSF WT and TbGPI13-3Myc expressing cell lines were cultured, harvested and lysed in 0.5% 
digitonin lysis buffer. Identical quantities of the supernatants were subjected to anti-Myc 
agarose bead immunoprecipitation and the bound proteins were eluted from the beads with SDS 
sample buffer. The eluted proteins were reduced, alkylated and digested with trypsin and the 
resulting peptides analysed by LC-MS/MS. B: Volcano plot comparing protein groups present 
in the anti-cMyc immunoprecipitates from TbGPI3-3Myc expressing cell lysates versus WT cell 
lysates. Mean values (from biological triplicate experiments) for each protein group (dots) are 
plotted according to their minus log10 False Discovery Rate values (y-axis), calculated by 
MaxQuant, and the enrichment rank (x-axis). The enrichment rank was computed with the 
ProtRank algorithm using the iBAQ values calculated by MaxQuant. The higher the rank value 
on the x-axis, the higher the abundance in the TbGPI3-3Myc samples. The putative subunits of 
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UDP-GlcNAc : PI α1-6 GlcNAc-transferase in T. brucei are highlighted in red and annotated 
with their corresponding names (Table 5.1). C: Relative intensity plot using a new algorithm. 
The same data as (B) are plotted with a different y-axis, whereby each protein group is assigned 
an intensity rank from the most abundant protein group (1) to least abundant protein groups 
(7149) based on their summed eXtracted Ion Currents (XICs) for the total BSF proteome. 
(Details of the mass spectrometry and data analysis are provided in in Materials and Methods.) 
 
5.5 Investigating co-IP proteins of TbGPI3-3Myc using cross-linking 
proteomics. 
5.5.1 Optimisation of cross-linking conditions for TbGPI13-3Myc 
To investigate whether there might be more novel subunits in the GPI GnT complex in 
T. brucei, in particular possible soluble partner proteins, the cross-linking proteomics 
methodology established for TbGPI12 (section 4.2) was adapted and applied to TbGPI3.  
First, whole hypotonic cell lysate (membranes and cytosol), and the membrane fraction 
collected by centrifugation therefrom, were incubated with 8 mM DTSSP. The TbGPI3-
3Myc protein was present in high apparent MW complexes in both samples (Fig 5.5A, 
lanes 2 and 4) as compared to the non DTSSP-treated controls (lanes 1 and 3). 
However, more TbGPI-3Myc appeared in the whole cell lysate sample (lane 2). This 
suggested that using whole cell lysate for the cross-linking reaction, rather than the 
membrane fraction, might be advantageous in identifying components of cross-linked 
TbGPI-3Myc-containing complexes. 
Next, the concentration of DTSSP cross-linker was optimised. Under all conditions 
tested (1, 2, 4 and 8 mM DTSSP), high apparent MW protein complexes containing 
TbGPI3-3Myc were detected, with no significant differences between these samples 
(Fig 5.5B). Therefore, a concentration of 1mM DTSSP was chosen for subsequent 
experiments as a higher concentration crosslinker might lead to the identification of 




Figure 5.5 Optimisation of cross-linking reactions for TbGPI3-3Myc. 
 A: Comparison of two different sample preparations for cross-linking reactions. Lane 1 and 2: 
TbGPI3-3Myc expressing cells were hypotonic lysed and cross-linking reactions were 
performed to the whole cell lysate with 0 and 8 mM DTSSP. Lane 3 and 4: The membrane 
fraction of the cell lysates of the TbGPI3-3Myc expressing cell were collected and cross-linking 
reactions were performed with 0 and 8 mM DTSSP. Proteins were then solubilised with 2% 
TX-100 and IPs were performed. Eluted proteins were analysed by SDS-PAGE following by 
anti-Myc Western blot. B: Optimisation of the DTSSP crosslinker concentration: TbGPI3-3Myc 
expressing cells were lysed and cross-linking reactions were performed using 8, 4, 2, 1 and 0 
mM DTSSP (lanes 1-5, respectively). IPs were performed on the 2% TX-100 solubilised 
proteins and an anti-Myc Western blot was performed subsequently on the eluted proteins.  
 
5.5.2 Identification of co-IP proteins of TbGPI3-3Myc through cross linking 
proteomics 
A scaled-up cross-linking reaction was then set up for the whole cell lysate of TbGPI3-
3Myc expressing cells using 1 mM DTSSP followed by 2% TX-100 solubilisation and 
anti-Myc immunoprecipitation. The eluted proteins were separated by SDS-PAGE and 
the gel regions that contained TbGPI3-3Myc complexes, and the corresponding BSF 
WT control counterparts (Fig 5.6A, lane 1 and 2, outlined in red) were cut and send for 
label free quantitative proteomics identification. The proteins identified were plotted as 
the log2 values of the ratios (TbGPI3-3Myc IP sample (bait) to the BSF WT (control) IP 
sample) of their Maxquant computed intensities (x axis) and the Log10 value of sum of 
their intensities detected in both samples (y axis) (Fig 5.6B). A protein cut-off score of 5 
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was also applied, to control for protein identification quality by mass spectrometry, and 
the proteins with log2 bait/control values >2 are listed in (Table 5.2). 
Only TbGPI3 out of eight putative GPI GnT subunits (Table 5.1) was enriched and 
identified by this approach, and the quality of the protein identification by mass 
spectrometry was not ideal with calculated protein scores less than 15.  Of the other 
proteins: Tb927.6.3800 is unlikely to be a specific partner protein for TbGPI3-3Myc as 
it thought to be a mitochondrial heat shock 70 (HSP70) protein. It is notable that it is a 
very abundant cellular protein according to its ranking from the total T. brucei cell 
proteomics data. Tb927.9.14280 is a 187 kDa cytosolic protein and contains two protein 
domains which are a concanavalin A-like lectin domain (Con A-like domain) 
(SSF49899) and an armadillo (ARM) repeat superfamily domain (SSF48371) annotated 
in the SUPERFAMILY dataset (Wilson et al., 2007). Proteins containing Con A-like 
domains are predicted to be involved in cell recognition and adhesion. However, Con-A 
itself is an -Man-specific lectin, and GPI intermediates (Man2GlcN-PI and beyond) are 
able to bind to it (Vidugiriene and Menon, 1994). Thus, it is conceivable that 
Tb927.9.14280 could bind to and possibly sense GPI intermediate levels and regulate 
the first step of the pathway, however, this is highly speculative. While there are several 
different classes of function for proteins containing ARM repeat domains, these include 
roles in vesicular transport and membrane tethering, both of which could speculatively 
be relevant for ER membrane-based GPI biosynthesis (Striegl et al., 2010).  
Tb927.10.7130 is a hypothetical protein with no predicated signal peptide or 
transmembrane domain. The localisation of  N and C-terminal tagged Tb927.10.7130 
suggests it residues at cortical cytoskeleton (Dean et al., 2017) which indicates this 
protein is unlikely involved in the GPI anchor biosynthesis pathway in  the ER. 
Tb927.10.2020 is hexokinase which is cytoplasmic and involved in glycolysis and other 
carbohydrate metabolic processes. Hexokinase is an abundant protein (29th ranking out 
of 7149 detected proteins) and, like the mitochondrial HSP70, unlikely to be 
specifically enriched with TbGPI3-3Myc. In summary, the candidate hit most worthy of 
any further investigation is Tb927.9.14280.  However, confidence in this hit is 
diminished by the lack of “positive control hits” in the form of one or more of the other 
known GPI GnT complex components (Table 5.1). In particular the data from 
Kinoshita’s group on the mammalian GPI GnT suggest that, by analogy with the PIGA, 
C and H subcomplex, TbGPI3 ought to be physically associated with TbGPI2 and 
TbGPI15 (Hong et al, 1999). The reasons for their absence could be due to any or all of 
the following factors: ⅰ, The experimental conditions may have been sub-optimal for 
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cross-linking, in particular (Fig 5.6A) suggests that less of the TbGPI3-3Myc containing 
protein complexes were formed in the scaled up cross-linking experiment compared 
with the small-scale trial experiment (Fig 5.5B). This indicates that the cross-linking 
reaction in the scaled-up experiment was insufficient and the TbGPI3-3Myc containing 
complexes that were not stabilised by the crosslinker would be disrupted with stringent 
2% TX-100 solubilisation following the cross-linking reaction. ⅱ, The efficacy of cross-
linking reactions to cross link the specific partner proteins of TbGPI3 may have been 
diluted when applied to the whole cell lysate, as opposed to the lower protein content 
washed membrane fraction. The idea of using whole cell lysate for cross-linking in 
TbGPI3-3Myc IP experiment was to identify novel soluble co-IP proteins for TbGPI3-
3Myc which, on the other hand, may have also introduced abundant soluble proteins 
(like hexokinase and mitochondrial HSP70) for artefactual cross-linking to TbGPI3-
3Myc. ⅲ, Lack of biological replicates for rigorous proteomics identification.  
 
 
Figure 5.6 Identification of TbGPI3-3Myc co-IP proteins after cross-linking of the 
hypotonic whole cell lysate. 
 A: Cross- linking experiments were performed on TbGPI3-3Myc expressing and BSF WT total 
cell lysates using 1 mM DTSSP. An anti-Myc IP was then performed on 2% TX-100 solubilised 
proteins. Proteins eluted from the beads were detected by anti-Myc Western blotting. The gel 
regions (red rectangles) from another gel run in parallel were sent for label free proteomics.   B: 
Plot of proteins identified by LC-MS/MS performed on the regions shown in panel A. X axis: 
log 2 ratio of protein intensities detected in the TbGPI3-3Myc IP sample to their intensities 
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detected BSF WT IP samples. Y axis: log 10 value of the sum protein intensities obtained in 
both TbGPI3-3Myc and BSF WT IP samples.  
  
Table 5.2 List of proteins that co-IP with TbGPI3-3Myc identified by cross linking proteomics 
Gene ID  Log2 
bait/control 





Tb927.2.1780 10.40 TbGPI3 
(N-acetylglucosaminyl-phosphatidylinositol 
biosynthetic protein, putative) 
6475 
Tb927.9.14280 7.63 hypothetical protein, conserved 5392 
Tb927.10.7130 4.02 hypothetical protein, conserved 3367 
Tb927.10.2020 3.69 hexokinase 29 




















6 Results Ⅲ - The identification of a Trypanosoma brucei 
GPI anchor inositol deacylase (TbdeAc2) partner protein. 
6.1 Identification co-IP proteins of TbdeAc2-3Myc using cross-linking 
proteomics. 
6.1.1 Analysis of TbdeAc2 Gene Product  
The gene product of  Tb927.3.2610, GPI inositol deacylase 2 (TbdeAc2) was identified as a 
GPI anchor inositol deacylase in T. brucei through BLAST search using rat PGAP1 amino acid 
sequence as query sequence (Hong, et al., 2006). TbdeAc2 encodes a protein of  815 amino 
acids (91.4 kDa theoretical MW) with 11 predicted transmembrane domains (Käll, Krogh and 
Sonnhammer, 2004).  Like its yeast homologue Bstp1 (Tanaka et al., 2004), it contains an ~50 
amino acid extension at its N-terminus compared to PGAP1.  Knockdown of TbdeAc2 by 
RNAi (Hong, Nagamune, Morita, et al., 2006) showed that that TbdeAc2 removes the inositol-
linked acyl chain and that this needs to occur before fatty acid remodelling and attachment of 
the GPI anchor to VSG in BSF T. brucei. These data, and the observation that GPI 
intermediates from Man1GlcN-PI onwards are in equilibrium between their inositol acylated 
and inositol deacylated forms, were consistent with those previously reported using chemical 
inhibition of inositol deacylation with diisopropylfluorophosphate (DFP) (Güther and 
Ferguson, 1995). The structure and biosynthesis of GPI anchor intermediates in PCF 
trypanosomes was described by Field and colleagues (Field, Menon and Cross, 1991)(Field, 
Menon and Cross, 1991)(Field, Menon and Cross, 1992) and these studies showed that inositol 
deacylation does not occur in this lifecycle stage. Consistent with this, the TbdeAc2 mRNA 
transcript levels were found to be 6-fold lower in PCF than in BSF cells (Hong, Nagamune, 
Morita, et al., 2006).  
The fact that TbdeAc2 catalyses several deacylation steps in the BSF GPI anchor 
biosynthesis pathway, i.e., removing the acyl chain from Man1GlcN-(acyl)PI, 
Man2GlcN-(acyl)PI, Man3GlcN-(acyl)PI and from glycolipid C (Fig 1.10) suggests that 
it may physically interact with one or several of the enzymes catalysing adjacent 
biosynthetic steps. Further, it may require chaperone and/or regulatory proteins for its 
function. In particular, since TbdeAc2 action is a pre-requisite for fatty acid 
remodelling, we considered it possible that it might be associated with components of 
that machinery, such as the unknown component GPI phospholipase A2 (PLA2). For 
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these reasons we aimed to establish whether TbdeAc2 was present in a protein complex 
and, if so, identify its partner protein(s).  
6.1.2 In situ epitope tagging TbdeAc2 and native PAGE of TbdeAc2-3Myc 
To investigate whether TbdeAc2 was present in protein complex(es), in situ epitope 
tagging of TbdeAc2 with a 3 × c-Myc epitope tag at its C-terminus was achieved using 
the same method described in Section 5.2 with primers OL3 and OL4. The success of 
expressing TbdeAc2-3Myc protein was examined by anti-Myc Western blot. Cell 
lysates in SDS sample buffer (5 × 106 cell equivalents per lane) were separated by SDS-
PAGE and Western blotted with anti-Myc antibody, however, no signal was detected 
(data not shown). We concluded from this that TbdeAc2 was most likely of very low 
abundance in BSF trypanosomes, and this is consistent with our recent whole proteome 
data where TbdeAc2 ranks 5175th in abundance out of 7149 detected proteins (Ji et al., 
2021) supplementary Table 1). A sequential anti-Myc pull down, similar to that 
described in Section 4.1.2, was then performed using a 1% TX-100 cell lysates 
containing 2 × 108 cell-equivalents of the TbdeAc2-3Myc expressing cell line in parallel 
with identical lysates of the BSF WT cell line. The proteins eluted with SDS sample 
buffer were then subjected to denaturing SDS-PAGE and analysed by anti-Myc Western 
blot. TbdeAc2-3Myc was detected in the first pull down at a ~ 90 kDa apparent MW 
(Fig 6.1A, lane 1), but not in the second pull down (Fig 6.1A, lane 3). As expected, 
there was no signal detected in BSF WT control samples (Fig 6.1A, lanes 2 and 4). 
These data indicated that under the conditions used, TbdeAc2-3Myc proteins could be 
quantitatively immunoprecipitated by a single pull down.  
To enable later native-PAGE analysis of TbdeAc2-3Myc IP products, a mild lysis 
condition using 0.5% digitonin as detergent for pull down and a compatible mild elution 
method, with c-Myc peptide, were assessed. Anti-Myc Western blot after the pull down 
showed that TbdeAc2-3Myc could be successfully solubilised by 0.5% digitonin, bound 
to anti-Myc beads and eluted with either c-Myc containing buffer (Fig. 6B, lane1) or 
SDS sample buffer (Fig 6B, lane2), albeit in lower yield than using 1% TX-100 lysis 
and SDS sample buffer elution. The c-Myc peptide eluted samples were then analysed 
by native-PAGE following by anti-Myc Western blot. As expected, nothing was 
detected in the sample for the WT control cell lysate (Fig. 6C, lane 1), whereas 
TbdeAc2-3Myc was clearly detected in a single band at with an appMW of ~ 240 kDa 
(Fig. 6C, lane 1).  This appMW is 2-3 times higher than that of a TbdeAc2 monomer, 
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indicating it was present as either a homodimer or homotrimer, or a in complex with 
another protein or proteins.  
  
 
Figure 6.1 Immunoprecipitation and anti-Myc Western Blot of TbdeAc2-3Myc. 
A: Anti-Myc Western blot analysis of the IPs from TbdeAc2-3Myc expressing (lane 1 and lane 
3) and BSF WT (lane 2 and 4) T. brucei 1%TX-100 cell lysates following two sequential IPs 
with anti-Myc agarose beads. B: TbdeAc2-3Myc expressing cells were lysed with 0.5% 
digitonin followed by anti-Myc pull down. Proteins were eluted with 0.5% digitonin buffer 
containing 1 mg/mL c-Myc peptide (lane 1) or SDS sample buffer (lane 2) and subjected to 
reducing SDS-PAGE and anti-Myc immunoblotting. C: A duplicate IP to that described in 
(panel B), and a control IP made using equivalent 0.5% digitonin WT cell lysate, were eluted 
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with c-Myc peptide and subjected to native PAGE and anti-Myc Western blot analysis. Lane 1, 
sample from WT control lysate; lane 2 from TbdeAc2-3Myc expressing cell lysate.  
 
6.1.3 Attempt to identify co-IP proteins with TbdeAc2-3Myc by label-free 
proteomics 
Having established appropriate pull-down conditions that preserve the protein complex 
that TbdeAc2-3Myc forms, label free quantitative proteomics were performed with the 
TbdeAc2-3Myc and BSF WT IPs to further identify the components within the 
complex. For this experiment, BSF WT and TbdeAc2-3Myc expressing parasites were 
grown under identical conditions and the same numbers of cells were harvested and 
lysed in 0.5 % digitonin lysis buffer. Pull down was performed with the cell lysates and 
proteins were eluted with SDS sample buffer, resolved by SDS-PAGE, gel pieces were 
cut and digested with trypsin and analysed by LC-MS/MS. The proteins identified from 
proteomics were plotted by the Log10 value of their protein intensity detected by mass 
spectrometry (y axis) against the log2 value of the ratio of their intensities in the 
TbdeAc2-3Myc IP sample versus in the BSF WT IP sample. As shown in (Fig 6.2), the 
most highly enriched protein was Tb927.11.17650 which is a truncated variant surface 
glycoprotein sequence of 134 amino acids with an N-terminal signal peptide. However, 
it was more enriched than the TbdeAc2-3Myc bait protein, so we expect this is an 
artefact. Although TbdeAc2-3Myc was the second most enriched protein, there were 
another109 proteins detected with log 2 bait/control values greater than 5, and 465 
proteins with log2 bait/control values greater than 2 
(https://github.com/mtinti/TbdeAc2attempt1). It seemed very unlikely that we were 
seeing selective enrichment of proteins with TbdeAc2-3Myc in this experiment, so we 
investigated alternative approaches. If we were to return to this label-free approach, we 





Figure 6.2 Identification of co-IP proteins of TbdeAc2-3Myc by label-free quantitative 
proteomics. 
 Plot of TbdeAc2-3Myc versus BSF WT IP results. The plot shows the Log2 value of the 
intensity of proteins in the bait (TbdeAc2-3Myc) IP relative to the control (BSF WT) IP (x axis) 
against the Log10 value of protein intensity (y axis). The TbdeAc2-3Myc (bait) protein is 
annotated and highlighted in red. 
 
6.1.4 Identification of co-IP proteins with TbdeAc2-3Myc through cross-linking 
proteomics 
As TbdeAc2 is a transmembrane protein, and the partner proteins associated with 
TbdeAc2 may also contain hydrophobic domains, the cross-linking method that was 
developed for studying transmembrane protein complexes (Section 4.2) was applied to 
TbdeAc-3Myc. Briefly, BSF T. brucei cells expressing TbdeAc2-3Myc were subjected 
to hypotonic lysis and the membrane fraction from the lysate was collected by 
centrifugation. Cross-linking reactions were performed on the re-suspended membrane 
fractions by adding different concentrations of DTSSP. The proteins were then 
solubilised with 2% TX-100 followed by anti-Myc immunoprecipitation, the proteins 
eluted from the beads with SDS sample buffer were analysed by either immunoblotting 
or mass spectrometry.   
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First, different concentrations of DTSSP were tested to define the optimal concentration 
for the TbdeAc2-3Myc cross-linking reaction. From the test reactions (0, 1, 2, 4 and 8 
mM DTSSP), DTSSP-dependent high-molecular weight smeared bands appeared in a 
DTSSP concentration-dependent manner (Fig. 6.3A, lanes 1-5). Based on these results, 
we selected 4 mM DTSSP for the following proteomics experiments, based on similar 
considerations described in (Section 4.2).  Scaled-up the cross-linking experiments 
using 4 mM DTSSP were performed on washed cell membranes from the TbdeAc2-
3Myc expressing cell line and from control WT cells. The cross-linked membrane 
pellets were solubilised and anti-Myc pull downs were performed as previously 
described (Section 4.2). The eluted proteins were separated by SDS-PAGE and analysed 
by either anti-Myc Western blot (Fig 6.3B) or LC-MS/MS. The gel regions that were 
sent for proteomics are illustrated in the red rectangle regions in (Fig 6.3B).   
The proteomics data were plotted as the ratio of the intensity of the protein in the 
TbdeAc2-3Myc tagged sample divided by the sum intensity of the protein in both 
samples (x axis) and the log10 value of the protein scores. In this analysis, the proteins 
that were specifically enriched (i.e., TbdeAc2-3Myc and its partner proteins) should 
have a ratio that is very close to 1. A cut off-off of protein scores >15 was also applied 
for this dataset. Under these criteria, there were two protein groups identified with ratio 
of 1 (Fig 6.3C). The one with a higher protein score was the bait protein TbdeAc2-
3Myc, the other protein(s) was/were Tb927.11.11740 and/or Tb927.11.11750 which are 
too similar in sequence to be discriminated by the LC-MS/MS data. One or both of 





Figure 6.3 Cross-linking proteomics of TbdeAc2. 
 A, Optimisation of cross-linker concentrations for TbdeAc2-3Myc. TbdeAc2-3Myc expressing 
cells were lysed and the membrane fraction was collected and cross-linking reactions were 
performed using 0, 1, 2, 4 and 8 mM DTSSP (lanes 1-5, respectively). Membrane proteins were 
then solubilised in 2% TX-100 and IPs were performed. Eluted proteins were separated on SDS 
PAGE and anti-Myc Western blotting was performed on the transferred membrane. B, Cross-
linking experiments were performed on TbdeAc2-3Myc expressing (lane 1) and BSF WT (lane 
2) washed cell membranes using 4 mM DTSSP. An anti-Myc Western blot was performed to on 
the proteins that were eluted after IP. Duplicate gel regions to those indicated in red rectangles 
were sent for proteomics. C, Plot of label-free quantitative proteomics data obtained from the 
regions shown in panel B. X axis: ratio of protein intensities detected in the TbdeAc2-3Myc IP 
113 
 
sample compared with the sum of their intensities detected in the TbdeAc2-3Myc and BSF WT 
samples. Y axis: log 10 value of the Andromeda protein score calculated by Maxquant. 
 
6.2 Identification co-IP proteins of TbdeAc2-3Myc by SILAC proteomics 
6.2.1 Identification of co-IP proteins of TbdeAc2-3Myc with 0.5% digitonin 
buffer as lysis condition for pull down 
To validate the co-IP proteins of TbdeAc2-3Myc identified by cross-linking proteomics, 
an orthoganal pull-down experiment was then carried out under very mild solubilisation 
conditions and using SILAC proteomics methodology. For this experiment (Fig 6.4A), 
BSF WT and transgenic parasites (expressing TbdeAc2-3Myc) were grown under 
identical conditions for nine cell divisions, except that the TbdeAc2-3Myc expressing 
cell line was grown in “heavy medium” containing stable isotope labelled Lys and Arg 
(R6K4), while the BSF WT cells were grown in “light medium” containing unlabelled 
Lys Arg (R0K0). The BSF WT and the transgenic TbdeAc2-3Myc cells were counted 
and mixed together in a 1:1 ratio and lysed in 0.5% digitonin buffer after harvesting and 
washing steps. After immunoprecipitation by Myc-TrapTM beads, the proteins eluted 
with c-Myc peptide were processed to tryptic peptides for LC-MS/MS analysis. In this 
SILAC experiment, TbdeAc2-3Myc and any proteins that were specifically associated 
with it can be distinguished from non-specific proteins by the isotope ratios of their 
tryptic peptides: TbdeAc2-3Myc and its true partner protein peptides will have high 
heavy/light isotope ratios whereas non-specific proteins will have roughly equal 
heavy/light isotope ratios. This experiment was performed in biological triplicates to 
provide statistical power.  The raw data from this SILAC experiment was used to search 
a T. brucei predicted protein database using MaxQuant software. Each protein was 
displayed on a plot of the mean of the minus log10 p value of a t-test (between the 
TbdeAc2-3Myc and the BSF WT sample) (y axis) and the log2 value of the heavy to 
light isotope ratios of the same peptides (x axis) (Fig 6.4B). The bait protein TbdeAc2-
3Myc protein had the highest heavy/light ratio (14:1), and there was only one other 
protein group that was significantly enriched (i.e., with a heavy/light ratio > 4). This 
corresponded to Tb927.11.11740 or/and Tb927.11.11750 with a heavy/light ratio of 6.  
The reproducibility of the SILAC experiment was also visualised with three different 
types of pair-plots (histogram, scatter and density plots) using the log2 value of the 
heavy to light isotope ratios of the protein peptides collected from each replicate (Fig 
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6.4C). The Pearson correlation coefficient values calculated for each pair were very 
close to 1 (0.88 for replicates 1 and 2, 0.88 for replicates 1 and 3 and 0.90 for replicates 
2 and 3), indicating these three triplicates were highly correlated with each other.  
The identification of Tb927.11.11740 and/or Tb927.11.11750 as the co-IP protein(s) of 
TbdeAc2 through both cross-linking and SILAC proteomics analyses strongly 
supported the conclusion that TbdeAc2-3Myc interacts with Tb927.11.11740 and/or 
Tb927.11.11750. To examine whether both or only one of Tb927.11.11740 and 
Tb927.11.11750 is/are true partner protein(s) of TbdeAc2-3Myc, the two proteins were 
studied individually in later pull-down experiments.  
 
 
Figure 6.4 Summary of SILAC proteomics experiment. 
 A: Scheme of SILAC proteomics to identify proteins that specifically co-IP with of TbdeAc2-
3Myc. B: Volcano Plot of the combined SILAC proteomics data from 3 biological replicates. X 
axis: log 2 value of heavy to light isotope ratios of proteins peptides. Y axis: mean of minus 
log10 value of p values from a t-test. C: Reproducibility analysis of three replicates from 
SILAC proteomics data. A pairwise comparison of the log2 value of the heavy to light isotope 
ratios of the protein peptides of three replicates visualizing with histogram counts (a, e, i) scatter 
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plots (b, c, f) and density plots (d, g, h). The Pearson correlation coefficient values (abbreviated 
as p) of each pair are also reported on the density plots.  
 
6.2.2 Attempt to find additional co-IP proteins of TbdeAc2-3Myc using 0.3% 
digitonin containing lysis buffer for pull down 
When performing pull down experiments coupled with SILAC proteomics identification 
methods searching for the co-IP proteins of TbdeAc2, another milder lysis condition 
which utilises 0.3% instead of 0.5% digitonin containing buffer was tested for protein 
solubilisation for pull down. All the other procedures were identical as described in 
section 6.2.1 and this experiment was also performed in biological triplicates. The 
proteins that were identified were plotted by mean of minus log10 p value of a t-test 
(between the TbdeAc2-3Myc and the BSF WT sample) (y axis) and the log2 value of 
the heavy to light isotope ratios of the same peptides (x axis) (Fig 6.5). TbdeAc2-3Myc 
protein had the highest heavy/light ratio which was 16:1, while the other protein whose 
heavy/light ratio was higher that 4 (with ratio 4.6:1) was Tb927.4.4580 which was not 
the same co-IP protein identified in previous two proteomics methods. Tb927.4.4580 is 
a hypothetical protein ranking the 2711th out of 7149 identified proteins based on the 
BSF whole proteins proteomics dataset (Ji, Tinti and Ferguson, 2021) which indicated 
that it was a relatively abundant protein that may have been  non-specifically bound to 
TbdeAc2-3Myc. According to TritrypDB (Aslett et al., 2010), Tb927.4.4580 is a 
cytoplasmic protein that does not contain signal peptide or transmembrane domain. 
There are no known motifs or domains annotated in this protein either. The features of 
this protein suggests that it is not involved in the GPI anchor biosynthesis pathway, thus 
we did not perform further studies on it. In this experiment Tb927.11.11740/50 did not 
appear at all in the pull-down dataset, perhaps suggesting that 0.3% digitonin failed to 




Figure 6.5 Volcano Plot of the combined SILAC proteomics data from 3 biological 
replicates. 
 X axis: log 2 value of heavy to light isotope ratios of proteins peptides. Y axis: mean of minus 
log10 value of p values from a t-test. 
 
6.3 Identification of Tb927.11.11750 as the sole co-IP protein of TbdeAc2 
through reverse pull down 
6.3.1 Analysis of Tb927.11.11740 and Tb927.11.11750 
The co-IP protein(s) of TbdeAc2 found by two different proteomics approaches is/are a 
hypothetical protein(s) encoded by one or both of two closely-related tandemly arrayed 
genes. These two genes are Tb927.11.11740 and Tb927.11.11750 which share 94.5% 
identity in nucleic acid sequence, further, 248 bp of 5’ untranslated region (UTR) 
sequence upstream of the start codons of both genes are identical. Analysis of the 
predicted amino acid sequences of these two proteins show they share significant 
similarities but some differences: The alignment of amino acid sequences of 
Tb927.11.11740 and Tb927.11.11750 (Fig 6.6A) shows they share 92 % identity in 
amino acid sequence but with 52 amino acid differences at their C-termini. This high 
degree of sequence identity is why the proteomics methods could not distinguish these 
two proteins based on tryptic peptide mass spectrometry as no unique C-terminal 
peptides of these two proteins were identified. Both proteins contain a 24 amino-acid 
(aa) predicted signal peptide (SP) at their N-termini (Kall et al., 2004) (Käll, Krogh and 
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Sonnhammer, 2004) and one transmembrane domain near their C-termini (Käll, Krogh 
and Sonnhammer, 2004).  In addition, both proteins have a putative catalytic lipase 
motif GXSXG (Derewenda and Sharp, 1993) and a potential N-glycosylation site 
(Gupta and Brunak, 2002). However, only protein Tb927.11.11750 has a possible ER 
retention signal (KXKXX)(Kruzel et al., 2017) at its C-terminus, indicating that 
Tb927.11.11740 and Tb927.11.11750 may have different subcellular localisations. 
There is also a phosphoglycerate mutase-like Histidine phosphatase superfamily domain 
(SSF53254) (Wilson et al., 2007) found in both proteins. The orthologs of both two 
genes have been only identified in the kinetoplastidea class (Trypanosoma theileri, 
Trypanosoma Cruzi ect) indicating they likely emerged at the same time point in the 
evolutionary progress. To investigate the associations of these two proteins with 
TbdeAc2 individually, epitope tagging of Tb927.11.11740 and Tb927.11.11750 was 





Figure 6.6 Summary of protein features of Tb927.11.11740 and Tb927.11.11750. 
 A: Alignment of amino acid sequences of Tb927.11.11740 and Tb927.11.11750 generated by T 
coffee. * = identical residues, : = conserved residues. Protein sequences were retrieved from 
TritrypDB dataset (Aslett et al., 2010). Amino acid residues 1-448 of these two proteins are 
identical. B: Comparison of Tb927.11.11740 and Tb927.11.11750 proteins. Different domains 
and motifs are indicated. Amino acid numbers are above the models. 
 
6.3.2 Tb927.11.11740 does not form a protein complex with TbdeAc2 
To independently investigate whether Tb927.11.11740 forms complex with TbdeAc2, 
in situ tagging of Tb927.11.11740 at its C-terminus with triple human influenza 
hemagglutinin (HA) tag was achieved using same strategy introduced in Section 5.2 by 
changing the template plasmid from pMOTag43M to pMOTag4H (Oberholzer et al., 
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2006) with primers OL5 and OL6. Although Tb927.11.11740 and Tb927.11.11750 
share very high identity at the nucleic acid sequence level, the unique 3’end coding 
sequence and 3’UTR sequence of Tb927.11.11740 makes it possible to in situ tag 
Tb927.11.11740 without interfering with Tb927.11.11750. The in situ tagging construct 
was amplified from pMOTag4H and transfected into BSF WT cell line, hygromycin 
was added for selection. Recovered cells from the transfection were cloned by limit 
dilution and three clones picked to be checked by immunoblotting. Aliquots of cell 
lysates prepared with 1 × SDS sample buffer (equivalent to 5 × 106 cells) of the three 
clones were subjected to SDS-PAGE and anti-HA Western blot. However, no signal 
was detected in this experiment (data not shown). This was expected as Tb927.11.11740 
is a low abundance protein with a ranking 6882th out of 7149 detected proteins from our 
quantitative proteomics dataset (Ji, Tinti and Ferguson, 2021). After this test 
experiment, 5 × 107 Tb927.11.11740-3HA expressing cells of these three clones were 
then lysed with 1% TX-100 and immunoprecipitation was carried out with anti-HA 
magnetic beads. After washing, the proteins were eluted with 1 × SDS sample buffer 
and analysed by denaturing SDS-PAGE followed by anti-HA Western blot. 
Tb927.11.11740-3HA was detected in all three clones at an apparent molecular weight 
of ~64 kDa (Fig 6.7A lane 1-3), which was higher than its theoretical molecular weight 
54 kDa; the possible reasons for detection of higher molecular weight bands will be 
explained later. Subsequently, mild lysis and elution conditions for pulling down 
Tb927.11.11740-3HA were examined. From the anti-HA Western blot of different IP 
samples separated on a denaturing gel (Fig 6.7B), 0.5% digitonin lysis buffer (lane 2) 
could solubilise Tb927.11.11740-3HA protein, albeit with less efficiency compared to 
1% TX-100 (lane 1), using 1 × SDS sample buffer as the elution condition. Proteins 
bound to the beads could also be recovered by HA peptide elution buffer (lane 3) under 
the 0.5% digitonin lysis condition. However, more than half of the HA-tagged protein 
was left on the beads, as revealed by subsequently boiling the same beads in 1 × SDS 
sample buffer (lane 4). No HA-tagged proteins or anti-HA cross-reacting proteins were 
detected in the BSF WT samples, demonstrating the specificity of the pull down and 
detection system (lane 5). To check whether Tb927.11.11740 was present in any protein 
complexes, 6 × 108 BSF WT and Tb927.11.11740-3HA expressing cells were lysed 
with 0.5% digitonin containing buffer and immunoprecipitation was performed on the 
supernatants after centrifugation. Proteins that bound to the beads were eluted with 1 
mg/mL HA peptide containing buffer. In this experiment, duplicated samples of each 
cell line were prepared, one duplicate was subjected to denaturing SDS-PAGE and the 
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other was analysed by native-PAGE followed by anti-HA Western blot. The blot of the 
denaturing gel (Fig 6.7C, lane 1) showed a stronger detection of Tb927.11.11740-3HA 
compared to the 5 × 107 cell lysate with no detection in BSF WT sample. The duplicate 
samples on the native-PAGE (Fig 6.7D) showed that Tb927.11.11740-3HA was 
detected in two dominant bands. The stronger band that was at 66 kDa was similar to 
the apparent molecular weight of the protein monomer detected in the denaturing gel 
while the other band migrated between 146 to 242 kDa, suggesting that at least part of 
Tb927.11.11740-3HA was present in a protein complex.  
To ascertain what this protein complex was composed of, and whether TbdeAc2 was 
within the complex, triplicate IP samples of Tb927.11.11740-3HA and BSF WT were 
applied to native-PAGE and the gel regions that contained the Tb927.11.11740-3HA 
protein complexes and its counterparts in the control sample were sent for quantitative 
label free proteomics identification. The proteins identified from mass spectrometry 
were plotted by log10 value of their protein peptide intensities (y axis) and the log2 
value of the peptide intensity detected in the Tb927.11.11740-3HA sample (bait) versus 
in the BSF WT (control) sample (Fig 6.8). As expected, the bait protein 
Tb927.11.11740-3HA was the most highly-enriched protein, however, TbdeAc2 
(Tb927.3.2610) was not detected in this experiment indicating that Tb927.11.11740-
3HA does not form a protein complex with TbdeAc2.  Besides the bait protein, there 
were nine proteins identified with a log2 bait/control ratio greater than 2 as listed in 
(Table 6.1). Of these proteins, most of them were very high abundance proteins based 
on the protein ranking from the whole BSF WT proteomics dataset (Ji et al., 2021). 
These proteins were most likely non-specific proteins co-immunoprecipitated with 
Tb927.11.11740. Of these: Tb927.10.13800 has a protein ranking 1400th out of 7149th 
identified proteins (Ji et al., 2021) and is therefore a relatively high abundance protein. 
It has no predicated signal peptide or transmembrane domains so we consider this 
protein to be unlikely to be a specific partner protein of Tb927.11.11740. Tb927.3.4080 
is a putative pyruvate transporter whose protein ranking in the BSF total proteomics 
data is close to that of the bait protein. It is a 583 amino acid protein containing 14 
predicted transmembrane domains and a MFS general substrate transporter domain 
(SSF103473) (Wilson et al., 2007). This superfamily of proteins are membrane 
transport proteins that facilitate movement of small solutes across cell membranes in 
response to chemiosmotic gradients. It is possible that Tb927.3.4080 is a true partner 
protein for Tb927.11.11740 but, if so, it might suggest that they reside in the plasma 
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membrane. Their association would need to be verified with more biological replicates 
before performing function studies.  
 
 
Figure 6.7 Investigation of Tb927.11.11740 binding partners. 
A: Anti-HA Western blot of Tb927.11.11740-3HA after pull-down. Three clones of BSF 
Tb927.11.11740-3HA expressing cells (5×107 cells) were lysed in 0.5% digitonin lysis buffer 
and IP was performed on the supernatant after centrifugation using anti-HA magnetic beads. 
The beads were washed three times with washing buffer and proteins bound to the beads were 
eluted with SDS sample buffer and analysed by denaturing gel followed by anti-HA Western 
blot. B: Test of mild lysis and elution conditions. Tb927.11.11740-3HA was enriched as in 
panel A except using different lysis and elution conditions. Lane 1: 1% TX-100 lysis buffer and 
1 × SDS sample buffer for elution; lane 2: 0.5% digitonin lysis buffer and 1 × SDS sample 
buffer for elution; lane 3: 0.5% digitonin lysis buffer and 1 mg/mL HA peptide buffer for 
elution. Lane 4: same beads as lane 3 and sequentially eluted with 1 × SDS sample buffer. Lane 
5: BSF WT cell line 1% TX-100 lysate and eluted with 1 × SDS sample buffer. C and D: 
Tb927.11.11740-3HA and BSF WT cells were immunoprecipitated as in panel B with 0.5% 
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digitonin as lysis detergent and 1 mg/mL HA peptide solution as elution buffer. Eluted proteins 
were applied to either denaturing gel (C) or nativePAGE (D) transferred to nitrocellulose (C) or 
PVDF (D) membranes and detected by anti-HA antibody. 
 
 
Figure 6.8 Identification of co-IP proteins of Tb927.11.11740 through quantitative label 
free proteomics. 
Plot of proteins identified by LC-MS/MS that were carried out on the high-MW complexes 
regions of the NativePAGE gels after immunoprecipitating equivalent numbers of 
Tb927.11.11740-3HA and BSF WT cells. Proteins identified by mass spectrometry were plotted 
by log 10 intensity of the peptides (y axis) against log2 fold change between the peptides 
detected in the Tb927.11.11740-3HA bait versus BSF WT control sample. 
  
Table 6.1 List of proteins that co-IP with Tb927.11.11740-3HA identified by label free 
proteomics. 
Gene ID  Log2 
bait/control 





Tb927.11.11740 4.651396 membrane-bound acid phosphatase, putative 6882 
Tb927.11.5520 4.224686 triosephosphate isomerase 137 
Tb927.1.2410 3.472147 beta tubulin, pseudogene 11 
Tb927.10.13800 3.154322 hypothetical protein, conserved 1400 
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Tb927.3.4080 2.998646 Pyruvate transporter, putative 5922 
Tb927.9.10770 2.733352 polyadenylate-binding protein 2 133 
Tb927.4.2740 2.680354 p25-alpha, putative 294 
Tb927.3.3450 2.117101 
ADP-ribosylation factor-like protein 3, 
putative 
146 






6.3.3 Tb927.11.11740-3HA is N-glycosylated  
Previous anti-HA Western blot of Tb927.11.11740-3HA IP products separated on 
denaturing gel showed that the apparent molecular weight (appMW) of 
Tb927.11.11740-3HA (~64 kDa) was higher than its theoretical MW (the sum MW of 
Tb927.11.11740 and triple HA tag is ~ 57 kDa). The prediction of N-glycosylation of 
Tb927.11.11740 indicated this protein was N-glycosylated (Fig 6.6B) which might be 
the reason for the detection of extra MW for the protein. To test this hypothesis, 
digestion was performed using Peptide -N-Glycosidase F (PNGaseF). Briefly, IPs were 
performed on Tb927.11.11740-3HA and BSF WT 1% TX-100 cell lysates, as described, 
and after washing steps the proteins bound to the beads were denatured before setting 
up the digestion with or without PNGaseF, followed by SDS-PAGE and Western 
blotting with anti-HA antibodies. The blot showed that after PNGaseF treatment, the 
band corresponding to Tb927.11.11740-3HA shifted below its original detected position 
(Fig 6.9 A lane1: non treated, lane 2: treated) with no detection in the BSF WT cell 
controls (Fig 6.9A lane 3: non treated, lane 4: treated). The apparent MW of the 
detected bands of Tb927.11.11740-3HA were estimated based on the positions and MW 
of protein markers bands. The correlation of positions of protein marker bands and their 
molecular weights were plotted by log10 value of the MW (y axis) versus the Rf value 
of corresponding bands (x axis). In this case, the values of the 100, 75 and 50 kDa 
bands that were closer to the Tb927.11.11740-3HA bands were chosen to get better 
correlations. By using this method, the Rf values of Tb927.11.11740-3HA in the 
PNGase F treated and non-treated samples (0.361 and 0.378) resulted in appMW 
estimates of  ~65 kDa and ~ 61 kDa, respectively. The apparent MW of 
Tb927.11.11740-3HA in the PNGase F treatment sample (61 kDa) is close to the 
theoretical MW of 57 kDa indicating that the detection of higher MW band in the non-




Figure 6.9 Detection of N-glycosylation of Tb927.11.11740-3HA. 
 A: Pull down experiments were performed with 5 × 107 Tb927.11.11740-3HA and BSF WT 1% 
TX-100 cell lysates. The proteins that bound to beads were denatured in 1 × Glycoprotein 
Denaturing Buffer (NEB) at 50 °C for 10 min. The PNGaseF digestions were then performed in 
1 × GlycoBuffer(NEB) in the presence of 10% NP-40. The samples were subjected to 
denaturing SDS-PAGE followed by anti-HA Western blot. (Lane 1 and 2, PNGaseF non-treated 
and treated Tb927.11.11740-3HA samples; lane 3 and 4, PNGaseF non-treated and treated BSF 
WT samples). B: Plot of correlations of protein migration positions and molecular weights. X 
axis: Rf values of proteins (Distance travelled protein divided by distance travelled by the 
running buffer front). Y axis: log10 value of MWs of proteins.  The equation and the R squared 
value of the trend line were also displayed on the plot.   
 
6.3.4 Attempt to pull down Tb927.11.11750 with specific anti-peptide antibodies 
Reverse pull down of Tb927.11.11740-3HA showed that it was not the partner protein 
of TbdeAc2, leaving the hypothesis that Tb927.11.11750 is the co-IP protein of 
TbdeAc2. To verify the protein associations between TbdeAc2 and Tb927.11.11750, 
reverse pull down of Tb927.11.11750 is required. However, the sequence analysis of 
Tb927.11.11750 shows that it contains a 24 aa signal peptide at its N-terminus and a 
putative ER retention signal (K(X)KXX) at its C-terminus, making it unwise to tag this 
protein at its C- or N- terminus. Therefore, we attempted to raise anti-peptide antibodies 
against unique peptide sequences of Tb927.11.11750. These were raised by two 
different manufacturers (Davids Biotechnologie and Moravian Biotech) using two 
different peptide sequences SLYADEAILTGGVVASLC and CMYPVMFKQKMAV. 
The detection and specificity of these two antibodies were first tested by Western blot 
against T. brucei BSF cell lysates. For the anti-peptide antibody generated by Davids 
Biotechnologie, 5 × 106 (Fig 6.10 A and B, lanes 1 and 3) and 1 × 107 (Fig 6.10A and B, 
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lanes 2 and 4) BSF WT cell lysates were prepared and separated on a denaturing gel 
followed by the probing for Tb927.11.11750 by Western blot using the affinity-purified 
anti-peptide antibody at 0.5 (Fig 6.10B lanes 1 and 2) and 1 µg/mL (Fig 6.10B lanes 1 
and 2). Under these conditions, there was one band detected at ~50 kDa which was 
close to the theoretical MW of Tb927.11.11750 without its signal peptide. However, 
very high abundance proteins of T. brucei like tubulin and VSGs are also close to the 
detected bands, thus these detections could be non-specific. Similar detections were also 
observed when using the anti-peptide antibody raised by Moravian Biotech.  In this 
experiment, 2.5 × 106 cell lysates of BSF WT (Fig 6.10D lanes 1 and 3) and 
Tb927.11.11750 overexpressing cell line (Fig 6.10D lanes 2 and 4) were tested. The 
tested overexpression cell line were generated by introducing an ectopic copy of 
Tb927.11.11750 into BSF WT which was constructed in plew100 original version 
plasmid (Wirtz et al., 1999).  From the Western blot detection using 1 µg/mL (Fig 
6.10D lanes 1 and 2) and 2 µg/mL (Fig 6.10D lanes 3 and 4), one band at ~50 kDa was 
detected in all samples with no significant differences of intensities among them. To 
check whether this detected band represents Tb927.11.11750 or not, these two different 
antibodies were coupled to protein A agarose beads to perform pull down experiments. 
Briefly, lysates equivalent to 1 × 108 cell lysates per sample were prepared with 2%TX-
100 lysis buffer, 2 µg of each antibody and protein A agarose beads were added for 1 h 
incubation, and control samples without antibodies were carried out in parallel. After 
washing steps, the proteins bound to the beads were eluted and separated on denaturing 
gel, the gel regions that were expected to contain the Tb927.11.11750 were sent for 
label free quantitative proteomics identification. The proteins identified by LC-MS/MS 
were plotted by log10 value of their protein peptide intensities (y axis) and log2 value of 
the peptide intensities of bait versus control. Unfortunately, Tb927.11.11750 was not 
detected in either of these pull-down experiments, indicating neither of these two anti-
peptide antibodies were able to immunoprecipitate Tb927.11.11750 from T. brucei cell 
lysate. The only highly enriched protein was the IgG protein of rabbit, which suggested 
that antibodies were bound to protein A agarose beads and that, therefore, the failure in 
pulling down Tb927.11.11750 was not due to inefficiency of the antibody coupling but 




Figure 6.10 Tests for Tb927.11.11750 anti-peptide antibodies. 
A and B: Ponceau staining and Western blot using Tb927.11.11750 anti-peptide antibody raised 
by Davids Biotechnologie. Lane 1 to 4: 1% TX-100 lysates equivalent to 5 × 106 BSF WT cells. 
The concentration of primary antibody used is indicated at the bottom of panel B. C and D: 
Ponceau staining and Western blot using Tb927.11.11750 anti-peptide antibody raised by 
Moravian Biotech. Lanes 1 to 2: 1% TX-100 lysates equivalent to 2.5 × 106 BSF WT cells. Lane 
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2 and 4: 1% TX-100 lysates equivalent to 2.5 × 106 Tb927.11.11750 overexpressing cells. The 
concentration of primary antibody used is indicated at the bottom of panel D. 
 
 
Figure 6.11 Plot of proteins identified from Tb927.11.11750 anti-peptide antibody pull 
down proteomics experiments. 
 A and B: 1% TX-100 cell lysates equivalent to 1 × 108 BSF WT cells were incubated with 
(lanes 1 and 3) and without (lanes 2 and 4) 2 µg Tb927.11.11750 anti-peptide antibodies that 
were raised by Davids Biotechnologie and Moravian Biotech, respectively. Eluted proteins from 
the protein A beads were separated by denaturing gel and the band regions at ~50 kDa were cut 
off for proteomics identification. Proteins identified by mass spectrometry were plotted by 
log10 value of intensity of the peptides (y axis) against log2 fold change between the peptides 





6.3.5 Introducing an ectopic copy of internal 12Myc tagged Tb927.11.11750 
After the failed attempts at generating useful Tb927.11.11750 specific anti-peptide 
antibodies, a different strategy for tagging the protein which could facilitate later pull-
down experiments was designed. An overexpression plasmid for expressing a 12×c-
Myc internal tagged version of Tb927.11.11750 was made using the Gibson assembly 
method (Gibson et al., 2009), as shown in Fig 6.12A. Basically, an 12×Myc insert was 
PCR amplified with primers OL19 and OL20 from a synthetic gene sequence in which 
21 bp of the sequences encoding the first and last Myc repeat had been re-coded 
(designed with help of Dr Sam Duncan and synthesised by Genscript). Meanwhile, a 
vector was also PCR amplified from a previously generated plew100_v5 
Tb927.11.11750 overexpression plasmid (Wirtz et al., 1999) with ends containing the 
two Myc sequence with different codons using primers OL21 and OL22. After Gibson 
assembly reaction, the 12×Myc sequence was inserted between the signal peptide and 
the rest of the Tb927.11.11750 DNA sequence (the tagged protein is termed SP-12Myc-
Tb927.11.11750 hereafter). This construct was then linearised with Not Ⅰ and 
transfected into T. brucei BSF and the cells were selected with phleomycin. Clones 
were obtained by limit dilution and the expression of SP-12Myc-Tb929.11.1175 protein 
from three clones was analysed by anti-Myc Western blot under +/- tetracycline (Tet) 
conditions. Ponceau staining of the membrane shows similar amount of cells were 
loaded among different samples (Fig 6.12B); anti-Myc Western blot (Fig 6.12C) of the 
same membrane shows the detection of bands at ~ 80 kDa (theoretical MW of 
Tb927.11.11750-12Myc protein is ~68 kDa) in all three tested clones in the + Tet 
samples but not in - Tet samples, suggesting SP-12Myc-Tb927.11.11750 protein is 





Figure 6.12 Internal 12×Myc tagging of Tb927.11.11750. 
A: Scheme of construction of plew100_v5 SP-12Myc-Tb927.11.11750 plasmid using Gibson 
assembly. Different fragments of the constructs are annotated by colour coding. Yellow: First 
Myc with different codons. Blue: Last c-Myc with different codons. Red: 10 identical Myc 
sequences with the same codons. Dark green: Tb927.11.11750 signal peptide sequence. Light 
green: Tb927.11.11750 C-terminal sequence without signal peptide. B and C: Ponceau staining 
and anti-Myc Western blot of cell lysates from three clones expressing SP-12Myc-
Tb927.11.11750 with or without Tet induction. For each lane, 5 e 6 cells per lane were lysed 
with SDS sample buffer, subjected to SDS-PAGE and transferred to nitrocellulose membrane. 
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The blot was probed with anti-Myc antibody. Lane 1, 3, 5 are + Tet samples of clone 1, 2, 3. 
Lane 2, 4, 6 are - Tet samples of clone 1, 2, 3. 
 
6.3.6 SP-12Myc-Tb927.11.11750 is present in high molecular weight complexes 
Previous TbdeAc-3Myc pull down experiments had shown that it forms a ~240 kDa 
complex. To investigate whether SP-12Myc-Tb927.11.11750 forms a similar complex, 
pull down experiments of SP-12Myc-Tb927.11.11750 were performed in parallel with 
TbdeAc2-12Myc. For the generation of a TbdeAc2-12Myc expressing cell line, the 997 
bp ORF of TbdeAc2 was amplified with primers OL7 and OL8 and cloned into 
pNATx12MYC vector (Alsford and Horn, 2008). The plasmid was linearised with AscⅠ 
and transfected to the BSF WT cells, the 613 bp C-terminal ORF of TbdeAc2 within the 
construct was used for targeting the origin locus of the gene through homologous 
recombination. Cells were further selected with BSD and subcloned (Fig 6.13D). Using 
previously optimised detergent and elution conditions to IP low abundant 
transmembrane proteins, SP-12Myc-Tb927.11.11750 expressing cells were lysed with 
0.5 % digitonin lysis buffer, and immunoprecipitation was performed using Myc-
TrapTM beads. The beads were then washed three times and proteins bound to the beads 
were eluted with SDS sample buffer and analysed by denaturing gel following by anti- 
Myc Western blot. An identical amount 1% TX-100 SP-12Myc-Tb927.11.11750 cell 
lysate served as a positive control (Fig 6.13A).  Both lysis condition could extract the 
protein with a comparable efficiency while there is no band detected in wild type lysate 
sample. For compatible elution conditions for nativePAGE, c-Myc peptide elution was 
tested after pulling down from a SP-12Myc-Tb927.11.11750 cell lysate (Fig 6.13B). 
The anti-Myc Western blot shows success using this elution method. Sample replicates 
were then applied to nativePAGE and analysed by anti-Myc Western blotting, this is 
accompanied by TbdeAc2-12Myc IP products with the same IP and detection 
conditions. TbdeAc2-12Myc was detected in complexes at ~ 240 kDa, as before, while 
SP-12Myc-Tb927.11.11750 was found in multiple complexes ranging from ~180 to 430 
kDa (Fig 6.13C). From this analysis, we can conclude that the dominant complexes 
containing SP-12Myc-Tb927.11.11750 forms are not the same as for TbdeAc2. 
Nevertheless, some of the SP-12Myc-Tb927.11.11750 does appear with similar native 
apparent MW as the TbdeAc2-containing complex, and it should be noted that whereas 
TbdeAc2 was in-situ tagged, by necessity, SP-12Myc-Tb927.11.11750 was 




Figure 6.13 Overexpressed SP-12Myc-Tb927.11.11750 forms multiple complexes. 
A. Optimisation of detergent conditions for extraction and pull down of SP-12Myc-
Tb927.11.11750. Lane 1: BSF WT 1% TX-100 cell lysates, lanes 2 and 3 are SP-12Myc-
Tb927.11.11750 expressing BSF 1% TX-100 and 0.5% digitonin cell lysates, respectively. 
These cell lysates equivalent to 5×107 cells per lane were immunoprecipitated with Myc-Trap 
agarose beads and subjected to denaturing gel further analysed by anti-Myc Western blot. B. 
Test of c-Myc peptide elution conditions. Myc-Trap pull downs from 0.5% digitonin lysates of 
BSF WT (lane 1) and Tb927.11.11750-12Myc expressing BSF cells (lane 2) were performed as 
described before, and proteins were eluted by 2.5 mg /mL c-Myc peptide elution buffer three 
times. Combined elutes were then analysed by anti-Myc Western blot. C. NativePAGE anti-
Myc Western blot of the cMyc peptide eluates of My-Trap pull downs from BSF WT (lane 1), 
SP-12Myc-Tb927.11.11750 overexpressing (lane 2) and TbdeAc2-12Myc expressing (lane 3) 
BSF 0.5% digitonin lysates. .D Scheme for in situ tagging of TbdeAc2 with 12 c × Myc at C 
terminus using pNAT12MYC vector. Linearised pNAT12MYC vector containing 631 bp C terminal 
ORF of TbdeAc2 and 12 c × Myc, blasticidine resistance cassette (BSD) in frame of intergenic 
region 1( igr1: βα tubulin mRNA) and igr2 (actin mRNA) was transfected to the BSF WT cells, 




6.3.7 Proteomics identification of SP-12Myc-Tb927.11.11750 binding partners  
To find out whether TbdeAc2 is a specific partner for SP-12Myc-Tb927.11.11750, 
immunoprecipitation of lysates from BSF WT and SP-12Myc-Tb927.11.11750 
expressing cell lines were performed with the standardised pull-down method 
established above. Proteins eluted with c-Myc peptide were subjected to NativePAGE, 
and bands containing SP-12Myc-Tb927.11.11750 complexes on a duplicate gel (the 
regions were annotated in rectangles in Fig 6.13C) and corresponding bands from the 
BSF WT sample were excised and sent for in gel trypsin digestion followed by LC-
MS/MS analysis. Proteomics data were analysed using MaxQuant software and a newly 
developed data analysis method written in Python called ProtRank (Medo, Aebersold 
and Medová, 2019), The protein groups identified were displayed on a plot of the sum 
iBAQ score of peptides (y-axis) and enrichment rank (x-axis) between the bait versus 
control. By doing this, bait protein SP-12Myc-Tb927.11.11750 has the highest 
enrichment and its putative partner protein TbdeAc2 was the second most highly 
enriched protein (Fig 6.14A). This data strongly supports the physical association of SP-
12Myc-Tb927.11.11750 with TbdeAc2.  
 The data were also processed in a different way that plots the experimental rank (x-
axis) against the rank order of estimated abundances of the protein groups, generated 
from data in (Tinti, Maria Lucia S Güther, et al., 2019), on the y-axis (the higher the 
protein ranks, the lower abundance it has) (Fig 6.13B). This plot also shows a clear 
association between Tb927.11.11750 and TbdeAc2 (Tb927.3.2610), and also 
emphasises that both are very low abundance proteins in the total trypanosome 





Figure 6.14 Identification of TbdeAc2 by co-immunoprecipitation with SP-12Myc-
Tb927.11.11750 from BSF T. brucei digitonin lysates. 
 A. A plot comparing protein groups present in the anti-cMyc immunoprecipitates from SP-
12Myc-Tb927.11.11750 expressing cell lysates versus BSF WT cell lysates. Each protein group 
is plotted according to its Sum iBAQ values (y-axis), calculated by MaxQuant, and the 
enrichment rank (x-axis). The enrichment rank was computed with the ProtRank algorithm 
using the iBAQ values calculated by MaxQuant. Tb927.11.11750 and Tb927.3.2610 are 
highlighted in red. (B) Relative intensity plot using a new algorithm. The same data as (A) are 
plotted with a different y-axis, whereby each protein group is assigned an intensity rank from 
the most abundant protein group (1) to least abundant protein groups (7,149) based on their 
summed eXtracted Ion Currents (XICs) for the total BSF proteome.  
While the reciprocal pull-downs (of Tb927.11.11750 with TbdeAc2-3Myc and TbdeAc2 with 
SP-12Myc-Tb927.11.11750 ) are consistent with the two proteins forming a stable complex, the 
differences in their nativePAGE patterns suggests that overexpressed SP-12Myc-
Tb927.11.11750 is not exclusively co-localised with TbdeAc2. The proteomics data in (Fig 
6.14A) show that the overexpressed SP-12Myc-Tb927.11.11750 protein is indeed present in 
excess over TbdeAc2 in the Myc-Trap pull down according to the summed iBAQ scores. This is 
in contrast to the native situation, where the protein rankings for TbdeAc2 and Tb927.11.11750 
and Tb927.11.11740 together are 5715th and 6882nd out of 7149 protein groups, respectively (Ji 
et al., 2021). These protein rankings, and the apparent homogeneity of the ~240 kDa TbdeAc2-
3Myc and TbdeAc2-12Myc in-situ tagged complexes, as visualised by native PAGE (Fig 6.1C, 
lane 2 and Fig 6.13C, lane 3), suggest that native TbdeAc2 and Tb927.11.11750 are perhaps 




6.4 TbdeAc2 and Tb927.11.11750 are localised in endoplasmic reticulum  
Previous work has shown that GPI anchor precursors are present in the endoplasmic 
reticulum (ER) (Vidugiriene and Menon, 1994). It is therefore a reasonable assumption 
that the enzymes catalysing GPI synthesis also reside in ER. Nevertheless, apart from 
the ER-localisation of TbdeAc1(Güther et al., 2003) and very recently for GPI2 (Jenni 
et al., 2021), there are no experimental data on the localisation of GPI anchor 
biosynthesis pathway enzymes. To address this deficit, the subcellular localisations of in 
situ tagged TbdeAc2-12Myc and SP-12Myc-Tb927.11.11750 were analysed in T. 
brucei BSF cells by immunofluorescent microscopy (IFM). TbdeAc2-12Myc (Fig 
6.15A) and SP-12Myc-Tb927.11.11750 (Fig 6.15C) were found to substantially co-
localise with the known ER protein marker BiP (Bangs et al., 1993). Both stains showed 
typical ER reticulated staining and clear perinuclear rings. This is not only consistent 
with TbdeAc2 being an ER resident membrane enzyme, as expected, but also 
demonstrates the co localisation of TbdeAc2 and Tb927.11.11750, providing supporting 
evidence that Tb927.11.11750 may be involved in the GPI anchor biosynthesis 
pathway. The absence of anti-Myc staining in the BSF WT cells demonstrates the 
specificity of the staining for transgenic TbdeAc2-12Myc and SP-12Myc-
Tb927.11.11750.  
We also tried to localise in situ tagged Tb927.11.11740-3HA, but the signal was below 
the limit of detection (data not shown). The TrypTag.org detection for Tb927.11.11740-
mNeonGreen (Fig 6.15B) was inconclusive with possible suggested localisations of 
“cytoplasm, nuclear lumen and endocytic” (Dean et al., 2017). In any case, the pattern 





Figure 6.15 Localisations of TbdeAc2-12Myc, Tb927.11.11740-mNeonGreen and SP-
12Myc-Tb927.11.11750. 
 A and C: Fixed and permeabilized BSF WT T. brucei and parasites expressing in situ tagged 
TbdeAc2-12Myc and internal 12Myc tagged SP-12Myc-Tb927.11.11750 were co-stained with 
anti-Myc antibodies to detect TbdeAc2/Tb927.11.11750 (green) and anti-BiP to detect the ER 
(red). The cells were also stained with DAPI to detect the nuclear and kinetoplast DNA. The 
parasites were further imaged by DIC. Similar staining patterns were observed in the anti-BiP 
and anti-Myc channels suggesting both TbdeAc2 and Tb927.11.11750 localise in the ER. B: 
Localisation of in situ C-terminal mNeonGreen tagged Tb927.11.11740 (two fields) was 
analysed by TrypTag.org (Dean, Sunter and Wheeler, 2017). The pattern of mNeonGreen signal 
suggested that Tb927.11.11740 was unlikely an ER resident protein. Scale bars: 5 µm. 
 
6.5 Knock down of Tb927.11.11740 and Tb927.11.11750 
Having confirmed that TbdeAc2 forms a protein complex with Tb927.11.11750 but not 
with Tb927.11.11740, and provided evidence of them being ER resident proteins, the 
next question we wanted to address was: What are the roles that Tb927.11.11750 and/or 
Tb927.11.11740 might play in the GPI anchor biosynthesis pathway? Due to the high 
sequence identities between these two genes and encoded proteins, several different 
gene manipulation approaches were applied to Tb927.11.11750 and Tb927.11.11740 
simultaneously and individually to try to generate different types of mutant cell lines for 
functional studies. By comparing the GPI anchor biosynthesis pathway products 
between the mutant cell lines and WT cell lines, we hoped that we might uncover the 
functions of Tb927.11.11750 and/or Tb927.11.11740. 
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6.5.1 Knock down of Tb927.11.11740 and Tb927.11.11750 using a p2T7 RNAi 
construct 
Since Tb927.11.11740 and Tb927.11.11750 have the same predicted catalytic domains 
and motifs (Fig 6.6B) but different subcellular localisations (Fig 6.15), we hypothesize 
that these two proteins have similar enzymatic functions but in different subcellular 
environments. To preclude functional compensations that may happen between 
Tb927.11.11740 and Tb927.11.11750, a knock down construct that targets both genes 
was assembled in the p2T7 plasmid (Alibu et al., 2005) to generate inducible RNAi 
strains with primers OL9 and OL10. The sequence that was chosen for the knock down 
construct was determined through RNAit tool (Redmond, Vadivelu and Field, 2003) in 
which the sequences were BLAST searched against the whole T. brucei genome to 
minimise off target effects. Six clones were picked after transfection and hygromycin 
selection for further analysis. The growth curves of these six clones were monitored 
with and without RNAi induction by tetracycline (Tet) over 7 days. There was no 
significant growth defect associated with the knock down (Fig 6.16A), suggesting that 
both genes are dispensable for BSF T. brucei survival. However, when the extent of the 
RNAi knockdown was measured by real time qRT-PCR (Fig 6.16B) with primers OL35 
and OL36 a reduction of only ~40% of the targeted mRNAs was observed after Tet 
reduction for 8 h and this reduced further to ~20% when after 24 h of Tet induction. 
This modest extent of RNAi knockdown was insufficient for biochemical 
characterisation and so this RNAi knockdown approach was abandoned. 
 
 
Figure 6.16 Knock down of Tb927.11.11740 and Tb927.11.11750 using p2T7 construct. 
 A: Cumulative growth of six clones following tetracycline (Tet) induced knockdown of 
Tb927.11.11740 and Tb927.11.11750. Minus Tet: solid line with black solid dots; Plus Tet: 
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solid line with hollow dots. B: Real time quantitative RT-PCR analysis of the relative 
abundance of Tb927.11.11740 and Tb927.11.11750 mRNA transcripts after 8 h and 24 h of 
RNAi induction with tetracycline (Tet) of clone 1. The y axis represents the relative abundance 
mRNA of 8h and 24h time point +Tet sample compared to that of the RNA from -Tet cells (set 
at 1.0). Error bars indicate one standard deviation. 
 
6.5.2 Knock down Tb927.11.11740 and Tb927.11.11750 through pRPa RNAi 
construct 
The inefficient knock down using the p2T7 RNAi construct led us to try an alternative 
RNAi method based on pRPa plasmid which was established to generate stem loop 
RNAi transcripts from a specific ribosomal RNA (rRNA) locus in T.brucei (Alsford and 
Horn, 2008). To enable the construct to integrate into this specific targeted rRNA locus, 
BSF 2T1 WT cell line was used as the parental cell line (Alsford et al., 2005). The 
target sequence for RNAi construct was the same as p2T7 construct which was a 486 bp 
identical region of Tb927.11.11740 and Tb927.11.11750, amplified with primers OL11 
and OL12. Three independent RNAi knockdown clones were isolated and induced with 
tetracycline. No significant growth defect was associated with Tet induced knockdown 
(Fig 6.17A). The extent of the RNAi knockdown level of these three clones was 
measured by real time qRT-PCR after 24 h Tet induction (Fig 6.17B). Among these 
three clones, clone 1 had the highest knockdown level with a reduction of ~70% while 
clone 2 and 3 had ~60% reduction. To further investigate the knockdown efficiency of 
clone 1, a time course of knockdown was examined at 8, 24, 48 and 72 h time points 
(Fig 6.17C). The RT-qPCR assay revealed that the most efficient knock down for 
Tb927.11.11740 and Tb927.11.11750 was reached after 24 h with a ~70% reduction at 
the mRNA level and this reduced to ~ 50% after 72 h of induction. While the 
knockdown was not as deep as we would have liked, we decided to perform functional 
studies on this RNAi cell line to check whether there were any observable differences in 





Figure 6.17 Knock down of Tb927.11.11740 and Tb927.11.11750 using pRPa construct. 
 A: Cumulative growth of three clones following tetracycline (Tet) induced knockdown of 
Tb927.11.11740 and Tb927.11.11750. Minus Tet: solid line with black solid dots; Plus Tet: 
solid line with hollow dots. B: Real time quantitative RT-PCR analysis of the relative 
abundance of Tb927.11.11740 and Tb927.11.11750 mRNA transcripts after 24 h of RNAi 
induction with tetracycline (Tet) of clone 1, 2 and 3. The y axis represents the relative 
abundance of each mRNA compared to that of the RNA from -Tet cells (set at 1.0). Error bars 
indicate one standard deviation. C: Time course of real time qRT-PCR analysis of relative 
mRNA abundance of Tb927.11.11740 and Tb927.11.11750 transcripts of RNAi knock down 
clone 1 after 8 h, 24 h, 48 h and 72 h Tet inductions.  
 
6.5.3 Comparison of the GPI products synthesized by the trypanosome cell-free 
system between Tb927.11.11740 and Tb927.11.11750 RNAi and BSF 2T1 WT cell 
lines 
As Tb927.11.11750 is closely associated with TbdeAc2 and both Tb927.11.11750 and 
Tb927.11.11740 contain a predicted lipase motif GXGXG, one a reasonable hypothesis 
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for their roles in GPI anchor biosynthesis pathway is that one or other might be the 
unknown component GPI phospholipase A2 (PLA2), which is the enzyme catalysing 
the next step after TbdeAc2.  
The different subcellular localisations of Tb927.11.11740 and Tb927.11.11750 could 
also be explained as a previous study showed that, in addition to GPI fatty acid 
remodelling in the ER (Masterson et al., 1990) here is a separate acyl chain remodelling 
for mature VSG-linked GPI anchors in endocytic pathway (Buxbaum et al., 1994).   
To test this GPI PLA2 hypothesis, three T. brucei cell-free systems were prepared of 
from BSF 2T1 WT cells and from the Tb927.11.11740 and Tb927.11.11750 RNAi 
knockdown line harvested before and after Tet uninduction to perform the 
radiolabelling of GPI glycolipid intermediates in the GPI anchor biosynthetic pathway, 
as described previously (Güther et al., 1994) (Fig. 6.18A). Briefly, the cells were 
subjected to hypotonic lysis and the membrane fraction (cell-free system) containing the 
GPI biosynthetic machinery was recovered by centrifugation. Pulse-labelling of the cell-
free system with GDP-[3H]Man was performed and the labelled glycolipids were 
extracted and resolved by high-performance thin layer chromatography (HPTLC) and 
visualised by auto-fluorography. In this experiment, BSF 2T1 WT cell line (Fig 6.18B, 
lane 1) sample was served as positive control, and the pattern of the labelled GPI 
intermediates was the same when using cell-free system prepared from T. brucei 
(variant MITatl.4) BSFs that were isolated from infected rats (Güther, Masterson and 
Ferguson, 1994) . The Tb927.11.11740 and Tb927.11.11750 RNAi knockdown cell 
lines were collected after 24 h induction with or without Tet for cell-free system 
preparation. The radiolabelled GPI anchor products on the HPTLC plate are tentatively 
assigned according to their migration positions. If the PLA2 hypothesis was correct, we 
might expect that there would be less glycolipid θ product in the induced RNAi 
knockdown cell line.  However, there were no significant differences in the labelled GPI 
anchor intermediates among the three tested cell-free systems, as shown in (Fig 6.18B). 
This result suggested that either Tb927.11.11740 and Tb927.11.11750 do not function 
as a GPI PLA2 enzymes, or the 70% RNAi knockdown is insufficient for detection of 
any functional perturbation. Therefore, we determined that a null or conditional null 
mutant cell line for Tb927.11.11740 and Tb927.11.11750 was necessary to provide a 




Figure 6.18 GPI anchor products in BSF 2T1 WT and Tb927.11.11740 & Tb927.11.11750 
RNAi knockdown T. brucei cell-free system. 
 A. Scheme of cell-free radiolabelling system in T.brucei. The cell-free system is incubated with 
GDP-[3H]Man in the presence of 1 mM UDP-GlcNAc. All the radiolabelled glycolipid 
intermediates formed in such a reaction are annotated in red with asterisks. The key for the 
components of the glycolipids were indicated at the bottom right of the scheme. B. T. brucei 
cell-free system was prepared for BSF 2T1 (lane 1) and Tb927.11.11740 & Tb927.11.11750 
RNAi knockdown Tet uninduced (lane 2) and induced (lane 3) for 24 h. Glycolipids of each 
sample (equivalent to 2.5 × 106 cells/lane) were extracted with solvent and analysed by HPTLC 
and fluorography. The descriptors θ, A', C, M3, M2, acyl-M3 and M1 next to lane 3 correspond 
to glycolipids θ, A', C, Man3GlcN-PI, Man2GlcN-PI, Man3GlcN(acyl)PI and Man1GlcN-PI 
respectively. DPM corresponds to dolichol phosphate-mannose. 
 
6.6 Attempts at CRISPR-Cas9 mediated gene knock out of Tb927.11.11740 and 
Tb927.11.11750 in BSF T. brucei 
6.6.1 Attempt at the generation of Tb927.11.11740 and Tb927.11.11750 null 
mutant by CRISPR-Cas9 
The RNAi knock down experiments of Tb927.11.11740 and Tb927.11.11750 suggested 
that both genes might be non-essential in BSF T. brucei, however the maximal 
knockdown of transcripts was only ~70% based on qRT-PCR analysis so that this 
conclusion is questionable. Nevertheless, to explore the function of these two proteins, 
CRSIPR Cas9 mediated gene editing was attempted, aiming to knock out both genes 
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simultaneously through a previously described strategy (Rico et al., 2018). Basically, an 
sgRNA sequence was selected before a PAM motif in the identical regions of both genes, 
using BLAST searches to select sequences likely to minimise potential off target effects. 
The sgRNA construct was amplified with primers OL39 and OL40 and, along with a 
repair template with a puromycin acetyl transferase resistance cassette (PAC), was 
transfected into T. brucei BSF expressing Cas9 under Tet regulation (described as “Cas9 
WT” hereafter). After tetracycline-induced Cas9 editing, the cells were selected with 
puromycin and sub-cloned for genotype screening (Fig 6.19A). We hoped that Cas9 
editing would lead to double strand DNA breaks within both alleles of Tb927.11.11740 
and Tb927.11.11750 and that the whole locus, including the intergenic region (igr), would 
be replaced by a PAC resistance cassette through homologous recombination (Fig 6.19B). 
The repair template used in this experiment was PCR amplified from a plasmid containing 
PAC flanked with 800 bp 5’UTR sequence of Tb927.11.11740 and 500 bp 3’UTR 
sequence of Tb927.11.11750 using primers OL23 and OL28. The template was first 
assembled to pUC57 vector, primers OL23 and OL24 were used for amplifying the 800 
bp 5’ UTR of Tb927.11.11740, OL25 and OL26 were used for amplifying the PAC 
resistance cassette, OL27 and OL28 were used for amplifying 500 bp 3’UTR of 




Figure 6.19 Scheme of CRISPR-Cas9 gene editing. 
 A: A Tb927.11.11740 and Tb927.11.11750-specific sgRNA construct and a repair template 
were transfected into a BSF T.brucei Cas9 WT cell line generated previously to express Cas9 
under Tet induction (Rico et al., 2018). After 24 h of Cas9 editing, there should be three cell 
populations: non-edited cells (blue), edited cells without repair template (red) and edited cells 
with the puromycin resistance (PAC) template (yellow). Puromycin was then added for 
selection and the cells recovered after 7 days treatment are subcloned. B: Expected gene 
homologous recombination after Cas9 editing. Double strand DNA break caused by Cas9 
occurs at specific regions (dark triangles) guided by sgRNA. The PAC repair template 
containing the specific 5’UTR of Tb927.11.11740 and 3’UTR of Tb927.11.11750 should 
integrate into the genome as indicated if the proteins encoded by Tb927.11.11740 and 




6.6.2 Genotyping CRISP-Cas9 edited Tb927.11.11740 and Tb927.11.11750 
mutants  
To check how the repair templates were integrated to Cas9 edited clones, a Southern 
blot was performed to genotype several clones of the recovered Cas9 mutant cell line. 
NcoⅠ was selected to perform endonuclease reaction on genomic DNA that was 
extracted from the cloned cell lines, as described in Materials and Methods. The 
sequence of the locus gives different predicted restriction fragments sizes for 
Tb927.11.11740 (5725 bp), Tb927.11.11750 (3302 bp) and for the expected PAC-
containing gene replacement product (4681 bp), enabling us to distinguish these two 
genes at the endogenous locus from the locus replaced with PAC (Fig 6.20A). Three 
Cas9 edited clones were tested along with Cas9 WT cells using digoxigenin (DIG) 
labelled probes for detection of a common ORF fragment for both genes (the gene of 
interest, GOI probe, and for the PAC resistance cassette, PAC probe). Primers OL41 
and OL42 were used to amplify the GOI probe from the plew100_v1 Tb927.11.11750 
overexpression plasmid which contains the full ORF of Tb927.11.11750 (the 
construction of this plasmid was introduced in section 6.8). Primers OL43 and OL44 
were used to amplify the PAC probe from a plasmid containing full PAC ORF 
generated in our lab. If the Cas9 mediated gene editing occurred as expected for non-
essential genes, the GOI probe should give a two-band restriction fragment pattern for 
the Cas9 WT cells and no band in the Cas9-induced null mutant cell lines. Conversely, 
the PAC probe should detect one band in the Cas9 edited clones and no band in the 
Cas9 wild type cells.  
The Southern blot (Fig 6.20C) showed that the PAC repair template had integrated into 
one genomic locus in Cas9 mutant clone 1 and into two loci in Cas9 mutant clones 2 
and 3 (Fig 6.20C). However, the band detected in clone 1 was around 6.5 kb and the 
bands detected in clones 2 and 3 were 6.5 kb and 4.0 kb. The 6.5 kb and 4.0 kb bands 
are larger and smaller, respectively, than the predicted 4681 bp fragment, suggesting 
that PAC integration was not into the Tb927.11.11740 / Tb927.11.11750 locus. Further, 
although the GOI probe blot (Fig 6.20B GOI) showed disappearance of two wild type 
GOI bands of the wild type cell, these are replaced by either one (clone 1) or two 
(clones 2 and 3) bands of different sizes. Thus, we concluded that all clones survived by 
both acquiring PAC and by retaining copies of Tb927.11.11740 and/or Tb927.11.11750. 
This suggested that Tb927.11.11740 and/or Tb927.11.11750 are most likely essential 
genes. Interestingly, in all three clones it is possible that the upper 6.5 kb restriction 
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Figure 6.20 CRISPR Cas9 edited clones show aberrant gene rearrangements. 
 A: Schematic representation of NcoI digestion sites and the expected restriction fragments for 
detection by the Tb927.11.11740 and Tb927.11.11750 GOI probe before and after CRISPR 
Cas9 editing, assuming both genes to be non-essential. The probes used for detection are 
indicated below the scheme of the gene locus, the expected sizes of bands detected by the 
probes are indicated above the scheme of the gene locus. B and C: Southern blot of BSF T. 
brucei gDNA (5 μg/ lane) of Cas9 WT and Cas9 mutant clones 1 to 3 digested with NcoI. GOI 
ORF (corresponding to 1000 bp identical region of Tb927.11.11740 and Tb927.11.11750) (B) 




6.6.3 Phenotyping CRISPR Cas9 mutant clone 1 
To assess whether these aberrant gene rearrangements in the CRISPR Cas9 mutants 
were due to the essentiality of Tb927.11.11740 and/or Tb927.11.11950, we decided to 
find out how the PAC repair template was integrated into the genome in the Cas9 
mutant clone 1 in which the genotype appeared the simplest among the three mutant 
clones. The PAC-containing region was amplified and cloned into a plasmid as 
indicated in (Fig 6.21A). After transfecting this vector to bacteria, 8 clones were picked 
and sent for plasmid insert sequencing. The sequencing results suggested that there was 
allelic variation in PAC integration in Cas9 mutant clone 1. Thus, both alleles show 
replacement of Tb927.11740 and the intergenic region (igr) with the full-length 
sequence of the PAC repair template followed by a substantial remnant of Tb927.11750 
after the PAM motif. The sequencing results for both alleles are shown in (Fig 6.21A): 
The first allele retained 16 bp from the repair template that contains a potential start Met 
codon, followed by the sequence AQWR, with the Tb927.11750 remnant encoding a 
(∆1-64)Tb927.11.11750 protein in frame with that sequence. The second allele retained 
15 bp from the repair template such that the potential Met start site is followed by the 
sequence AQWQ and an out of frame nonsense version of the Tb927.11.11750 remnant 
(there are nonsense codons downstream of the translations shown in Fig 6.21A). 
Although the genotype of CRSIPR Cas9 mutant clone 1 is complex (i.e., null for 
Tb927.11.11740 and containing a single translation-competent truncated version of 
Tb927.11.11750), a cell-free system of this mutant cell line was prepared together with 
two WT cell line cell free systems. These were used to assess whether CRSIPR Cas9 
mutant clone 1 showed any defects in GPI anchor biosynthesis, particularly any 
deficiency in the production of glycolipid θ products based the hypothesis that 
Tb927.11.11740 and/or Tb927.11.11750 might function as GPI PLA2 enzymes. The 
cell-free system preparation and radiolabelling experiments were carried out as 
described in section 6.5.3 with the addition of a subsequent chase with or without 
unlabelled excess GDP-Man to push the cell-free system towards the synthesis of the 
glycolipid θ product. The labelled glycolipids were extracted and resolved by HPTLC 
and visualised by auto-fluorography. Under these conditions, the Cas9 WT sample 
formed labelled Man1-3GlcN-PI and glycolipids A’ and θ, with the label in the Man1-
3GlcN-PI intermediates chasing into glycolipids A’ and θ when a cold-chase with GDP-
Man was applied (Fig 6.21B, lanes 1 and 2). Any significant diminution in PLA2 
activity would be expected to lead to the disappearance or reduction in the intensity of 
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glycolipid θ and accumulation of label in glycolipid A’. As can be seen (Fig 6.21B, 
lanes 3 and 4), the CRSIPR Cas9 mutant clone 1 mutant cell-free system behaved 
identically to the Cas9 WT cell-free system, suggesting no effect on GPI PLA2 activity. 
In this experiment the samples prepared from T. brucei BSF WT cell-free system (Fig 
6.21B lanes 5 and 6) were run in parallel with no differences detected in the labelled 
glycolipids compared to the Cas9 WT cell-free system suggesting that the genome 
modifications in the Cas9 WT cell line did not interfere with the GPI anchor 
biosynthesis pathway.  
This result leaves us with the question as to whether the absence in GPI biosynthesis 
deficiencies in the Cas9 mutant clone 1 is due to the fact that neither Tb927.11.11740 
nor Tb927.11.11750 encode GPI PLA2 activity, or whether the 1-64 truncated version 
Tb927.11.11750 can still encode GPI PLA2 activity, despite lacking a signal peptide.  
To check whether the truncated Tb927.11.11750 gene is transcribed, and the therefore 
could potentially retain function in clone 1, real time qRT-PCR was employed to 
analyse the mRNA level of Tb927.11.11750 in mutant clone 1 in comparison with the 
Cas9 WT cell line.  Almost same amount of mRNA was transcribed in both cases (Fig 
6.21C) indicating that the Cas9 mutant clone 1 was not a null mutant cell line for 
Tb927.11.11750. Thus, unfortunately, we could not conclude from the cell-free system 
data whether Tb927.11.11750 encodes GPI PLA2 activity or not.  
In summary, our interpretations of these data are: (i) That Tb927.11740 and the igr are 
dispensable to the parasite. (ii) That Tb927.11.11750 is essential. (iii) That although the 
predicted MAQWR-(1-64)Tb927.11.11750 fusion protein lacks a signal peptide, 





Figure 6.21 Characterisation of the genotypes and GPI anchor products of Cas9 mutant 
clone 1. 
 A: Sequences of the Tb927.11.11740 and Tb927.11.11750 gene loci following genetic 
rearrangements in the Cas9 mutant clone 1. Sequence analysis of 8 amplicon clones indicated 
that the two alleles were each modified in different ways: One allele contains the PAC selection 
marker followed by 500 bp of 3’UTR Tb927.11.11740 targeting sequence, followed by 16 bp of 
the repair template sequence that places the Tb927.11.11750 remnant sequence encoding (∆1-
64)Tb927.11.11750 in-frame with to potentially produce a MAQWR-(∆1-64)Tb927.11.11750 
fusion protein. The other allele has similar arrangement but with only 15 bp of repair template 
sequence giving rise to a nonsense truncated gene downstream of the potential Met start site. 
The forward and reverse primers used for amplifying the fragments for sequencing have been 
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annotated as “For” and “Rev”, respectively. B: Cell-free systems were labelled with GDP-
[3H]Man with or without a chase using cold GDP-mannose. The lipid extracts were analysed by 
HPTLC using the solvent described at Materials and Methods and analysed by fluorography. 
Glycolipid products A’ and θ are indicated. Lane 1 and 2: Cas9 WT samples; Lane 3 and 4: 
Cas9 mutant clone 1 samples; Lane 5 and 6: BSF WT samples. Lanes 1, 3 and 5 without cold 
GDP-Man chase, lanes 2, 4 and 6 with cold GDP-Man chase. C: Real time RTq-PCR showed 
similar levels of Tb927.11.11750 mRNA in the Cas9 WT and Cas9 mutant clone 1 cell lines. 
Error bars indicate one standard deviation.  
 
6.7 Attempts at the generation of Tb927.11.11740 and Tb927.11.11750 null and 
conditional null mutants through conventional homologous recombination  
The CRISPR Cas9 mediated gene manipulation of Tb927.11.11740 and 
Tb927.11.11750 failed to generate a null mutant cell line for both genes simultaneously. 
Therefore, an alternative approach based on conventional homologous recombination 
was applied to try to make conditional null mutant cell lines. For the first step using this 
strategy, we attempted to replace the 1st allele of Tb927.11.11740 and Tb927.11.11750 
with PCR amplicons containing the PAC gene flanked by 800 bp 5’UTR of 
Tb927.11.11740 and 500 bp 3’UTR of Tb927.11.11750 (same as the CRISPR Cas9 
repair template used in Section 6.6) to generate a ΔTb927.11.11740 & 
Tb927.11.11750::PAC/Tb927.11.11740 & Tb927.11.11750 single knock out cell line 
(sKO) (Fig 6.22A). To check for correct gene replacement, the PAC-resistant clones of 
were assessed by Southern blot probed sequentially with a PAC ORF probe and a GOI 
ORF probe. NcoⅠ was used to digest the genomic DNA extracted from the cloned cell 
lines. The predicted locus for Tb927.11.11740 (5725 bp) and Tb927.11.11750 (3302 bp) 
and for the expected PAC-containing gene replacement product (4681 bp) are indicated 
in (Fig 6.22B). The Southern blot probed with the PAC probe (Fig 6.22C) showed the 
same single band detection in three mutant clones (lane 2-4) and no detection in the 
BSF WT sample (lane 1). However, the size of this detected band in the three mutant 
clones was not at the expected position, which was 4681 bp. Instead, a much larger 
DNA fragment was observed (>8.6kb). The same size band was observed in the three 
mutant clones when the same blot was subsequently stripped and probed with the GOI 
probe, along with bands consistent with the presence of endogenous copies of 
Tb927.11.11740 and Tb927.11.11750 (Fig 6.22D). The BSF WT sample showed the 
same expected bands for Tb927.11.11740 and Tb927.11.11750. However, comparison 
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of the band intensities suggests that the three mutant clones may contain only one copy 
of Tb927.11.11740 in its original locus but both copies of Tb927.11.11750 in their 
original loci. It is clear from these data that simple gene replacement by homologous 
recombination has nit occurs in any of the three mutant clones. One possible 
explanation for the unusual genotypes generated is that the PAC resistance cassette has 
inserted into the locus to generate a tandem PAC Tb927.11.11740 sequence upstream of 
the central NcoⅠ site and displacing the 5’ NcoⅠ site. Whatever the explanation, this 
unexpected genetic rearrangement failed to support further planned steps for generating 
the Tb927.11.11740 and Tb927.11.11750 null and/or conditional null mutant cell lines 
(i.e., introducing an ectopic copy expressing Tb927.11.11740 and Tb927.11.11750 and 
replacing the second allele of endogenous locus). Therefore, we did not pursue these 




Figure 6.22 Attempt of generating Tb927.11.11740 and Tb927.11.11750 sKO cell lines. 
 A: To create the BSF single knock out for Tb927.11.11740 and Tb927.11.11750, the first allele 
was targeted for replacement by PAC.  B: Schematic representation of NcoI digestion sites and 
expected fragments to be detected by GOI and PAC probes for the Tb927.11.11740 and 
Tb927.11.11750 locus. The probes used for detection are indicated below the scheme of the 
gene locus, the expected size of bands detected by the probes are indicated above the scheme of 
the gene locus. C and D: Southern blot of BSF T. brucei gDNA (5 µg/ lane) of BSF WT (lane 1) 
and putative BSF Tb927.11.11740 and Tb927.11.11750 single knockout clones 1 to 3 (lanes 2-
4) digested with NcoI. PAC probe (C) and GOI ORF (corresponding to 1000 bp identical region 
of Tb927.11.11740 and Tb927.11.11750) (D) and were used for probing sequentially, with the 




6.8 Attempts to generate a Tb927.11.11750 conditional null mutant cell line 
through different conventional homologous recombination strategies 
6.8.1 Attempt to generate Tb927.11.11750 conditional null mutant cell line with 
an ectopic copy introduced with plew100_v1 Tb927.11.11750.  
Since the CRISPR Cas9 mediated gene manipulation of Tb927.11.11740 and 
Tb927.11.11750 and our attempt to replace one allele of both genes simultaneously both 
resulted in abnormal gene rearrangements, we decided to simplify our gene editing 
strategy to focus on generating a Tb927.11.11750 conditional null mutant. The planned 
strategy is described in (Fig 6.23). The Tb927.11.11750 ORF was amplified with 
primers OL13 and OL14 and inserted into the plew100 original version (plew100_v1) 
plasmid (Wirtz et al., 1999). This allows the introduction of an ectopic copy of 
Tb927.11.11750 into the rRNA locus under the control of a tetracycline-inducible 
promoter using phleomycin selection. Following cloning and under induction with 
tetracycline, the first allele of Tb927.11.11750 would be then replaced by homologous 
recombination with linear DNA containing hygromycin phosphotransferase (HYG) 
flanked by 500 bp 5’UTR and 3’UTR of Tb927.11.11750. After cloning and confirming 
the correct genotype of the conditional sKO cell line by Southern blotting, the second 
allele would be replaced with the puromycin resistance gene (PAC) by homologous 
recombination, generating the final BSF 
∆Tb927.11.11750::HYG/∆Tb927.11.11750::PAC conditional null mutant cell line (Fig 
6.23A).  
The PAC construct for knocking out (KO) Tb927.11.11750 was synthesised by 
Genscript and the HYG construct was generated by Gibson assembly (Gibson et al., 
2009) as indicated in (Fig 6.23B). The DNA fragment that contained 5’UTR and 3’UTR 
of Tb927.11.11750 was amplified from the synthesised pUC57-PAC plasmid with 
primers OL33 and OL34 in which the product would be lack of the PAC part. And the 
HYG gene was amplified using primers OL31 and OL32 from a HYG containing 
plasmid generated previously in lab. After Gibson assembly, the HYG construct for KO 
Tb927.11.11750 was generated with HYG flanked by 500 bp 5’UTR and 3’UTRs of 





Figure 6.23 Planned strategy for the creation of the Tb927.11.11750 conditional null 
mutant. 
 A: In order to create the BSF conditional null mutant for Tb927.11.11750, an ectopic copy of 
Tb927.11.11750 that was tetracycline-inducible would be introduced into the ribosomal DNA 
locus, the first allele of Tb927.11.11750 would be replaced by HYG followed by the 
replacement of second allele with PAC. B: Generation of HYG construct for knocking out 
Tb927.11.11750 by Gibson assembly. Different DNA segments are annotated. HYG: 




To generate the construct of the ectopic copy of Tb927.11.11750, the open reading 
frame (ORF) of Tb927.11.11750 was amplified from T.brucei gDNA using primers 
OL47 and OL48 This PCR product was further cloned to plew100_v1(Wirtz et al., 
1999) plasmid through HindⅢ and BamHⅠ restriction enzyme sites and the correct 
insertion was verified through DNA sequencing. We chose the relatively low 
overexpression level vector plew100_v1 to try to mimic the low endogenous expression 
of Tb927.11.11750. To introduce an ectopic copy of Tb927.11.11750, T. brucei BSF 
WT cell line was transfected with NotⅠ linearised plew100_v1 Tb927.11.11750 
construct and after phleomycin selection and cloning, six clones were taken for 
genotype analysis by Southern blotting. The gDNA extracted from these six mutants 
and BSF WT were digested with NcoⅠ and EcoRⅤ to provide restriction fragments that 
represented endogenous Tb927.11.11740 (5711 bp),  endogenous Tb927.11.11750 
(3306bp) and the ectopic copy of Tb927.11.11750 (2228 bp) (Fig 6.24 A). Despite 
imperfections of of the Southern blot, there were clearly two bands representing 
Tb927.11.11740 and Tb927.11.11750 detected in the BSF WT sample (Fig 6.24 B, lane 
1) and an extra band for the ectopic copy of Tb927.11.11750 was detected at the 
predicted position in all six overexpression clones (Fig 6.24B, lanes 2-7). This 
suggested that the ectopic copy of Tb927.11.11750 was successfully introduced to 
T.brucei BSF WT in all clones. The overexpression level of clone 1 was then assessed 
through real time RT-qPCR in which the specific transcripts of Tb927.11.11750 was 
~2.5 fold higher in the plus Tet sample than in the minus Tet sample (Fig 6.24C) 






Figure 6.24 Introducing an ectopic copy of Tb927.11.11750. 
 A: Schematic representation of NcoI and EcoRⅤ digestion sites and expected restriction 
fragments containing the ectopic copy of Tb927.11.11750 and the endogenous copies of 
Tb927.11.11740 and Tb927.11.11750 as detected with a GOI probe. B: Southern blot of BSF 
T.brucei gDNA (5 µg/ lane) of BSF WT (lane 1) and BSF WT Tb927.11.11750 overexpression 
mutant clones 1 to 6 (lanes 2-7) digested with NcoI and EcoRⅤ. The GOI ORF (corresponding 
to 1000 bp identical region of Tb927.11.11740 and Tb927.11.11750) was used for probing. C: 
Comparison of Tb927.11.11750 specific transcript levels of clone 1 of Tb927.11.11750 
overexpression cell line without or with Tet induction examined by real time RTq-PCR. Error 
bars indicate done standard deviation. 
 
After the induction of expression of the ectopic copy of Tb927.11.11750, the first 
endogenous allele of Tb927.11.11750 was replaced with HYG flanked with 500 bp 5’ 
and 3’ UTRs of Tb927.11.11750. The generation of this HYG KO construct was 
described previously. The cells recovered from hygromycin selection were subcloned 
for the genotype analysis by Southern blot. For this analysis, endonuclease digestion by 
NcoⅠ was performed on gDNAs extracted from T.brucei BSF cell lines, and the 
expected sizes of fragments to be detected with the GOI and HYG ORF probes are 
indicated in (Fig 6.25A). Since the GOI probe detects both Tb927.11.11740 and 
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Tb927.11.11750 we would expect the intensity of the Tb927.11.11750 band (at 3302 
bp) to be half that of the Tb927.11.11740 band (at 5725 bp). We could not predict the 
size of the ectopic copy of Tb927.11.11750, but by the comparison between the BSF 
WT sample and the plew100_v1 Tb927.11.11750 overexpression sample we were able 
to determine that it resides within a 7.4-8.6 kb fragment (Fig 6.25B, lanes 1 and 2). We 
were also able to predict that when HYG is integrated to the correct locus, the HYG 
probe should detect two bands at 736 bp and 2124 bp (Fig 6.25A). For the Southern 
blot, gDNAs of nine clones recovered from HYG selection were prepared in parallel 
with BSF WT and plew100_v1 Tb927.11.11750 overexpression cell lines for NcoⅠ 
endonuclease reaction. The GOI probe detected the ectopic copy of Tb927.11.11750 at 
7.4-8.6 kb in all of the HYG selected clones (Fig 6.25B, lanes 3-11). Among these 
putative “sKO” mutants, there were four clones where the band corresponding to the 
Tb927.11.11750 locus (3302 bp) was clearly half intensity of the band corresponding to 
Tb927.11.11740 locus (5725 bp) (Fig 6.25B, lanes 3, 4, 8 and 9) corresponding to 
clones 1, 2, 7 and 7. This suggested that one allele of Tb927.11.11750 was successfully 
replaced by HYG, the integration of which was confirmed in the HYG probe blot (see 
corresponding lanes with HYG probe in Fig 6.25B). However, in all cases there was 
another GOI band (annotated with asterisk) running below the endogenous 
Tb927.11.11750 band in all nine clones, suggesting that replication and transposition of  
Tb927.11.1150 or Tb927.11.11740 also occurred during the replacement of 
Tb927.11.11750 by HYG. As for the HYG probe blot, although the expected two bands 
(736 bp and 2124 bp) were detected, there was also another band (dagger symbol) 
detected suggesting that HYG was also incorporated into another locus in the genome. 
The two bands that were labelled with question mark were non-specific detections when 
using HYG probe as they were detected in the BSF WT sample as well. 
While we do not fully understand the rearrangements that occurred in what should have 
been a simple gene replacement, possible explanations include: (ⅰ) Insufficient 
expression of the hygromycin resistance cassette by the Tb927.11.11750 endogenous 
promotor, such that only clones that incorporated a second copy of HYG survived the 
selection. A similar problem was observed with the generation of a BSF GDP-fucose 
biosynthesis null mutant (Turnock et al., 2007). (ⅱ) Haploid insufficiency of 
Tb927.11.11750, even though the activated ectopic copy apparently delivers more 
mRNA than two endogenous alleles (Fig 6.24C). (iii) There is something unusual about 




Figure 6.25 Attempt of generating Tb927.11.11740 and Tb927.11.11750 conditional sKO 
cell lines. 
 A: Schematic representation of NcoI digestion sites and expected probe detection (GOI and 
HYG probes) for the Tb927.11.11740 and Tb927.11.11750 locus. The probes used for 
detections was indicated below the scheme of gene locus, the expected size of bands detected by 
the probes were indicated above the scheme of gene locus. B: Southern blot of GDNA (5 µg/ 
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lane) of BSF WT (lane 1) , BSF plew100_v1 Tb927.11.11750 overexpression cell line (lane 2) 
and BSF conditional sKO mutants of Tb927.11.11750 clones 1 to 9 (lanes 3-11) digested with 
NcoI. GOI ORF (corresponding to 1000 bp identical region of Tb927.11.11740 and 
Tb927.11.11750) and HYG ORF probe were used for probing sequentially. 
 
 
6.8.2 Attempt to generate a Tb927.11.11750 conditional null mutant cell line 
using KO constructs with actin regulation elements  
One of our hypotheses for why gene rearrangements occurred in (Fig.6.25 B, section 
6.8.1) when using a conventional knock out method was that transcription of 
endogenous Tb927.11.11750 locus in BSF WT might be insufficient to yield enough 
hygromycin resistance cassette to provide effective drug resistance during selection. To 
circumvent this situation, the PAC and HYG constructs for knocking out 
Tb927.11.11750 were modified with the addition of 5’UTR and 3’UTR elements of the 
highly-expressed actin gene (the sequences were retrieved from plew100_v1 plasmid 
where they were used for regulating PHLEO resistance cassette expression. By doing 
this, we expected that higher levels of PAC and HYG transcripts and PAC and HYG 
protein would be achieved, hopefully preventing abnormal gene rearrangements when 
generating the conditional null mutant of Tb927.11.11750 in BSF WT. A schematic 
representation of the creation of the conditional null mutant clones is shown in (Fig. 
6.26A), note: these gene replacements were attempted in the same BSF plew100_v1 
Tb927.11.11750 overexpression cell line characterised in (Fig 6.24). After introducing 
PAC and HYG replacement constructs in two rounds of transfection and selection, 
gDNA from mutant clones was analysed by sequential Southern blotting using GOI, 
PAC and HYG ORF probes to check the genotype. Schematic detections for PAC and 
HYG ORF probes were shown in (Fig 6.26B) while the GOI ORF probe detection is 
indicated in (Fig 6.25A). Unfortunately, the blot with the GOI probe showed that the 
plew100_v1 Tb927.11.11750 overexpression cell line had lost the ectopic copy after 
recovering from liquid nitrogen stabilate (Fig 6.25A, lane 2). The PAC conditional sKO 
clone 1 (Fig 6.26C, lane 3) showed loss of one allele of endogenous Tb927.11.11750 as 
the intensity of the band corresponding to endogenous Tb927.11.11750 (3302 bp) was 
half the intensity of the band corresponding to endogenous Tb927.11.11740 (5725 bp). 
However, the same Tb927.11.11750 band was also observed in the three putative 
conditional null mutant clones (Fig 6.26C, lanes 4-6) where the last  Tb927.11.11750 
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allele should have been replaced if both the PAC and HYG replacement cassettes 
integrated to the correct loci. The blot probed with PAC ORF probe (Fig 6.26D) showed 
expected band (2858 bp) detected in the conditional sKO (lane 3) and putative 
conditional null mutant clones 1-3 (lanes 4-6) suggesting that the PAC resistance 
cassette had integrated to the correct locus. However, an extra band (asterisk labelled) 
was detected just below the expected band indicating that PAC resistance cassette 
inserted to another locus in the T.brucei genome. While the blot probed with HYG ORF 
probe showed HYG resistance cassette had integrated to the correct locus in the three 
mutant clones. Together, the Southern blot data showed that PAC and HYG resistance 
cassettes had replaced two alleles of the endogenous Tb927.11.11750 even though that 
the PAC resistance cassette inserted to another locus, while there was still endogenous 
remaining Tb927.11.11750 detected with the GOI ORF probe. This suggested that 
either there were more than two copies of Tb927.11.11750 in the BSF WT genome to 
begin with, or (more likely) that a gene duplication and transposition of Tb927.11.11750 
occurred when replacing the two genes in the absence of an activated ectopic copy. In 





Figure 6.26 Schematic strategy for the creation of the Tb927.11.11750 conditional null 
mutant. 
 A: The conditional null mutant for Tb927.11.11750 was generated in the plew100_v1 
overexpressing Tb927.11.11750 BSF WT cell line described in Fig 6.24. Two alleles of 
endogenous Tb927.11.11750 were replaced with PAC and HYG resistance cassette sequentially 
where the PAC and HYG were flanked with 5’ UTR and 3’ UTR of actin gene for high 
transcription of the resistance cassettes together with the 5’UTR and 3’UTR of Tb927.11.11750 
for homologous recombination. B: Schematic representation of NcoI digestion sites and 
expected probe detection (PAC and HYG probes) for the Tb927.11.11750 locus. The probes 
used for detection are indicated below the scheme of the gene locus, the expected size of bands 
detected by the probes are indicated above the scheme of gene locus. C, D and E: Southern blots 
of gDNA (5 µg/ lane) extracted from BSF WT (lane 1), BSF plew100_v1 Tb927.11.11750 
overexpression cell line (lane 2), putative BSF conditional sKO clone 1 (lane 3) and putative 
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BSF conditional null mutants clones 1-3 (lanes 4-6). GOI ORF (corresponding to 1000 bp 
identical region of Tb927.11.11740 and Tb927.11.11750), PAC and HYG ORF probes were 
used for probing sequentially.  
 
 
6.8.3 Attempt to generate a Tb927.11.11750 conditional null mutant cell line with 
ectopic copy introduced using plew100_v5 Tb927.11.11750. 
Our attempt to generate a Tb927.11.11750 conditional null mutant using a plew100_v1 
Tb927.11.11750 ectopic copy had failed, and we wonder if it was the overexpression 
level of this ectopic copy Tb927.11.11750 using plew100_v1 vector was not sufficient 
to compensate for the of the endogenous Tb927.11.11750 copies. Therefore, the BSF 
WT was transformed with an ectopic copy of Tb927.11.11750 using a plew100_v5 
vector which generally results in about 10-fold higher Tet induced expression than 
plew100_1 constructs (Fig 6.28A). Primers OL15 and OL16 were used to amplify the of 
Tb927.11.11750 ORF and OL17 and OL18 were used to amplify the linearised 
plew100_v5 vector. The gDNA of the clones recovered from the phleomycin selection 
were used for PCR analysis (Fig 6.28A) using the indicated primers. The five tested 
clones (Fig 6.28B, lanes 1-5) showed specific 2205 bp amplicons consistent with the 
successful integration of the ectopic copy into the T. brucei ribosomal DNA locus. The 
PCR amplification from the plew100_v5 Tb927.11.11750 plasmid using the same pair 
of primers (Fig 6.28B, lane 6) was included as a positive control. The overexpression 
level of clone 1 mutant was then examined through real time RT-qPCR with or without 
24 h Tet induction using primers OL37 and 38. Transcripts of Tb927.11.11750 were 
~50 fold higher in the plus Tet sample than in the minus Tet sample (Fig 6.28C), 
suggesting a high overexpression Tb927.11.11750 mutant cell line was generated as 
expected. Then, the endogenous Tb927.11.11750 were replaced by transfections of 
HYG and PAC integration constructs as indicated in the scheme of (Fig 6.23A). After 
two rounds drug selection and subcloning, gDNA from mutant clones was analysed by 
Southern blotting using the GOI ORF probe to check the genotype. Schematic detection 
for GOI ORF probe was indicated is (Fig 6.25A). The blot with the GOI probe showed, 
disappointingly, that although phleomycin resistance had been retained, the ectopic 
copy of Tb927.11.11750 had been lost during the transformations (Fig 6.28D, lanes 1 
and  2). The intensity of the band representing Tb927.11.11750 was half the intensity of 
the band representing Tb927.11.11740, suggesting that HYG had integrated to one 
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allele of Tb927.11.11750 locus (Fig 6.28D, lane 3). However, there was an extra band 
detected in what should have been the conditional single knock out (sKO) cell line, 
indicating a duplication and transposition of the Tb927.11.11750 gene had occurred in 
this mutant cell line. The pattern was found in all the tested conditional “null mutant” 
clones (Fig 6.28D, lanes 4-7). These data show that we failed to obtain the expected 
conditional null mutant for Tb927.11.11750 even when starting with a highly 
overexpressing ectopic copy of Tb927.11.11750. Indeed, it is possible that 
Tb927.11.11750 overexpression causes a growth defect such that cells harbouring 
ectopic Tb927.11.11750 can be outgrown by those that lose the transgene while 




Figure 6.27 Attempt to generate a conditional null mutant of Tb927.11.11750 using an 
ectopic copy delivered with plew100_v5 Tb927.11.11750. 
 A: Schematic representation of introducing an ectopic copy of plew100_v5 Tb927.11.11750. 
The insertion of the ectopic copy was analysed by PCR amplification of the gDNA of mutant 
clones giving 2205 bp product using specific primers (annotated with dark arrows): For, anneals 
to PHLEO region; Rev, anneals to Tb927.11.11750 ORF region. B: PCR products from five 
clones (lanes 1-5) of plew100_v5 Tb927.11.11750 overexpressing cell line were separated on 
agarose gel and analysed by electrophoresis. The PCR product using the plew100_v5 
Tb927.11.11750 plasmid as a template served as positive control. C: Comparison of 
Tb927.11.11750 specific transcript levels of clone 1 of Tb927.11.11750 overexpression cell line 
without or with 24 h Tet induction as determined by real time RTq-PCR. Error bars indicate one 
standard deviation. D: Southern blot of gDNA (5 µg/ lane) extracted from BSF WT (lane 1), 
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BSF plew100_v5 Tb927.11.11750 overexpression clone 1 (lane 2), BSF putative conditional 
sKO clone 1 (lanes 3) and BSF putative conditional null mutants clones 1-4 (lanes 4-7) digested 
with NcoI. GOI ORF (corresponding to 1000 bp identical region of Tb927.11.11740 and 
Tb927.11.11750) probe was used for probing. 
 
6.9 GPI PLA2 enzymatic assay test for Tb927.11.11740 and Tb927.11.11750 
All of our attempts to generate a conditional null mutant for Tb927.11.11740 and/or 
Tb927.11.11750 had failed, therefore we could not apply biological function studies on 
Tb927.11.11740 and Tb927.11.11750 by comparing BSF WT and the Tb927.11.11740 
and Tb927.11.11750 null mutant cell lines and their cell-free systems.  
Our series of pull-down experiments coupled with proteomics analyses have elucidated 
that TbdeAc2 forms a complex with Tb927.11.11750, but not with Tb927.11.11740. 
However, due to the facts that Tb927.11.11740 and Tb927.11.11750 share 90% amino 
acids sequence identity, and since both share a lipase motif (GXSXG), we postulate that 
Tb927.11.11740 harbours a similar protein function as Tb927.11.11750 but in a 
different subcellular environment. As GPI phospholipase A2 (PLA2) is the enzyme 
catalysing the next step after TbdeAc2, one of our hypotheses is Tb927.11.11750 and/or 
Tb 927.11.11740 play the role of GPI PLA2 in the GPI anchor biosynthesis pathway 
and/or in the GPI anchor endocytic recycling pathway (Buxbaum et al., 1996). To test 
this hypothesis, on-bead digestions of radiolabelled glycolipid A’ which is the substrate 
of GPI PAL2 were performed with Tb927.11.11740-3HA and Tb927.11.11750-12Myc 
pull down products respectively. 
To achieve this, a T. brucei cell-free system was prepared to perform the radiolabelling 
of GPI glycolipid intermediates in the GPI anchor biosynthetic pathway, as described 
previously (Fig. 6.18A). Briefly, the cells were subjected to hypotonic lysis and the 
membrane fraction (cell-free system) containing the GPI biosynthetic machinery was 
recovered by centrifugation. Pulse-labelling of the cell-free system with GDP-[3H]Man, 
with a subsequent chase with unlabelled excess GDP-Man, was performed and the 
labelled glycolipids were extracted and an aliquot resolved by high-performance thin 
layer chromatography (HPTLC) and visualised by auto-fluorography. The silica plate 
containing glycolipids A’ and θ products (that had not been sprayed with enhancer for 
auto-fluorography) was scraped where glycolipids A’ and θ were expected and the 
glycolipids were recovered by extraction with 1-butanol. As shown in (Fig 6.29A), pure 
glycolipid A’ (lane 2) and θ (lane 1) were purified with the A’ product slightly 
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contaminated by another radiolabelled component. On-bead digestion of the purified A’ 
product was set up to test Tb927.11.11740 and Tb927.11.11750 for GPI PLA2 
enzymatic activity. For this assay, 2 × 108 BSF WT and Tb927.11.11740-3HA 
expressing cells were lysed with 1% TX-100 and immunoprecipitation was performed 
with anti-HA magnetic beads. After washing for 3 times, radiolabelled A’ products 
were added to the beads for enzymatic reaction. The lipids were then extracted from 
these reactions after the incubation. Glycolipid A’ product incubated with only anti-HA 
magnetic beads (Fig 6.29B, lane1) was added as a negative control, while digestion with 
bee venom PLA2 served as a positive control. These samples were analysed by HPTLC 
and visualised by auto-fluorography. Radiolabelled GPI anchor glycolipid mix was run 
in parallel to indicate the positions of glycolipids A’ and θ. As shown in (Fig 6.29B), 
bee venom PLA2 could digest most glycolipid A’ to θ (lane 4). However, there was no 
significant θ product produced in the Tb927.11.11740-3HA digestion sample. Only 
trace amounts of θ product was found in that sample and in all negative controls. We 
conclude from this experiment that Tb927.11.11740 does not have detectable GPI PLA2 
enzymatic activity in this assay.  
The same enzymatic assay was performed for Tb927.11.11750-12Myc pull down 
products that were immunoprecipitated with MycTrap™ beads. As for the 
Tb927.11.11740-3HA protein assay, the positive control bee venom PLA2 could digest 
most glycolipid A’ to θ (Fig 6.29C, lane 3). However, the Tb927.11.11750-12Myc (lane 
2) pull down products did not produce any obvious θ product from A’, with only trace 
amounts of θ product present that was also detected in the MycTrap™ beads only 
digestion sample (lane 1). Together, our PLA2 enzymatic assay for Tb927.11.11740 and 
Tb927.11.11750 suggested that neither of these two proteins has GPI PLA2 enzymatic 





Figure 6.28 Tb927.11.11740-3HA and Tb927.11.11750-12Myc enzymatic assay. 
 A: HPTLC of purified radiolabelled glycolipids. Lane 1, purified glycolipid θ; lane 2, 
glycolipid A’; lane 3, radiolabelled GPI glycolipids mixture. B: Tb927.11.11740-3HA IP 
products on bead digestion test with glycolipid A’. Lane 1, glycolipid A’ with anti-HA magnetic 
beads (negative control); lane 2, glycolipid A’ incubated with BSF WT cell lysates IP products 
by anti-HA magnetic beads (negative control); lane 3, glycolipid A’ incubated with 
Tb927.11.111740 cell lysates IP products by anti-HA beads; lane 4, glycolipid A’ incubated 
with bee venom PLA2 (positive control); lane 5, radiolabelled GPI glycolipid mixture 
(standards). C: Tb927.11.11750-12Myc IP products on bead digestion test with glycolipid A’. 
Lane 1, glycolipid A’ incubated with BSF WT cell lysates IP products by MycTrap™ beads 
(negative control). Lane 2, glycolipid A’ incubated with Tb927.11.11150 cell lysates IP 
products by MycTrap™ beads. Lane 3, glycolipid A’ incubated with bee venom PLA2 (positive 










7.1 No evidence for direct protein interactions between TbGPI12 and TbMTⅠ 
The hypothesis that TbGPI12 might have associations with TbMTⅠ came from studies 
on the acceptor specificities of GPI pathway enzymes. These studies used an assay 
based on the BSF trypanosome cell-free system described in (Section 5.3). The system 
was modified to include N-ethylmaleimide (NEM), which inhibits the endogenous GPI 
GnT of the pathway (Milne et al., 1992) So that it could be used for testing the abilities 
of exogenously added synthetic GlcNAc-PI and GlcN-PI, and analogues thereof, to 
prime the GPI pathway (Smith et al., 1996). The read-out was based on the 
incorporation of [3H]Man from GDP-[3H]Man (via Dol-P-[3H]Man) into the 
downstream GPI intermediates from Man1GlcN-PI  to glycolipid A’. In several such 
studies, GlcNAc-PI was always more efficient than GlcN-PI at priming the pathway. An 
example is shown in (Fig. 7.1).  
 
Fig 7.1 GlcNAc-PI is more efficient at priming the GPI pathway than GlcN-PI.  
The HPTLC auto-fluorograph shown that the NEM-treated BSF cell-free system incubated with GDP-
[3H]Man makes only Dol-P-[3H]Man (DPM) (lane 2) whereas the addition of synthetic GlcN-PI (lane 3) 
and GlcNAc-PI (lane 4) primes the production of downstream GPI intermediates, as indicated. Note the 
greater priming with GlcNAc-PI compared to GlcN-PI. These data are abstracted from Figure 2 of 
(Sharma et al., 1997).  
  
This phenomenon of the earlier intermediate (GlcNAc-PI) accessing TbMTI and the rest 
of the pathway more efficiently than its immediate substrate (GlcN-PI) suggested a 
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degree of substrate channelling between TbMTⅠ and the preceding enzyme, the 
GlcNAc-PI de-N-acetylase (TbGPI12). Thus, we hypothesised that the two enzymes 
might form a protein complex. However, the immunoprecipitation experiments of 
TbGPI12-Myc coupled with either SILAC or cross-linking following by proteomics 
performed in this thesis failed to identify TbMTⅠ as a partner protein for TbGPI12 
(Section 4). Nor did a preliminary experiment described briefly in (Appendix A).  
We also tried to perform the reverse pull-down by in situ tagging TbMTI with 3 x cMyc 
at the C-terminus to look for associated TbGPI12, this time in BSF cells (Appendix B). 
However, even starting with 1 e 9 cells we were barely able to detect the tagged protein 
in anti-Myc IPs (Appendix B, Fig S2) and so we did not follow this up.   
In retrospect, since we now know that endogenous TbMTⅠ is undetectable in our deep 
whole proteome dataset for BSF T. brucei (Ji, Tinti and Ferguson, 2021), it may be that 
we never had enough sensitivity to find TbMTI in overexpressed TbGPI12-Myc 
pulldowns. Thus, while we can provide no evidence for TbGPI12 – TbMTI association, 
we can still not rule it out.  
Regardless, the native-PAGE anti-Myc Western blot of the TbGPI12-Myc IP product 
(Fig 4.4A) does suggest that TbGPI12 exists in a protein complexes, running between 
the 66 and 480 kDa markers. TbGPI12-Myc has a predicted MW of about 29 kDa and 
these complexes could be homo- or hetero-oligomers. After data filtering with stringent 
criteria for the proteomics data, the SILAC proteomics method identified 13 co-IP 
proteins of TbGPI12 (Table 4.1), while the cross-linking proteomics method identified 
15 co-IP proteins (Table 4.2). The only protein that was present in both proteomics 
datasets is the Tb927.10.14510 gene product which encodes a 95 kDa putative root hair 
defective 3 GTP-binding protein (RHD3). While it is not obvious why such a protein 
might be a component of the GPI pathway, one might speculate that is could play a 
regulatory role, as many GTP-binding proteins do. Any conclusions must, however, 
await more detailed studies, starting with the reverse pull down experiment.  
Although our attempts to verify interactions between TbGPI12 and TbMTⅠ failed, the IP 
studies using TbGPI12-Myc protein did benefit our later studies on other enzymes, in 
the GPI anchor biosynthesis pathway through: (i) The optimisation of the IP and 
detection conditions for low abundance membrane proteins; (ⅱ) The set up for the 
SILAC proteomics identification and analysis methodology; (ⅲ) Adoption of cross-
linking methodology to study membrane protein-protein interactions. These conditions 




7.2 New components of GPI GnT in T. brucei 
GPI anchor biosynthesis in all organisms is initiated with the transfer of GlcNAc from 
UDP-GlcNAc to phosphatidylinositol (PI) catalysed by the GPI GnT complex. The first 
component identified in this complex was PIGA in mammalian cells (Miyata et al., 
1993). The concept used in this paper was through a complementation experiment 
carried out in a GPI-deficient cell line JY5 with an Epstein-Barr virus vector-based 
cDNA library. Later, through affinity immunoprecipitation of PIGA, the PIGH subunit 
was found (Watanabe et al., 1996). In this paper, the authors also proved that PIGA was 
the catalytic subunit and played its function on the cytoplasmic side of the ER lumen. 
Although the role of PIGH is not clear, it is essential for the activity of GPI GnT. The 
homologue of PIGC, GPI2, was first characterised in yeast, identified in a protein 
complex formed with GPI1 and GPI3 (Leidich et al., 1995). After this, PIGC was also 
observed in mammalian cells (Inoue et al., 1996).  The yeast GPI2 is an essential gene 
and PIGC is essential for GPI biosynthesis in mammalian cells. However, a recent study 
on the T. brucei homologue, TbGPI2, has shown that a null mutant of TbGPI2 only 
exhibits a reduction in GPI GnT activity (Jenni et al., 2021). PIGQ was found to be the 
mammalian homologue of yeast GPI1 and proved to be a non-essential gene for GPI 
biosynthesis (Watanabe et al., 1998). Another two components in this complex, PIGP 
and DPM2, were co-immunoprecipitated with PIGA in a two-step affinity purification. 
PIGP was shown to be an essential component for GPI GnT activity, while DPM is 
involved in the regulation of GPI GnT. In yeast, an ERI1 gene product is another 
component for GPI GnT, whose activity is negatively regulated by Ras2 protein in the 
ER (Sobering et al., 2004). The mammalian homologue of ERI1, PIGY, was also 
identified later (Murakami et al., 2005). These studies have established that in 
mammalian cells, the GPI GlnT has at least seven components: PIGA, PIGH, PIGC, 
PIGQ, PIGP, PIGY and DPM2. In yeast, the GPI GnT complex contains all the 
corresponding homologues of these mammalian subunits except DPM2.  
Although the studies on the GPI GnT complex are well established in mammalian and 
yeast cells, surprisingly, there was no experimental analysis for this complex in T. 
brucei before our study. With the established IP coupled with proteomics identification 
method described for TbGPI12 protein, we, therefore, performed IP for the epitope-
tagged TbGPI3 protein, which is the catalytic subunit in this complex, followed by 
proteomics identification to explore the composition of the GPI GlnT complex in T. 
brucei and also to investigate whether any new components are specific for T. brucei.    
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The proteomics data in (Section 5) suggest that: (i) The T. brucei UDP-GlcNAc: PI α1–
6 GlcNActransferase complex (GPI GnT) contains the expected subunits TbGPI3, 
TbGPI15, TbGPI19, TbGPI2, TbGPI1 and TbERI1. (ii) Like yeast, but unlike 
mammalian cells, DPM components are not subunits of the parasite complex. (iii) An 
Arv1-like protein (TbArv1) is a part of the parasite complex. (iv) A putative E2-ligase 
UbCE may be a part of the parasite complex.  
The limitations of our study are that it does not attempt to assess stoichiometry, 
topology or inter-subunit associations of the T. brucei UDP-GlcNAc: PI α1–6 GlcNAc-
transferase complex components and that it lacks an orthogonal confirmation of the 
presence of TbArv1 and TbUbCE in the complex. Regarding to the inter-subunit 
associations, the connections of the subunits for the mammalian cells has been reviewed 
in (Kinoshita, 2014). The study on TbGPI2 (Jenni et al., 2021) in T. brucei has 
demonstrated that the absence of TbGPI2 causes the loss of most of TbGPI1 from the 
complex, indicating the important scaffolding role of TbGPI2 in the architecture of the 
GPI GnT complex in T. brucei.  
With respect to the lack of an orthogonal confirmation of the presence of TbArv1 and 
TbUbCE in the complex, we rely, instead, on the extremely high and reproducible 
enrichment of these two components in the TbGPI3-3Myc pull-downs: From 
undetectable (>7149th) and 2538th in the total cell proteome for TbArv1 and TbUbCE, 
respectively, to 6th and 7th in the TbGPI3-3Myc pull-down proteome. TbArv1 is 
predicted to contain four transmembrane domains and an Arv1 domain (PF04161). 
Previous studies in yeast have indicated that Arv1p, although non-essential for growth 
and therefore GPI-anchoring of proteins at 25˚C (McDonough et al., 2002) (Georgiev et 
al., 2013), is required for the efficient synthesis of Man1GlcN-(acyl)PI (Kajiwara et al., 
2008). It has been postulated to be a GPI flippase (Kajiwara et al., 2008)(Okai et al., 
2020) helping deliver GlcN-(acyl)PI, which is made on the cytoplasmic face of the ER, 
to the active site of mannosyl-transferase I (MT I) on the luminal face of the ER. The 
complementation of yeast Arv1 mutants by the human Arv1(Ikeda et al., 2016), and 
recent findings that human Arv1 mutations lead to deficiencies in GPI anchoring 
(Davids et al., 2020) (Segel et al., 2020), strongly suggest a related role in mammalian 
cells. However, whether it is a component of the mammalian and yeast GPI GnT 
complexes, or indeed of possible GlcNAc-PI de-N-acetylase or GPI flippase complexes, 
is unclear. It is possible that TbArv1 plays an analogous role to that proposed for Arv1 
in yeast and mammalian cells in the T. brucei GPI pathway. However, since (unlike 
yeast and mammalian cells) acylation of the PI moiety occurs strictly after the action of 
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MT I in T. brucei (Güther and Ferguson, 1995), TbArv1 would need to facilitate the 
delivery of GlcN-PI rather than GlcN-(acyl)PI to TbMT I in this parasite. Further, it is 
worth noting that unlike mammalian cells and yeast, which are thought to only 
translocate GlcN-(acyl)PI, T. brucei appears to flip-flop most of its GPI intermediates 
between the cytoplasmic and lumenal surfaces of the ER (Vidugiriene and Menon, 
1994). Thus, it is possible that T. brucei Arv1 protein, given its location, may play some 
other, perhaps regulatory, role in the GPI GnT reaction. This might also be the case in 
mammalian and yeast cells. 
Finally, a recent study in mammalian cells showed that GPI anchor biosynthesis is 
upregulated in endoplasmic-reticulum-associated protein degradation (ERAD) deficient 
and PIGS mutant cell lines, suggesting that the GPI anchor biosynthetic pathway is 
somehow linked to and regulated by the ERAD system (Wang et al., 2020). Since 
ERAD involves E2-dependent ubiquitylation of misfolded proteins as they exit the ER, 
it is possible that TbUbCE associated, in part, with the GPI GnT complex might play 
some role in regulation of the T. brucei GPI pathway. 
Lastly, while for GPI GnT the chemical cross-linking, stringent IP proteomics approach 
(section 5.5) was less productive than the digitonin-solubilisation, native complex IP 
proteomics approach, it did identify one highly speculative new component, namely 
Tb927.9.14280. This predicted 187 kDa cytosolic protein contains a concanavalin A-
like lectin domain that might, like Con A itself (Vidugiriene and Menon, 1994), be able 
to bind Man2GlcN-PI and downstream GPI intermediates which, uniquely in T. brucei, 
occur on both sides of the ER membrane though flip-flop. Therefore, a hypothesis that 
might be tested in the future is to see whether Tb927.9.14280 provides negative 
feedback on the GPI GnT complex if GPI intermediates accumulate in the cytoplasmic 
face of the ER membrane. For example, if VSG synthesis was inhibited by 
cycloheximide, would glycolipid A and C levels greatly increase in absence of 
Tb927.9.14280? Tb927.9.14280 also contains an armadillo (ARM) repeat superfamily 
domain, roles for which include vesicular transport and membrane tethering, either or 





7.3 Tb927.11.11750 - a possible regulatory role in GPI anchor biosynthesis in T. 
brucei 
As described in the introduction and result chapters, enzymes in the GPI anchor 
biosynthesis pathway tend to work in complexes in different organisms. In T. brucei, 
the GPI GnT was experimentally shown in this thesis to contain at least six subunits (Ji, 
et al., 2021) and the GPI transamidase contains at least five components (Lillico et al., 
2003) (Nagamune et al., 2003) (Hong, Nagamune, Ohishi, et al., 2006), in which TTA1 
and 2 are unique subunits to T. brucei in terms of sequence but are topologically similar 
to PIGS/GPI17 and PIGU/GAB1 in mammals and yeast (Nagamune et al., 2003). The 
ethanolamine phosphate transferase has also been shown to be two component complex 
of  TbGPI13, the catalytic subunit, stabilised by TbGPI11 (Stokes et al., 2014). 
TbdeAc2, together with TbdeAc1, catalyse GPI inositol-deacylation of GPI 
intermediates (Fig 2.1). The first GPI inositol-deacylase to be identified in T. brucei was 
TbdeAc (Tb927.10.4780) (Güther et al., 2001). It was activity-labelled with the GPI 
inositol deacylation inhibitor [3H]-diisopropylfluorophosphate (DFP) and purified. 
From peptide sequencing of the purified radiolabeled protein, TbdeAc1 was cloned and 
sequenced, showing high similarity with mammalian acyloxyacyl hydrolase. The 
conditional null mutant of TbdeAc1 in BSF showed that it is not essential, but its 
removal altered GPI precursor processing, leading to the accumulation on non-protein 
linked galactosylated free GPI glycolipids (Güther, Prescott and Ferguson, 2003). 
Immunofluorescence microscopy of C-terminal HA tagged TbdeAc1 suggested it is an 
ER-resident protein, although the co-localisation pattern with ER marker protein Bip 
was not homogeneous (Güther et al., 2003). In the BSF protein ranking (Ji, et al., 2021) 
TbdeAc1 ranks 2693rd out of 7149 identified protein groups, indicating that, with the 
exception of the transamidase complex, TbdeAc1 is a relatively abundant protein for the 
GPI pathway. We currently think that TbdeAc1 may be involved in the deacylation of 
excess glycolipid C to generate glycolipid A for galactosylation at a site distinct from 
that of GPI addition to VSG and other proteins. 
TbdeAc2 (Tb927.3.2610) was identified through BLAST search using its mammalian 
homologue PGAP1 (Hong, Nagamune, Morita, et al., 2006). The 70% knock-down of 
TbdeAc2 mRNA mediated by RNAi in BSF T. brucei caused accumulation of 
glycolipids C’ and lyso-C’ and a decrease of the non-inositol acylated inositol 
glycolipids A’ and θ. The inhibition of inositol deacylation also resulted in decreased 
surface expression of VSG, which caused cessation of growth – suggesting essentiality 
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of TbdeAc2 for BSF T. brucei. The phenotype of the TbdeAc2 knock-down is 
consistent with this enzyme catalysing the inositol-deacylation steps throughout the 
pathway leading to glycolipids A and C (Fig 1.10) and so we decided to focus on 
TbdeAc2 in this study.  
Despite the aforementioned details of TbdeAc2 function, there are no subcellular 
localisation or protein complex data for this protein. Nor does TbdeAc2 appear in the 
proteome-wide protein complex database reported by our laboratory (Crozier et al., 
2017), probably because it is of low abundance (5715th out of 7149 proteins (Ji, et al., 
2021)) and because the (Crozier et al., 2017) study was enriched for soluble protein 
complexes.  
Here, we have used immunofluorescence microscopy to localise TbdeAc2 to the ER, 
using an internal 12Myc in situ tagging approach to preserve its predicted N-terminal 
signal peptide and putative C-terminal ER retention signal. Further, we have provided 
evidence for specific protein-protein interaction between TbdeAc2 and 
Tb927.11.11750, and vice versa, through a series of in situ tagging and affinity 
immunoprecipitations followed by proteomics identification. The experiments 
performed are summarised in (Table 7.1). 
 
Table 7.1 List of proteomics methods applied for TbdeAc2 and its partner proteins 
Proteomics method Identified partner protein 
Label-free proteomics of TbdeAc2-3Myc IP products  No reliable co-IP protein  




SILAC proteomics identification of TbdeAc2-3Myc 0.5% 
digitonin lysis condition IP products  
Tb927.11.11740 and/or 
Tb927.11.11750 
SILAC proteomics identification of TbdeAc2-3Myc 0.3% 
digitonin lysis condition IP products 
No reliable co-IP protein  
Label-free proteomics of Tb927.11.11740-3HA IP products No reliable co-IP protein  




It is worth noting that we could not distinguish Tb927.11.11750 from its close 
homologue Tb927.11.11740 by proteomics but, whereas we could IP TbdeAc2 with 
tagged Tb927.11.11750, we could not with tagged Tb927.11.11740.  
The specific association between TbdeAc2 and Tb927.11.11750 strongly supports the 
notion that Tb927.11.11750 plays some role in the GPI anchor biosynthesis pathway in 
T. brucei. This could be either as an enzyme of the pathway itself, or as a regulatory 
and/or chaperone protein for TbdeAc2. With respect to the former possibility, we 
considered that Tb927.11.11750 (and its Tb927.11740 homologue) might encode GPI 
PLA2 activity since TbdAc2 and GPI PLA2 are adjacent activities in the GPI pathway 
(Fig 1.10) and since Tb927.11.11740 and Tb927.11.11750 contain GXSXG lipase 
motifs. Further, two versions of GPI PLA2 activity might be expected given that fatty 
acid remodelling occurs in the ER (Masterson et al., 1990) and fatty acid proof-reading 
of GPI-anchored VSG occurs in the endocytic system (Buxbaum et al., 1994) .  
However, in vitro enzymatic assay of endogenously expressed Tb927.11.11750 and 
Tb927.11.11740 failed to demonstrate any GPI PLA2 activity on radiolabelled 
glycolipid A’ substrate (Section 6.9). While GPI PLA2 activity cannot be ruled out for 
assay condition and sensitivity reasons, our enthusiasm for the GPI PLA2 hypothesis is 
much diminished by this result.  
To enable us to determine the role of Tb927.11.11750 in GPI anchor biosynthesis 
pathway, our strategy was to generate either knockdown or conditional knock out 
mutants for Tb927.11.11750. If successful, this would allow us to radiolabel live 
trypanosomes depleted of Tb927.11.11750 with [3H]myristic acid, [3H]glucosamine and 
[3H]mannose in the presence of tunicamycin, and their cell free systems with UDP-
[3H]GlcNAc and/or GDP-[3H]Man in the presence of tunicamycin and with and without 
fatty acid remodelling mix (which provides myristoyl-CoA to drive the remodelling of 
glycolipid A’ through to glycolipids A and C). Such experiments, together with 
chemical and enzymatic characterisation of the GPI glycolipid products observable by 
HPTLC and fluorography (Guther at al., 1994), would then allow us to pinpoint any 
GPI pathway defects due to the depletion of Tb927.11.11750.  
We are able to obtain inducible RNAi clones that simultaneously knocked down 
Tb927.11.11740 and Tb927.11.11750. However, the best clones we could select gave 70% 
knockdown using the pRPA approach (Table 7.2) (Alsford et al., 2005). Unfortunately, when 
we made cell-free systems from these cells ±Tet, and from the parental cell-line, we were 
unable to detect any differences in GPI biosynthesis, as judged by GDP-[3H]Man pulse and 
pulse-chase labelling (Fig 6.18B). However, this result was inconclusive since knockout rather 
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than knockdown of enzyme activity is frequently needed to see a phenotype. To give one recent 
example, in genome-wide (RIT-seq) RNAi knockdown (Alsford et al., 2011), the novel 
mitochondrial fucosyltransferease (TbFUT1) showed no phenotype, whereas this gene proved to 
be essential for both BSF and PCF parasites using conditional null mutants for TbFUT1. 
 
Table 7.2 List of attempts for generation knockdown or conditional null mutant cell line for 
Tb927.11.11740 and/or Tb927.11.11750 
Attempts of generation knock 
down/cKO cell line 
Mutant cell lines generated  
p2T7 RNAi knock down  Insufficient knockdown (25-40%) 
pRPA RNAi knock down 70% knockdown after 24h Tet induction  
CRISPR-Cas9 mediated gene knock out   Knock out Tb927.11.11740 and intergenic region.  
Truncated Tb927.11.11750.  
Conditional knock out of Tb927.11.11740 
and Tb927.11.11750 simultaneously 
Duplication of Tb927.11.11740 and Tb927.11.11750 
gene locus  
plew100_v1 ectopic copy conditional null 
mutant  
(Resistance Marker integrated with 
Tb927.11.11750 UTRs) 
Duplicate gene locus of Tb927.11.11740 or 
Tb927.11.11750 was detected in the conditional sKO 
cell line.  
plew100_v1 cKO  
(Resistance Marker integrated with actin 
gene UTRs) 
Detection of duplicated Tb927.11.11740 or 
Tb927.11.11750 after two rounds of KO attempts  
plew100_v5 cKO  
(Resistance Marker integrated with 
Tb927.11.11750 UTRs) 
Detection of duplicated Tb927.11.11740 or 
Tb927.11.11750 in the conditional sKO cell line.  
 
As described in (Section 6.6), we attempted to delete both alleles of  
Tb927.11.11740 and Tb927.11.11750 by CRISPR-Cas9 mediated gene editing (Rico et 
al., 2018) using an sgRNA sequence common to both genes and a repair template 
containing PAC resistance cassette flanked with 800 bp 5’UTR of Tb927.11.11740 and 
500 bp 3’UTR of Tb927.11.11750. However, we ended up with clones with complex 
genotypes. The original study on CRISPR-Cas9 gene editing in T. brucei shows that the 
editing and repair of the aquaporin 2 locus could produce chimeras with the 
immediately adjacent and highly-homologous and aquaglyceroporin 3 gene (Rico et al., 
2018). A similar scenario may have occurred in our Tb927.11.11740 and 
Tb927.11.11750 CRISPR-Cas9 edited clones. All three clones (Fig 6.20) had gene re-
arrangements in the original locus. The dissection of the edited region of mutant clone 1 
by DNA sequencing showed integration of the PAC resistance cassette, taking out 
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Tb927.11.11740 but leaving in one allele a truncated versions of Tb927.11.11750 
encoding a (1-64)Tb927.11.11750 protein in-frame with a potential methionine start 
site provided by the repair template. In the other allele the truncated Tb927.11.11750 
sequence was out of frame with the potential methionine start site. A cell-free system 
was prepared for this mutant clone to phenotype the GPI anchor biosynthesis pathway. 
Disappointingly, there were no changes in the GPI anchor intermediates detected in the 
mutant clone (Fig 6.21). This might be explained if the truncated (1-
64)Tb927.11.11750 protein performs the same function as intact Tb927.11.11750. 
Despite the complexity of these results, they did at least inform us that the 
Tb927.11.11740 gene is non-essential and suggest that Tb927.11.11750 may be 
essential. 
We then tried to make conditional null mutants of the Tb927.11.11740 and 
Tb927.11.11750 locus and specifically of the Tb927.11.11750 locus (Sections 6.7 and 
6.8) and (Table 7.2). In all cases we failed to generate Tet-inducible conditional null 
mutants. It seems that, in general, while we can replace one copy of Tb927.11.11750 
with a selectable marker, this occurs with simultaneous incorporation of the selectable 
marker into another (unknown) locus and with the duplication and transposition of a 
copy of Tb927.11.11750 to another locus. Further, although we were able to introduce 
Tet-inducible ectopic copies of Tb927.11.11750 alone or together with Tb927.11.11740, 
the cells had a propensity to lose these transgenes while retaining the PHLEO selectable 
marker, making subsequent gene replacement of the endogenous alleles impossible if 
we assume that Tb927.11.11750 is essential. This occurred whether using low 
expression level plew100_v1 or higher expression plew100_v5 vector. It is possible 
that, given the aforementioned low transcription of the Tb927.11.11750 locus, even 
modest overexpression of Tb927.11.11750 is negatively selected.  
Regardless of the precise reasons for the genetic rearrangements we observed while 
trying remove Tb927.11.11750 by CRISPR Cas9 editing, and during attempts to make 
Tb927.11.11740 / Tb927.11.11750 and Tb927.11.11750 conditional null mutants, we 
are inclined to believe that these rearrangements point to Tb927.11.11750 being an 
essential gene. Unfortunately, our inability to generate cells sufficiently starved of 
Tb927.11.11750 to see a growth and biochemical phenotype means that we are unable 
to pin down its exact function. On the balance of probabilities, however, we suggest that  
Tb927.11.11750 serves as an essential subunit of the TbdeAc2 complex, possibly 
performing regulatory or stabilising functions for the catalytic subunit. Testing this 
hypothesis must await successful generation of a conditional null mutant. One approach 
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we might be try is the inducible di-Cre system, as recently reported for the GlcNAc-
transferase TbGT10 gene (Duncan et al., 2021).  
 
7.4 General discussion 
Studies on GPI anchor structure and biosynthesis began more than three decades ago; 
the first complete GPI anchor structure was solved in 1988 in T. brucei (Ferguson et al., 
1988). The importance of the GPI anchor was first implied in this organism as it is the 
membrane-attachment method for the variant surface glycoproteins (VSGs) which act as 
the defensive coat for this human disease-causing organism. The GPI structure has 
proven to be a universal protein attachment mechanism through almost all eukaryotes. 
The power of molecular biology in mammalian and yeast systems facilitated the 
identification and understanding of the enzymes of the GPI pathway. These enzymes, 
and the diseases caused by mutations of these enzymes, have been reviewed extensively 
(Kinoshita, 2020)(Kinoshita, 2014). Most of the enzymes in the T. brucei GPI pathway 
could be found via their mammalian or yeast homologous, as summarised in (Table 
1.1). However, for the parasite enzymes, including in the steps that are specific for T. 
brucei such as fatty acid remodelling, new approaches are needed to find unique 
components. The finding of these specific new components will complete our 
understanding of the GPI anchor biosynthesis pathway in T. brucei.  
Our studies described in this thesis have provided some alternative ways to look for 
unknown components of the GPI anchor biosynthesis pathway; taking account of the 
protein properties of the known enzymes and exploiting current proteomics 
identification methods. Our study on the protein interactions between TbGPI12 and 
TbMTⅠ suggests that these two proteins do not associate with each other, correcting 
prior assumptions. Nevertheless, the optimisation steps for immunoprecipitation of 
TbGPI12-Myc helped to set up procedures for the pull-down of low abundance 
transmembrane proteins and protein complexes. And we identified another novel 
protein that might form a protein complex with TbGPI12 which is Tb927.10.14510 
(RDH3). This protein might play a regulatory role in the GPI anchor biosynthesis 
pathway. And generation of conditional null mutant cell lines could be conducted to 
assess its protein role. When the standardised IP procedure was then applied to the T. 
brucei GPI GnT complex, all the expected subunits (apart from DPM2) and two more 
possible new components were found. With the additional cross-linking coupled 
proteomics method, the protein (Tb927.9.14280) that contains an ConA-like domain has 
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been identified. Epitope tagging of this protein could be performed to conduct reverse 
pull-down which will first confirm the complex it forms with the GPI GnT complex. In 
vitro on beads digestion would be then set up to with the IP products of this tagged 
protein to assess its enzymatic activity or regulation function including in the GPI 
anchor biosynthesis pathway. The co-IP study performed on TbdeAc2 has identified a 
new partner protein for it which is Tb927.11.11750. However, the functional studies 
performed on this protein failed to give clear conclusions. In vitro enzymatic assay 
strongly suggests that it does not display GPI PLA2 activity. All attempts to generate a 
conditional null mutant of Tb927.11.11750 ended up with gene re-arrangements at the 
locus, making it impossible to assay the phenotype through loss of expression. BLASTp 
analysis for the orthologs of Tb927.11.11750 shows it does not have any homologues in 
other species beyond Trypanosoma cruzi. The BLAST search using the Tb927.11.11750 
amino acid sequence as query found TcSYL_0181470. The T. cruzi predicted protein 
contains a putative signal peptide and a transmembrane domain, like Tb927.11.11750. 
Since gene manipulation of Tb927.11.11750 indicates that it is likely an essential gene 
for T. brucei, it is possible that TcSYL_0181470 may also be an essential gene for T. 
cruzi. The recent example of potent membrane protein-protein interaction inhibitors 
successfully curing animal models of dengue fever (Kingwell, 2021) provides some 
encouragement that the TbdeAc2 – Tb927.11.11750 interaction might also be a 
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Preliminary TbGPI12-Myc IP experiment using PCF cells. 
 
Samples of 6 × 108 PCF WT and TbGPI12 conditional null mutant Tet induced cells 
were lysed with either 0.5% digitonin (Fig S1A) or 1% TX-100 (Fig S1B) lysis buffer 
and IP was performed to the cell lysates with Myc-TrapTM beads as described in section 
4.1.3 and proteins were eluted with sodium citrate (pH 2.8), separated on SDS-PAGE 
and silver stained with Invitrogen SilverQuestTM. Although TbGPI12-Myc protein 
showed a strong signal when detected with rat anti-Myc antibody (Fig 4.3), there was 
no obvious corresponding silver stained band for TbGPI12-Myc at 28.6 kDa in the IPs 
(Fig S1A and B, lane 2), nor for its putative partner protein TbMTⅠ. Nevertheless, the 
regions (red rectangles) that were expected to contain TbMTⅠ (upper band) and 
TbGPI12 (lower band) were cut and send for proteomics. TbGPI12 was identified in 
both the 0.5% digitonin and 1% TX-100 IP samples with protein coverage of 15% and 
11%, respectively but there was no identification for TbMTⅠ from the upper bands. 
 
Figure S1 Silver staining of SDS-PAGE of TbGPI12-Myc IP products. 
 A: Cell lysates (0.5% digitonin) from the PCF WT (lane 1) or TbGPI12 conditional null mutant 
Tet induced (lanes 2) were subjected to IPs, and the proteins were eluted with sodium citrate 
(pH2.8). The eluted proteins were then resolved on SDS-PAGE, and silver staining was applied 
with Invitrogen set kit. The regions expected to contain TbMTⅠ and TbGPI12 (labelled with red 
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rectangles) were subjected to proteomics identification. B: Duplicate experiments but with 





In situ tagging and detection of TbMTI 
In this experiment, we used in situ C-terminal tagging of TbMTⅠ with 3 × c-Myc using 
the pMOTag plasmid (Oberholzer et al., 2006) described in section 5.1. Tagging in 
these clones was checked by immunoblotting; BSF TbMTⅠ-3Myc expressing cell lines 
were lysed with 1%TX-100 followed by pull-down with MycTrapTM beads, proteins 
were eluted from the beads with SDS sample buffer and detected by anti-Myc Western 
blot (Fig S2). Even with 1× 109 cells as input we could only detect a trace amount of 
TbMTⅠ-3Myc. To date, the in situ tagging of TbMTⅠ in PCF T. brucei hasn’t been 
successful and we have paused studies using TbMTⅠ as bait protein.  
 
 
Figure S2  Immunoprecipitation and Western blot of TbMTⅠ-3Myc. 
 A and B: Ponceau staining and anti-Myc Western blot of TbMTⅠ-3Myc IP products. 1 × 109 
TbMTⅠ-3Myc expressing cells (lane 1) were lysed with 1%TX-100 and IP was performed on 
the supernatant with Myc-TrapTM beads. Proteins were eluted with SDS sample buffer and 
separated on SDS-PAGE. After transferring to a nitrocellulose membrane, the blot was 
developed with a rat anti-Myc antibody.   
 
 
